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ABSTRACT 
Characterization of a novel Ser/Thr kinase/phosphatase pair in Escherichia coli  
Krithika Rajagopalan 
 
Regulatory protein phosphorylation is a well conserved mechanism of signal transduction in 
all biological systems. In bacteria, signal transduction by phosphorylation is thought to occur 
primarily on His and Asp residues. However, phosphoproteomic surveys in phylogenetically 
diverse bacteria over the past decade have identified numerous proteins that are phosphorylated 
on serine (Ser) and/or threonine (Thr) residues. Consistently, genes encoding Ser/Thr kinases are 
present in many bacterial genomes such as E. coli, which encodes at least three Ser/Thr kinases. 
Since Ser/Thr phosphorylation is a stable modification, a dedicated phosphatase is necessary to 
allow reversible regulation. Bacterial Ser/Thr phosphatases which have extensive sequence and 
structural homology to eukaryotic Ser/Thr PP2C-type phosphatases are referred to as eukaryotic-
like Ser/Thr phosphatases (eSTPs). eSTPs have been identified in a number of bacteria, but none 
have been reported in E. coli. The work presented in this thesis was aimed at identifying and 
biochemically characterizing a eukaryotic-like Ser/Thr phosphatase and its partner Ser/Thr kinase 
in E.coli. 
 Chapter 3 describes the identification of a novel PP2C-like Ser/Thr phosphatase PphC 
encoded by an E. coli ORF, yegK, and characterization of its biochemical properties including 
kinetics, substrate specificity and sensitivity to known phosphatase inhibitors. I investigated 
differences in the activity of this protein in closely related E. coli strains. Finally, I demonstrated 
that this eSTP acts to dephosphorylate a novel Ser/Thr kinase which is encoded in the same operon 
suggesting that they most likely function as a pair in regulating Ser/Thr phosphorylation.  
 
Chapter 4 describes the biochemical characterization of a Ser/Thr kinase YegI in E. coli. I 
show that YegI is an active kinase with significant structural homology to eukaryotic Ser/Thr 
kinases. The YegI kinase domain is tethered to a cytoplasmic C-terminal domain containing two 
non-specific DNA binding Helix-hairpin helix motifs. I have identified enolase and elongation 
factor-Tu (EF-Tu) as potential physiological substrates of YegI and have demonstrated that 
phosphorylation of EF-Tu by YegI inhibits protein translation in vitro.  
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CHAPTER 1 
Introduction 
1.1 Protein phosphorylation  
Post-translational modifications control the activity of many proteins in the cell. Protein 
phosphorylation is one of the most widely studied post-translational modifications and has 
emerged as a crucial mechanism for signal transduction and regulation of protein function (1). 
Protein phosphorylation involves covalent attachment of a phosphate group to an amino acid side 
chain in the protein. Addition of a phosphate group enhances the charge density and hydrophilicity 
of the amino acid side chain thereby causing a change in conformation and protein function.   
Phosphorylation is a rapid and reversible process mediated by the action of two opposing 
classes of enzymes: protein kinases and protein phosphatases. Protein kinases catalyze the 
hydrolysis of adenosine triphosphate (ATP) and generally transfer the 𝜸 phosphoryl group of ATP 
to phospho acceptor amino acids on a target protein. In eukaryotic cells, phospho acceptor amino 
acids are mostly hydroxyl group-containing amino acids such as serine, threonine and tyrosine. In 
several lower organisms such as bacteria, aspartate and histidine residues also act as phospho 
acceptor amino acids. Removal of a phosphate group from the phospho acceptor amino acids is 
catalyzed by protein phosphatases thereby restoring the target protein to its original state. This 
process is referred to as dephosphorylation.  
If the target protein is an enzyme, then phosphorylation/dephosphorylation can alter its 
enzymatic activity, potentially acting as an ON/OFF switch. Additionally, phosphorylation can 
regulate protein function by facilitating or disrupting protein-protein interactions; stabilizing 
protein structure or marking protein for proteasomal degradation. Phosphorylation plays a key role 
in several metabolic pathways including cell growth, cell division, cell cycle, transcription, 
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translation and hormonal responses. The first evidence of a regulatory role of phosphorylation was 
observed in glycogen metabolism. Krebs and Fisher, as well as Wosilait and Sutherland in two 
independent studies,  demonstrated that glycogen phosphorylase, an enzyme that plays a key role 
in glycogen metabolism, is subject to phosphorylation and dephosphorylation that affect its activity 
(2-5). Subsequently, over the years, many kinases, phosphatases, and phosphoproteins have been 
identified and characterized in phylogenetically diverse organisms, thereby establishing protein 
phosphorylation as a broadly important mechanism in regulating cellular processes. 
 
1.2 Protein phosphorylation in bacteria  
Historically, protein phosphorylation has been associated with eukaryotic cells (6). In fact, 
the question of whether this modification even existed in bacteria was a matter of debate. Initial 
studies to address this question were carried out in Escherichia coli, where the authors detected 
protein kinase activity by a cyclic AMP-dependent enzyme and subsequent phosphorylation of 
histone-like nucleoid structuring proteins (H-NS) (7). Cyclic AMP-dependent kinase activity was 
also detected in oral streptococci (8). However, due to a lack of chemical identity of residues and 
issues with reproducibility, these studies failed to conclude the presence of protein 
phosphorylation.  
Eventually, studies in the late 1970s demonstrated that this mechanism is not exclusive to 
eukaryotes but can also be observed in bacteria (9, 10). The first bacterial phosphoprotein detected 
was an NADP-dependent isocitrate dehydrogenase (IDH), an enzyme that catalyzes the 
metabolism of isocitrate in the Krebs cycle. Two forms of IDH were isolated, phosphorylated and 
unphosphorylated, and it was observed that the phosphorylated form of IDH was completely 
inactive (11, 12). Although IDH was phosphorylated on a serine residue, the kinase responsible 
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for this modification had no similarity to eukaryotic type Ser/Thr kinases (13). These results 
suggested that bacteria may lack the eukaryotic-like signal transduction mediated by Ser/Thr 
phosphorylation. Subsequently, studies in the mid-1980s discovered the presence of histidine 
kinases that lacked any sequence homology to eukaryotic kinases (14, 15). These kinases became 
part of the two-component systems that established protein phosphorylation by histidine kinases 
as a global mechanism of signal transduction in bacteria (16).  
 
1.3  Two-component systems: His/Asp phosphorylation 
            Unlike eukaryotes where signal transduction predominantly operates through 
phosphorylation on Ser/Thr/Tyr residues,  signal transduction in bacteria was found to take place 
primarily by the addition of a phosphate group to histidine or aspartate residues. This mechanism 
involves two main components: a sensor molecule and a response regulator. In response to external 
stimulus,  a sensor protein, most often a membrane-spanning histidine kinase, dimerizes and 
undergoes autophosphorylation on a conserved histidine residue. The autophosphorylated sensor 
kinase catalyzes the transfer of this phosphate group to a conserved aspartic acid residue in the 
response regulator. Upon phosphorylation, response regulators attain an active conformation and 
can affect the expression of genes via DNA binding (Fig.1.1) (17, 18).  
      In comparison to Ser/Thr kinases that create phosphoester intermediates, histidine kinases 
generate phosphoramide intermediates that are relatively labile. Therefore, they do not necessarily 
require a dedicated phosphatase to reverse the reaction. Interestingly, histidine kinases are thought 
to possess phosphatase activity (19). While the details of this activity remain somewhat 
mysterious,  the general assumption in the field is that the balance between the kinase and 
phosphatase activity of the histidine kinase determines the phosphorylation state of the target 
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response regulator. Both Gram-positive and Gram-negative bacteria possess histidine kinases that 
regulate a range of bacterial cellular processes including sporulation, virulence, antibiotic 
resistance and chemotaxis (16, 20).  
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Figure 1.1: Phosphorylation by two-component systems 
Inducing cues such as extra cytoplasmic stress (shown as yellow thunderbolt) are sensed by membrane 
bound histidine kinases (HK) that undergo dimerization and initiates autophosphorylation of Histidine 
residues and subsequent transfer of phosphoryl group to aspartate residues on response regulator (RR) in 
the cytoplasm. Phosphorylated response regulator functions as a transcriptional regulator by activating 
expression of target response genes (GeneX/ Y).  
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HK
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Gene X Gene Y
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1.4 Ser/Thr phosphorylation in bacteria 
The assumption that two component systems are only found in bacteria and that Ser/Thr 
kinase based systems are restricted to eukaryotes was found to be incorrect when studies emerged 
that plants and fungi have both these systems (21, 22). Similarly, the discovery of a gene (pkn1) 
encoding a Ser/Thr kinase in the Gram-negative bacterium Myxococcus xanthus indicated that 
Ser/Thr phosphorylation is not exclusive to eukaryotes. Specifically, the catalytic domain of Pkn1 
shares significant sequence similarity to eukaryotic serine-threonine kinases (23). Although the 
knockout of pkn1 did not affect viability, it was still important for the normal development of M. 
xanthus. A weak developmental defect and the lack of a difference in phosphorylation patterns 
between WT and ∆pkn1 strains suggested that there could be additional kinases with redundant 
functions (23). Subsequently, using pkn1 as a probe, the authors identified 26 additional genes with 
similarity to eukaryotic Ser/Thr kinases suggesting that Ser/Thr phosphorylation was important 
for normal development in M. xanthus (24-26). Following the identification of Ser/Thr kinases in 
M. xanthus,  whole genome sequencing led to the discovery of these type of Ser/Thr kinases in 
several bacterial species suggesting that these proteins are widely prevalent in bacteria (27). Since 
these kinases share significant sequence and structural homology to catalytic domains of their 
eukaryotic counterparts they have been termed as eukaryotic-like serine-threonine kinases 
(eSTKs). These kinases are also referred to as Hanks-type kinases as they contain the conserved 
domain features described by Hanks et al. in 1988 (28).  
eSTKs mediate phosphorylation of Ser/Thr residues, a modification that is relatively stable 
under physiological conditions as compared to phosphorylation on Asp/His residues. Therefore, a 
dedicated phosphatase is required to remove the phosphate group from Ser/Thr residues to reverse 
the phosphorylation reaction (Fig. 1.2). Consistently, whole genome sequencing of bacteria 
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revealed presence of eukaryotic-like Ser/Thr phosphatases (eSTPs) which bear a striking 
resemblance to a class of eukaryotic Ser/Thr phosphatases called Mg2+ or Mn2+ dependent protein 
phosphatases (PPM) (29). Genes encoding bacterial eSTPs often occur in the same operon as 
eSTKs and have been shown to counteract the kinase activity of eSTK by direct dephosphorylation 
of eSTK or eSTK substrates (30). The structural features and physiological role of eSTKs and 
eSTPs will be discussed in the following sections.  
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Figure 1.2: Ser/Thr phosphorylation 
In response to external signal, the Ser/Thr kinase (STK) undergoes autophosphorylation on Ser/Thr 
residues and subsequently transphosphorylates a substrate on Ser/Thr residue. This stable 
phosphorylation on substrate is catalytically reversed by a Ser/Thr phosphatase (STP). STP can also 
remove phosphate group from STK.  
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1.5 Eukaryotic-like Ser/Thr kinases: Structural features  
The catalytic domain of eSTKs is about 300 amino acids in length with sequence homology 
to eukaryotic protein kinases. The catalytic domain in eukaryotic Ser/Thr kinases is a bi-lobed 
structure containing a small N-terminal lobe primarily composed of β sheets and a large C-terminal 
lobe with mostly α helices (31). The catalytic site is present at the interface of the two lobes. While 
the N-terminal lobe orients and binds to ATP, the C-terminal lobe is responsible for binding to 
peptide substrate (Fig. 1.3A). The first crystal structure of an eSTK, Mycobacterium tuberculosis 
PknB, revealed significant structural homology to mouse cyclic AMP-dependent protein kinase 
(PKA), which is a member of eukaryotic Ser/Thr kinase superfamily (Fig.1.3B). The catalytic 
domain of eSTK contains twelve conserved Hanks subdomains numbered I-V, VIa, VIb and VII-
XI. Hanks subdomains are characterized by the presence of twelve invariant and absolutely 
conserved residues responsible for positioning of the ATP molecule and catalysis (13).   
The catalytic domain contains several essential structural features (Fig 1.3C).  First, a 
nucleotide binding domain is present in between motifs I-IV.  Nucleotide binding is mediated by 
motif I containing a glycine rich P-loop with sequence GXGXXGXV, a conserved lysine in motif 
II and a conserved glutamic acid in motif III. The P-loop is responsible for binding to the β and ɣ 
phosphates and catalyzes the transfer of the phosphate from ATP/ ADP during catalysis. Second, 
the catalytic loop present in motif VI is directly responsible for catalytic activity. The conserved 
aspartate residue in the catalytic motif D-X4-N is indispensable for catalytic activity and is 
conserved in all protein kinases. Third, the activation segment in the kinase domain is an important 
regulatory region that dictates activity of the kinase and it consists of the Mg2+-binding loop (DFG 
motif), the activation loop and the P+1 loop. The aspartate residue in the DFG motif along with 
the conserved aspartate in the catalytic motif directly participate in catalysis by recognizing one of 
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the ATP bound Mg2+ ions. The activation loop is poorly conserved and is responsible for substrate 
specificity (32, 33). Activation of several eSTKs is achieved either by autophosphorylation or 
transphosphorylation of a threonine residue in the activation loop (34-36). Phosphorylation in the 
activation loop stabilizes the activation loop in a set conformation such that it promotes substrate 
binding and catalysis (32, 33). The activation loop also regulates protein-protein interactions. The 
P+1 loop lies at the interface of kinase and substrate and is responsible for specificity of kinase to 
serine/threonine phosphorylation (37).  
Two possible mechanisms of kinase activation have been demonstrated: direct activation by 
ligand-promoted dimerization or indirect activation. The first evidence of ligand-promoted 
dimerization and activation of the kinase came from the crystal structure of M. tuberculosis PknB 
(35, 38). The PknB structure showed that it formed back-to-back dimers of the N-terminal lobe of 
the catalytic domain to undergo autophosphorylation. This mechanism of ligand-induced 
dimerization and activation was also observed for another M. tuberculosis eSTK, PknD (39), and 
the Pseudomonas eSTK PpkA (40).  In cases where the kinase lacks a ligand binding domain, an 
indirect mechanism is proposed as a model for activation. For example, the crystal structure of the 
PknB kinase domain alone with an ATP competitive inhibitor revealed formation of asymmetric 
front-to-front dimers via interaction between the αG helix and an ordered activation loop on one 
domain and αG helix and a disordered activation loop of the second domain. Substitutions in the 
αG helix interface resulted in decreased autophosphorylation suggesting that αG helix in the C-
terminal lobe of the kinase is important for activation. The conformation of the two proteins in the 
dimer is such that one monomer acts like an activator while the other monomer acts like a substrate 
very similar to a transphosphorylation model (41). This provides an alternate mechanism of 
activation especially for soluble kinases that lack a membrane bound domain.  
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Figure 1.3: Structure of Eukaryotic-like Ser/Thr kinase (eSTK) catalytic domain (A)Crystal structure of 
mouse PKA catalytic domain in complex with ATP and an inhibitor peptide (PDB ID: 1ATP). The N-terminal 
lobe of PKA is depicted in gray and the C-terminal lobe is shown in blue. ATP molecule is shown as sticks, 
two manganese ions are shown as purple spheres, 20 residue inhibitor peptide is shown in red.  
(B) Crystal structure of mouse PKA was superimposed on crystal structure of M tuberculosis eSTK PknB 
(PDB ID: 1MRU). Mouse PKA is shown in blue and PknB is shown in yellow.  
(C) Amino acid sequence alignment of mouse PKA (residues 33-283) and PknB (1-266) catalytic domains. 
The secondary structure elements are represented on top of the sequence. Conserved structural features 
are shown in boxes, while invariant residues are highlighted in black. Red and orange asterisks indicate 
catalytic site and conserved threonine in activation loop respectively. (Taken from (30)) 
 
 
 
 
 
 
 
 
 
A B
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1.5.1  Eukaryotic-like Ser/Thr kinases in Gram-positive bacteria 
eSTKs are observed in both Gram-positive and Gram-negative bacteria. Gram-positive 
eSTKs generally comprise of three domains: a cytoplasmic domain containing a highly conserved 
Hanks family kinase; a transmembrane domain that is connected to the cytoplasmic domain via a 
non-conserved juxta-membrane domain; and an extracellular region that consists of three or four 
peptidoglycan binding and Ser/Thr kinase associated (PASTA) repeats. The PASTA repeats are 
commonly found in penicillin binding proteins that participate in peptidoglycan biogenesis and are 
essential for growth and development (42, 43). The Dworkin lab demonstrated that the PASTA 
repeats of the Bacillus subtilis eSTK PrkC recognize peptidoglycan fragments (muropeptides) 
providing the first evidence of a possible ligand of a bacterial receptor eSTK (44).  
Although most Gram-positive eSTKs regulate essential bacterial processes, they are mostly 
non-essential with the exception of the M. tuberculosis eSTK PknB (45).  Gram-positive eSTKs 
containing PASTA domains have been found to play a role in sensing cell wall homeostasis and 
cell wall biosynthesis. For example, B. subtilis  eSTK PrkC is required for sensing muropeptides 
during spore germination as cells lacking PrkC were unable to germinate suggesting a possible 
role of PrkC in signaling the spore to germinate (exit dormancy) in response to muropeptides (44).  
PASTA-containing eSTKs also regulate cell division by directly interacting and modifying cell 
division proteins involved in septal formation. For example, Streptococcus pneumoniae StkP 
phosphorylates cell division protein DivIVA and regulates the transition from septal to peripheral 
peptidoglycan synthesis (46). StkP also regulates the stability of the eukaryotic tubulin homolog 
FtsZ by directly phosphorylating MapZ, a protein responsible for positioning FtsZ rings at the 
septum (47).   
The integral role of PASTA-containing eSTKs in cell division and cell wall homeostasis 
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suggested that eSTKs could regulate response to cell wall stress inducing antibiotics. Consistently, 
PASTA-containing eSTKs in  Staphylococcus aureus (48, 49),  Listeria monocytogenes (50, 51) 
and Enterococci (52, 53) are important for resistance to β-lactam antibiotics. However, the exact 
molecular mechanism of how eSTKs mediate  β -lactam resistance is still unknown. In addition to 
role in cell wall biosynthesis and cell division, PASTA containing eSTKs have been implicated in 
the virulence of multiple pathogens. For example, in Listeria monocytogenes, the presence of 
eSTK PrkA is critical for promoting survival within the host cytoplasm by predominantly 
regulating basic physiological processes like cell division and morphogenesis (54) and in rare 
instances by direct regulation of virulence factors (48). PASTA containing eSTKs have also been 
shown to play an important role in biofilm formation, which in some cases contributes to 
pathogenesis and disease progression. For example, in Streptococcus mutans, deletion of eSTK 
StkP impairs biofilm formation (55).  
 
1.5.2  Eukaryotic-like Ser/Thr kinases in Gram-negative bacteria 
 Much less is known about the physiological substrates of eSTKs in Gram-negative bacteria. 
Although there is no known structure of a Gram-negative eSTK, the predicted structure and 
features of the kinase domain in Gram-negative eSTKs are homologous to those seen in Gram- 
positive eSTKs. Unlike Gram-positive eSTKs, eSTKs identified in Gram-negative bacteria lack 
an extracellular PASTA domain.  Although not much is known about the substrates in Gram-
negative eSTKs, they have been shown to play an important role in regulating cellular processes 
including cell development, virulence, biofilm formation and stress response as I will discuss 
below.  
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One of the most well studied Gram-negative bacteria with eSTKs is M. xanthus. Over 102 
putative eSTKs have been identified (unpublished, Monsanto microbial sequence database of M. 
xanthus) of which only 13 eSTKs have been characterized (23, 26, 56-59). Some eSTKs in M. 
xanthus participate in a kinase cascade and regulate fruiting body formation. For example, under 
nutrient deprived conditions, M.  xanthus aggregates and forms multicellular fruiting bodies.  The 
M. xanthus eSTK Pkn8 phosphorylates and activates another eSTK, Pkn14, which in turn 
phosphorylates MrpC, a key transcriptional regulator that directly controls expression of genes 
responsible for fruiting body formation and spore development. Phosphorylation of MrpC inhibits 
the binding of MrpC to its own promoter resulting in downregulation of genes in involved in 
fruiting body development. Consistently in pkn8 and pkn14 deletion strains, fruiting body 
development progresses faster as compared to WT strain indicating a fundamental role of eSTK 
in Myxococcus development (25, 60).  
Some Gram-negative eSTKs have also been implicated in virulence. For example, the 
secreted eSTK YpkA is important for virulence of Yersinia pseudotuberculosis (61). The 
Pseudomonas aeruginosa eSTK PpkA plays an important role in bacterial virulence in neutropenic 
mice (62) and activation of Type VI secretion systems (40, 63). A recent study showed that 
mutations in PpkA also impacts biofilm formation and decreases tolerance to oxidative or osmotic 
stress (64).  
Although Ser/Thr phosphorylation was first reported in E. coli in the late 1970s (9, 10) and 
the whole genome was sequenced in 1997 (65), a gene encoding an eSTK was not identified until 
ten years later. YeaG is the first and only reported eSTK in E.coli (66) which was initially 
identified in a transcriptomic screen for genes upregulated in response to various stresses including 
low pH, osmotic stress, entry into stationary phase (67). Sequence analysis of YeaG showed the 
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presence of an N-terminal ATPase (AAA+) domain and a C-terminal kinase domain. Proteins 
containing AAA+ domains are often mechanochemical enzymes that convert chemical energy 
derived from ATP hydrolysis to mechanical force in order to induce conformational change in 
substrates. The kinase domain of YeaG is similar to that of the B. subtilis eSTK PrkA and exhibits 
distant homology to eukaryotic protein kinases (68). Biochemical analysis of YeaG showed that it 
is an active kinase which phosphorylates an unknown 65kda cytoplasmic protein (69).  
The global nitrogen-sensitive transcription factor NtrC activates yeaG expression in response 
to nitrogen starvation and deletion of yeaG led to decreased survival in response to sustained 
periods of nitrogen starvation (70). Catalytic activity of the YeaG AAA+ and kinase domains were 
crucial for adaptation to sustained nitrogen starvation (70). More recently, the molecular 
mechanism of how YeaG is important for adaptation to nitrogen starvation was characterized using 
transcriptomics and metabolomic approaches (71). Under sustained nitrogen starvation conditions, 
deletion of yeaG resulted in major transcriptome changes specifically the dysregulation of NtrC 
responsive methionine biosynthesis genes. Aberrant activation of methionine biosynthesis genes 
resulted in decreased survival of ∆yeaG strain under nitrogen starvation conditions (71). Together 
these results demonstrate that yeaG is important for adaptation to nitrogen starvation, however 
whether or not YeaG kinase activity or its presumed phosphorylation substrates contribute to this 
adaptation is still unexplored.  
 
1.6 Atypical Ser/Thr kinases in Escherichia coli 
Although most bacterial Ser/Thr kinases identified thus far belong to the Hanks family of 
kinases, there are some exceptions. So-called atypical Ser/Thr kinases lack the defined Hanks 
conserved motifs (72). However, despite the absence of these conserved motifs, these kinases 
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retained their catalytic activity. Phylogenetic analysis suggested that these atypical Ser/Thr kinases 
form a separate phyletic group that arose as early as the typical Hanks family of kinases. Classical 
examples of atypical Ser/Thr kinases in eukaryotic cells are aminoglycoside kinases, choline 
kinases and phosphatidylinositol 3-kinases (PI3K).  Aminoglycoside kinases and choline kinases 
have distinct structural modifications in the C-terminal lobe while PI3K have a more flat structure 
with an open active site as compared to Hanks family kinases.  
E.coli hipA encodes a Ser/Thr kinase that belongs to the phosphatidylinositol 3/4-kinase 
(PI3/4K) superfamily (73). Unlike other bacterial eSTKs, HipA does not possess Hanks domains 
or the absolutely conserved residues that are commonly observed in eSTKs (74). hipA was first 
identified in a genetic screen for genes responsible for increased tolerance to antibiotics. Mutations 
in hipA (notably the hipA7 allele) resulted in 1000-fold of persisters, cells with a heightened 
tolerance to antibiotics, as compared to WT strains (75, 76).  Subsequently, sequence analysis and 
biochemical characterization demonstrated that HipA together with HipB is part of a toxin-
antitoxin module that dictates multidrug tolerance states. Autophosphorylation of HipA on residue 
Ser-150 was crucial for multidrug tolerance states (73). Unlike eSTKs, Ser-150 is not present in 
the activation loop and instead is in the catalytic core in the P-loop. Phosphorylation of Ser-150 
stabilizes the HipA molecule in an off state by ejection of P loop thereby inactivating the kinase. 
Overexpression of hipA triggers growth arrest in E. coli by activation of stringent response 
resulting in translational inhibition (77). The exact molecular mechanism of HipA induced 
bacterial persistence was shown to be mediated via phosphorylation of glutamyl tRNA synthetase 
(GltX) on a single Ser residue. Phosphorylated GltX failed to aminoacylate tRNA resulting in 
accumulation of uncharged tRNA at the ribosome and activation of stringent response and bacterial 
persistence (78, 79). Although HipA phosphorylates GltX on a serine residue, the phosphatase 
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responsible for reversing this modification is still unknown. In this study, I have identified a novel 
Ser/Thr phosphatase in E. coli but was unable to demonstrate dephosphorylation of either HipA or 
GltX suggesting that there could be other Ser/Thr phosphatases that are yet to be identified.  
E. coli YihE, another atypical Ser/Thr kinase, has structural similarity to choline kinases and 
aminoglycoside kinases (80). Phenotypic analysis revealed that yihE is predominantly expressed 
in stationary phase in a CpxR dependent manner. CpxR is a response regulator which along with 
histidine kinase CpxA regulates the response to various cellular stresses including membrane 
damage, starvation and high osmolarity (81). Subsequent phenotypic analysis of yihE showed that 
in response to antimicrobial stress, YihE regulates programmed cell death in bacteria and protects 
E. coli from antimicrobials by antagonizing the action of MazEF toxin-antitoxin system (82). More 
recently, the yihE gene was shown to be upregulated in low-level quinolone resistant E. coli strains 
suggesting increased protection of resistant E. coli strains against programmed cell death (83). 
However,  the mechanistic basis of these phenotypes, specifically, the identity of YihE substrates, 
remains unknown.  
 
1.7 Eukaryotic-like Ser/Thr phosphatases 
The comparatively stable character of Ser/Thr phosphorylation requires a dedicated enzyme 
to remove the phosphate group in order to facilitate reversible phosphorylation. Protein Ser/Thr 
phosphatases mediate removal of a phosphate group from Ser/Thr residues. In eukaryotic cells, 
protein Ser/Thr phosphatases have been broadly classified into three major families depending on 
their protein structure, substrate specificity and sensitivity to phosphatase inhibitors. These are: 
aspartate based phosphatase family of phosphatases, phosphoprotein phosphatases (PPP) and 
metal (Mg2+ or Mn2+) dependent protein phosphatases (PPM). Homologs of PPP and PPM 
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phosphatases have been identified in bacteria  
        PPP phosphatases are further subdivided into seven subfamilies PP1, PP2A, PP2B, PP4, PP5, 
PP6 and PP7 that contain both a catalytic subunit and a regulatory subunit that dictates substrate 
specificity. Although PPP phosphatases are classified as Ser/Thr phosphatases, PPPs exhibit the 
ability to dephosphorylate phospho His and Tyr residues indicative of broad specificity (84, 85). 
Unlike PPP phosphatases, PPM phosphatases are more abundantly found in bacteria and are often 
encoded in the same operon as, and often adjacent to, genes encoding eSTKs suggesting that the 
function of PPM phosphatases is tightly connected with that of eSTKs. For every bacterial eSTP 
(PPM) there are one or more eSTKs, suggesting that eSTPs mediate complex regulation of eSTK 
signal transduction. For example, M. tuberculosis has eleven eSTKs and one eSTP (86). Unlike 
PPP phosphatases, PPM phosphatases do not contain a separate substrate recognition or a 
regulatory subunit. Therefore, regulation of PPM phosphatase activity and how PPM phosphatases 
specifically recognize their substrates remains unclear.  
 
1.8 PPM/PP2C phosphatases 
1.8.1 PPM/PP2C phosphatases: Structural features 
PPM phosphatases are Mg2+ or Mn2+ dependent Ser/Thr phosphatases that share significant 
structural and sequence homology to eukaryotic PP2C phosphatases (29, 87, 88). The catalytic 
domain of PPM/PP2C phosphatases is typically 200-290 amino acids in length with eleven to 
thirteen signature conserved motifs (89).  In addition to these signature motifs, PPM phosphatases 
contain eight absolutely conserved residues that include four aspartate residues in motif I, II, VII, 
and XI;  a threonine residue in motif IV; and three glycine residues in motif V, VI, and VIII 
(Fig.1.4A). Together these residues mediate metal coordination, substrate binding, and catalysis.  
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Bacterial PP2Cs are further subdivided into two groups depending on the presence of signature 
motifs 5a and 5b (89, 90). Group I PP2C-like phosphatases (eSTPs) contain all the thirteen 
signature motifs including motif 5a and 5b while Group II PP2Cs lacks motif 5a and 5b (89). The 
B. subtilis sporulation-specific PP2C-like phosphatase SpoIIE (91) and the stress response PP2C-
like phosphatases RsbX and RsbU (92, 93) are catalytically active despite the lack of motif 5a and 
5b indicating that these motifs are not crucial for activity. 
The catalytic core of a PPM phosphatase is buried in the central beta sandwich formed by 
anti-parallel beta sheets (94). Antiparallel alpha helices surround these sandwiched beta sheets. 
The metal ions are located in the cleft which is formed by the beta sandwich structure (Fig.1.4B). 
Metal ion coordination is mediated by conserved aspartate residues and a water molecule. The 
catalytic activity of PPM phosphatases is dependent on the presence of bivalent metal ions 
Mg2+/Mn2  which bind to a water molecule and initiate a nucleophilic attack on the phosphorous 
atom while a second water molecule protonates the oxygen on a modified Ser/Thr residue. 
Structures of several bacterial PP2Cs including Thermosynechococcus elongatus tPphA (95),  M. 
tuberculosis PstP (96), Mycobacterium smegmatis MspP (97) Streptococcus agalactiae Stp (98) 
and S. aureus Stp1(99) reveal significant structural homology to human PP2C with all the active 
sites conserved. The structures of human PP2C (Fig.1.4B) and T.elongatus tPphA (Fig.1.4C)  
illustrate this homology.   
Despite the overall similarity, there are however three notable differences in the structure 
between the bacterial and eukaryotic homologs. First, human PP2C contains a C-terminal domain 
consisting of three antiparallel alpha helices that are responsible for substrate recognition and 
specificity but does not impact the catalytic activity (Fig.1.4B). However, this domain is not 
present in tPphA and other bacterial PP2Cs (Fig.1.4C). Second, structures of the bacterial PP2Cs 
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show binding to three metal ions instead of two metal ions as seen in human PP2C. In the case of 
tPphA, two aspartate residues in motif V and VIII respectively mediate metal coordination of third 
metal ion.  Recently, the structure of S. aureus eSTP Stp1 revealed the presence of four metal ions 
suggesting differences in metal co-ordination within bacterial PP2Cs. (99). Third, human PP2Cs 
contains a flap domain ( Fig1.4B, C denoted in red) which is positioned away from the active site 
to allow substrate access. In bacterial PP2Cs, the flap subdomain is flexible and is positioned closer 
to the active site. For example, in tPphA, the arginine residue at position 169 acts as a hinge and 
is responsible for the flexible nature of flap subdomain. Mutation of Arg 169 impairs catalytic 
activity indicating that the flexible flap domain is essential for substrate binding and catalysis (95). 
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Figure 1.4: Structure of PPM family of Ser/Thr phosphatase 
(A)Amino acid sequence alignment of Human PP2C (residues 1-299) and Thermosynechococcus 
elongatus PphA (1-241) catalytic domains. The secondary structure elements are represented on top of the 
sequence. Conserved motifs 1-5, 5a, 5b and 6-11 as defined as in (89) are shown in boxes. Conserved 
amino acids are highlighted in black while residues involved in metal binding pocket are shown shaded in 
red.  
(B) Crystal structure of human PP2C structure (PDB ID: 1A6Q). The β sandwich is shown in yellow, α 
helices in blue, flap subdomain is shown in red while the two manganese ions are shown as gray spheres. 
His62 (orange) is shown as sticks. The C-terminal domain containing α-helices (α7, α8, α9) are absent in 
bacterial PP2Cs.   
(C) Crystal structure of Thermosynechococcus elongatus PPM phosphatase tPphA (PDB ID:2J86). The β 
sandwich is shown in yellow, α helices in blue, flap subdomain is shown in red while the three manganese 
ions are shown as gray spheres. Met62 (orange) is shown as sticks and occupies homologous position as 
His62.(Taken from (30) 
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1.8.2 Physiological role of Eukaryotic-like Ser/Thr phosphatases (PPM/PP2C) 
One important biochemical role of bacterial PP2Cs is to reverse the action of the kinase by 
directly dephosphorylating activated partner kinase. Examples include the B. subtilis eSTP PrpC 
which dephosphorylates the eSTK PrkC in vitro (100),   the S. agalactiae, eSTP Stp which reverses 
the action of the eSTK Stk (101) and M. tuberculosis PstP which dephosphorylates the eSTKs 
PknA and PknB in vitro (34, 102). Alternatively, bacterial PP2Cs also act by dephosphorylating 
eSTK substrates. For example, the S. agalactiae eSTK/ eSTP pair Stk/Stp reversibly regulates 
phosphorylation of inorganic pyrophosphatase (101). Other example include S. pneumoniae, 
eSTK/ eSTP pair StkP/PhpP which reversibly regulate phosphorylation of cell division protein 
DivIVA (103, 104) and the B. subtilis, eSTK/ eSTP pair PrkC/PrpC which reversibly regulate 
phosphorylation of two-component response regulator WalR (105).  
As compared to eSTKs, much less is known about the physiological role of bacterial PP2Cs. 
However, in a few instances, eSTPs have been reported to have opposing roles as eSTK in 
regulating cellular processes like cell growth, development, antibiotic resistance, and virulence.  
For example, deletion of the B. subtilis eSTP PrpC resulted in an extended stationary phase 
phenotype  which is the exact opposite of a deletion strain of eSTK PrkC that shows a defect in 
stationary phase (106).  In M. xanthus, deletion of eSTP Pph1 showed defects in the formation of 
multicellular fruiting bodies from viable spores under starvation conditions (107). Deletion or 
point mutations in S.aureus eSTP Stp1 results in reduced susceptibility to cell wall antibiotics 
vancomycin and daptomycin (108, 109). Similarly, mutations in S. aureus STP resulted in 
upregulation of genes that are responsible for cell wall thickening and increase resistance to 
lysostaphin (49) and downregulation of virulence genes (108). In Salmonella enterica serovar 
typhi, deletion of eSTP/eSTK operon prpZ/prkY/prkX resulted in decreased virulence in human 
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macrophages by promoting phagocytosis (110). Similarly, deletion of both the eSTK and eSTP in 
B. anthracis decreased survival in macrophages (111). However, whether this impact on virulence 
is due to eSTK or eSTP is still unclear. Although eSTPs impact multiple cellular processes, how 
eSTPs regulate these processes and the exact mechanism remains poorly understood. 
 
1.9 Identification of phospho substrates using phosphoproteomics  
      Ser/Thr kinases participate in regulatory networks of eukaryotic cells and initiate signaling 
cascades by phosphorylating substrate proteins on either a single or multiple Ser/Thr residues 
(112).  Although eSTKs were identified in several bacteria, little was known about specific protein 
substrates. Mass spectrometry-based phosphoproteomic analysis identified several cellular 
proteins that are phosphorylated on site-specific Ser/Thr residues (113). For example, ~100 cellular 
proteins were found to be phosphorylated on Ser/Thr residues in E. coli (114) and B. subtilis (115) 
whereas somewhat smaller phosphoproteomes were detected in Pseudomonas sp. (116) and 
Mycoplasma pneumoniae (117), each with around 50-60 phosphorylated proteins. One of the 
largest phosphoproteomes with >300 phosphorylated proteins was detected in M. tuberculosis 
(118) consistent with the presence of eleven eSTKs (86).  
In all these studies, a majority of these phosphorylated proteins have a wide array of 
functions. For example, phosphoproteomes of both Gram-positive and Gram-negative bacteria are 
overrepresented with enzymes that participate in central carbon metabolism specifically in 
glycolysis (115, 117, 119-122). In the case of E. coli and B. subtilis, almost all the enzymes 
involved in glycolysis are reported to be phosphorylated on Ser/Thr residues hinting at 
phosphorylation- mediated regulation of glycolysis (115, 120). It should be emphasized, however, 
that there exists little direct evidence of such regulation. 
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The metabolic and highly conserved enzyme enolase is reported to be phosphorylated on 
Ser/Thr/Tyr residues across multiple bacterial genomes. Enolase is a critical glycolytic enzyme 
that catalyzes the second last step in the glycolytic pathway, the interconversion of 2-
phosphoglycerate to phosphoenolpyruvate. In E. coli (114, 123), enolase is phosphorylated on Ser-
372, Thr-375, Thr-379 while in B. subtilis (115) enolase is phosphorylated at Thr-141, Ser 259, 
Tyr-281, Ser-325. However, the impact of phosphorylation on the regulation of glucose 
metabolism as well as the kinase/phosphatase responsible for the reversible modification of 
enolase is not known. In addition to its role in glycolysis, enolase is a vital component of the RNA 
degradosome complex which includes a major endoribonuclease RNase E, polynucleotide 
phosphorylase PNPase and an ATP-dependent RNA helicase RhlB (124). The RNA degradosome 
is responsible for orderly regulation and degradation of transcripts for controlling gene expression 
(125). A few studies have shed light on the possible role of enolase in the RNA degradosome. 
Under aerobic conditions, enolase in the RNA degradosome mediates rapid degradation of the 
glucose transporter ptsG mRNA in response to phosphosugar stress (126). More recently, under 
anaerobic conditions, enolase was reported to be essential for regulation of cell morphology by 
specifically stabilizing small RNA DicF, a known inhibitor of cell division protein FtsZ (127). 
However, the exact mechanism of how enolase dictates RNA cleavage depending on 
environmental conditions, substrate availability or specificity remains unclear. Furthermore, the 
possible impact of phosphorylation of enolase on RNA degradation is unexplored.  
Proteins involved in protein synthesis also have been identified to be phosphorylated on 
Ser/Thr residues in E. coli (114, 128), B. subtilis (115), M. tuberculosis (118), Lactococcus lactis 
(129) suggesting that Ser/Thr phosphorylation may regulate translation across bacterial species. 
For example, the universally conserved GTPase elongation factor Tu (EF-Tu) is phosphorylated 
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on conserved Ser/Thr residues in different species (130). EF-Tu is an essential translational factor 
that binds GTP (EF-Tu-GTP) and aminoacylated tRNA (aa-tRNA) to form a ternary complex and 
delivers the aminoacylated tRNA to the ribosome. Upon a correct codon-anticodon match, the 
ribosome activates the GTPase activity of EF-Tu thereby allowing accommodation of aa-tRNA 
into the ribosomal aa-tRNA binding site and release of EF-Tu-GDP from the ribosome (131). A 
few reports have demonstrated the regulation of EF-Tu function by Ser/Thr phosphorylation. For 
example, the M. tuberculosis eSTK PknB specifically phosphorylates EF-Tu on multiple threonine 
residues and inhibits its interaction with GTP resulting in decreased protein synthesis (132). Also, 
the B. subtilis, eSTK YabT phosphorylates EF-Tu on a conserved threonine residue in the GTPase 
active site which in turn inhibits GTPase activity of EF-Tu (133). In E. coli, phosphorylation of 
EF-Tu affects its GTPase activity as well as ternary complex formation (134, 135). However, the 
kinase responsible for this modification of EF-Tu is still unknown.   
Although some of these phosphorylated substrates such as EF-Tu are conserved in 
phosphoproteomes across several bacteria, the phosphorylation sites are not necessarily conserved. 
Furthermore, since phosphorylation is a dynamic process, the phosphorylation status of proteins 
could differ based on environmental conditions used. This was clearly demonstrated by 
comparative phosphoproteomics in E. coli where phosphorylation status was examined under 
different growth phases (123). Specifically, E. coli cells grown in minimal media showed a global 
increase in phosphorylation levels in late stationary phase, including those of EF-Tu, suggesting 
that phosphorylation is likely to occur in later phases of growth. Thus, phosphorylation of 
elongation factors could be (partially) responsible for the diminished rate of protein synthesis 
during stationary phase.  
In order to identify kinase specific substrates, comparative phosphoproteomics have been 
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carried out by comparing phosphoproteomes of a strain lacking either the eSTK or partner eSTP 
with the WT strain. This methodology has been utilized previously for identifying phospho 
substrates of B. subtilis PrkC using deletion strains of eSTK PrkC and eSTP PrpC (136). This 
methodology has also been successfully utilized in M. pneumoniae, where 4 out of the 63 
phosphorylated proteins were specifically enriched in a deletion strain of novel eSTK PrkC (117). 
Therefore, phosphoproteomic analysis can serve as a useful tool in identifying phosphorylated 
proteins.  
 
1.10 Escherichia coli as a model organism  
Escherichia coli is a Gram-negative bacterium and probably the most widely studied model 
organism among prokaryotes. Short generation time under laboratory conditions and relatively 
small genome size has made E. coli one of the earliest bacterial genomes to be sequenced and 
annotated (65). From the physiological context, E. coli has been widely used to understand 
intracellular signal transduction particularly in the context of His/Asp kinases in two- component 
systems that regulate cellular responses to changing environments. While bacterial signal 
transduction dependent on Ser/Thr phosphorylation was first identified in E. coli in the late 1970s, 
not much is known regarding the role of Ser/Thr phosphorylation in E. coli cell physiology. Despite 
sequencing the whole genome, eukaryotic-type serine/threonine kinases with conserved Hanks 
domain features were not identified. It was therefore assumed that E. coli may have very few or 
no eSTKs (137). However, the subsequent identification of  >100 Ser/Thr phosphorylated proteins 
by phosphoproteomic approaches, including essential enzymes involved in glycolysis and protein 
synthesis  (114, 123) indicates the presence of  the Hanks-type/eukaryotic-like serine threonine 
kinases and phosphatases that are responsible for these modifications. Additionally, the functional 
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consequences of phosphorylation of these key cellular proteins is still an unanswered question.  
 
1.11 Scope of this dissertation  
The goal of this dissertation was to understand how Ser/Thr phosphorylation is reversibly 
regulated in E. coli and identify the enzymes that catalyze reversible regulation. Although three 
Ser/Thr kinases have been identified and biochemically characterized in E. coli, a Ser/Thr 
phosphatase has not been identified. This dissertation includes two main studies. In the first part 
(Chapter 3), I describe the first PP2C-like Ser/Thr phosphatase in E. coli. I used homology-based 
search with B. subtilis PP2C PrpC as a model to identify a PP2C homolog encoded by yegK 
(renamed as pphC)  in E. coli. I used various in vitro biochemical assays to understand enzymatic 
properties of PphC and have identified a putative Ser/Thr kinase (YegI) encoded in the same 
operon as a physiological substrate for PphC. In the second study (Chapter 4) I show that YegI 
belongs to a class of well-conserved eukaryotic-like Ser/Thr kinases found in bacteria. Using in 
vitro biochemical assays and gene fusions, I have characterized the enzymatic properties of YegI 
and identified enolase and elongation factor-Tu (EF-Tu) as potential physiological substrates of 
YegI kinase.   
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CHAPTER 2 
Materials and Methods 
 
2.1 Bacterial strains and growth conditions 
E. coli DH5α cells were used for regular cloning and E. coli C43(DE3), BL21(DE3) and 
LOBSTR (BL21-DE3) strains were used for expression of recombinant proteins. E. coli REL606 
B strain was used for all the physiology experiments. E. coli cells for expression were grown in 
LB Lennox broth supplemented with ampicillin (100 µg/ml) or carbenicillin (100 µg/ml) at 37 ºC 
with shaking (220 rpm) unless otherwise specified. Genomic DNA from E. coli REL606 and 
MG1655 was isolated using a Wizard genomic DNA purification kit (Promega) following 
manufacturer’s instructions. Strains used in this study are described in Appendix A. Plasmids used 
in this study are listed in Appendix B. Oligos used in this study are listed in Appendix C.  
 
2.2 Cloning and expression of YegK (PphC)  
The E. coli yegK (pphC) gene was PCR amplified using Phusion polymerase (Thermo 
Scientific) from REL606 genomic DNA using primers (KR38/KR39). Sequence for an N-terminal 
His6 tag was included in the primer. The PCR product was digested with NcoI/PstI and ligated into 
similarly digested pBAD24 plasmid backbone. Ligation products were transformed into DH5α 
cells and selected on LB ampicillin plates. The resulting plasmid generated an N-terminal His6-
tagged YegK (PphC) fusion protein.  
For protein expression, all plasmids were transformed into C43(DE3) cells and plated on LB 
ampicillin (100 µg/ml) agar plates. Single colonies were inoculated into 3 ml LB supplemented 
with ampicillin (100 µg/ml) for overnight cultures. The next day, 400 ml cultures were diluted 
1:250 and grown to an OD600 of 0.6-0.8. Recombinant protein was induced by addition of arabinose 
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(0.2 % w/v) for 3h at 25 ºC. Cells were harvested at 6000 xg for 15 min at 4 ºC. Pellets were 
washed with ice-cold 50 mM EDTA and centrifuged at 7000 rpm for 15 min at 4 ºC. Washed pellets 
were saved at -80 ºC until use.  
 
2.3 Oligonucleotide site directed mutagenesis for YegK(PphC) point mutants 
Point mutation of aspartic acid residue D46 was generated by two step overlap PCR 
mutagenesis using primer pairs (KR38/ KR41) and (KR40/ KR39) with Phusion polymerase. A 
second PCR was performed with primers (KR38/ KR39) using primary PCR products as a template 
and the subsequent PCR products were digested with NcoI/PstI and ligated into pBAD24 to 
generate an N-terminal His6 tagged D46N YegK(PphC) fusion protein. Plasmid cloning was 
subsequently verified by restriction enzyme digest and DNA sequencing (Operon). 
Point mutation of serine residue S174 was generated by two step overlap PCR mutagenesis 
using primer pairs (KR38/KR129) and (KR128/KR39) with Phusion polymerase. A second PCR 
was performed with primers (KR38/KR39) using primary PCR products as a template and the 
subsequent PCR products were digested as above and ligated into pBAD24 to generate an N-
terminal His6 tagged S174A YegK(PphC) fusion protein. Plasmid cloning was subsequently 
verified by restriction enzyme digest and DNA sequencing (Operon). 
 
2.4 Purification of recombinant PphC 
Frozen pellets from protein expression were suspended in lysis buffer (20 mM Tris pH 8.0, 
250 mM NaCl, 30 mM imidazole, 10 mM β-mercaptoethanol, 0.2 % Triton-X 100, 10 mg/ml 
lysozyme, 1 mM PMSF) and incubated on ice for 30 min. Initial lysis was carried out by four 
cycles of freeze/thaw in dry ice/ethanol bath and 37 ºC. Lysate was passed through a 22-gauge 
 30 
needle and added to pre-chilled 2 mL screw cap tubes with 0.1mm silica beads.  Cells were lysed 
using a FastPrep-24 5G instrument (MP Biomedical) using 2 rounds of 6.5 m/s intensity for 40 
secs with 4 min incubation on ice between rounds. Lysates were cleared by centrifugation at 20,000 
x g for 30 mins at 4 ºC. Cleared lysates were incubated in Pierce 5ml columns with Ni-NTA agarose 
beads (Qiagen) at 4 ºC for 1 h. Lysate was allowed to flow through and beads were washed 10 
column volumes of wash buffer (20 mM Tris pH 8.0, 250 mM NaCl, 30 mM imidazole, 10 mM 
β-mercaptoethanol). His6-tagged protein was eluted using increasing concentrations of imidazole 
(100-500 mM) in 20 mM Tris pH 8.0, 250 mM NaCl. Elution fractions were analyzed on a 10 % 
SDS-PAGE gel and fractions containing protein were pooled and dialyzed overnight at 4 ºC using 
Slide-A-Lyzer mini dialysis device 10K MWCO (Thermo Scientific) in phosphatase storage buffer 
(20 mM Tris pH 8.0, 50 mM NaCl, 1 mM DTT, 1 mM MnCl2). Dialyzed samples were 
concentrated in Amicon Ultra 10K centrifugal filters to 1ml and then loaded onto a HiLoad 16/60 
superdex 75 prep grade (GE Biosciences) gel filtration column. The column was preequilibrated 
and run with phosphatase storage buffer. PphC elutes at a retention volume of ~70 ml. Fractions 
containing PphC were pooled, concentrated and assessed for purity using a 12 % SDS-PAGE gel. 
The catalytic variant D46N and S174A variant was purified using the same protocol. Proteins were 
stored at -80 ºC. 
 
2.5 Cloning and expression of HipA  
The E. coli hipA gene was PCR amplified using Phusion polymerase (Thermo Scientific) 
from MG1655 genomic DNA using primers (EN5/EN2). Sequence for an N-terminal His6 tag was 
included in the primer. The PCR product was digested with EcoRI/PstI and ligated into similarly 
digested pBAD24 plasmid backbone. Ligation products were transformed into DH5α cells and 
 31 
selected on LB ampicillin plates. The resulting plasmid generated an N-terminal His6-tagged HipA 
fusion protein.  
For protein expression, plasmid was transformed into C43(DE3) cells and plated on LB 
ampicillin (100 µg/ml) agar plates. Single colonies were inoculated into 3 ml LB supplemented 
with ampicillin (100 µg/ml) and grown until OD600 ~1. The same day, 500 ml cultures were diluted 
1:250 with inoculum culture and grown to an OD600 of 0.6-0.8. Recombinant protein was induced 
by addition of arabinose (0.2 % w/v) for 1h at 37 ºC. Cells were harvested at 6000 x g for 15 min 
at 4 ºC. Pellets were washed with ice-cold 50 mM EDTA and centrifuged at 7000 rpm for 15 min 
at 4 ºC. Washed pellets were saved at -80 ºC until use.  
 
2.6 Purification of recombinant HipA 
Frozen pellets from protein expression were suspended in lysis buffer (50 mM NaH2PO4 pH 
8.0, 300mM NaCl, 30mM imidazole, 0.2 % Triton-X 100, 20 mg/ml lysozyme, 1mM PMSF) and 
incubated on ice for 30 min. Initial lysis was carried out by four cycles of freeze/thaw in dry 
ice/ethanol bath and 37 ºC. Lysate was passed through a 22-gauge needle and added to pre-chilled 
2 mL screw cap tubes with 0.1 mm silica beads. Cells were lysed using a FastPrep-24 5G 
instrument (MP Biomedical) using 2 rounds of 6.5 m/s intensity for 40 secs with 4 min incubation 
on ice between rounds. Lysates were cleared by centrifugation at 20,000 x g for 30 mins at 4 ºC. 
Cleared lysates were incubated in Pierce 5ml columns with Ni-NTA agarose beads (Qiagen) at 4 
ºC for 1 h. Lysate was allowed to flow through and beads were washed 10 column volumes of 
wash buffer (50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 30 mM imidazole). His6-tagged protein was 
eluted using increasing concentrations of imidazole (100-500 mM) in 50 mM NaH2PO4 pH 8.0, 
300 mM NaCl . Elution fractions were analyzed on a 10 % SDS-PAGE gel and fractions containing 
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protein were pooled and dialyzed overnight at 4 ºC using Slide-A-Lyzer mini dialysis device 10 K 
MWCO (Thermo Scientific) in HipA storage buffer (50 mM Tris pH 8.0, 250 mM NaCl, 5 mM 
DTT, 10% glycerol). Dialyzed samples were concentrated in Amicon Ultra 10K centrifugal filters 
and assessed for purity using a 12 % SDS-PAGE gel. Proteins were stored at -80 ºC. 
 
2.7 Cloning and expression of GltX  
The gltX gene was PCR amplified using Phusion polymerase (Thermo Scientific) from E. 
coli MG1655 genomic DNA using primers (KR23/KR25). Sequence for N-terminal His6 tag was 
included in the primer. The PCR product was digested with NdeI/BamHI and ligated into similarly 
digested pET11a plasmid backbone. Ligation products were transformed in DH5α cells and 
selected on LB/ampicillin plates. The resulting plasmid pKR07 generated an N-terminal His6-
tagged GltX fusion protein. Plasmid cloning was subsequently verified by restriction enzyme 
digest and DNA sequencing (Operon).  
For protein expression, plasmid was transformed into C43(DE3) cells and plated on LB 
ampicillin (100 µg/ml) agar plates. Single colonies were inoculated into 3 ml LB supplemented 
with ampicillin (100 µg/ml) for grown overnight. The next day, 200 ml cultures were diluted 1:250 
and grown to an OD600 of 0.5. Recombinant protein was induced by addition of 1 mM IPTG  for 
3 h at 25 ºC. Cells were harvested at 6000 x g for 15 min at 4 ºC. Pellets were washed with ice-
cold 50 mM EDTA and centrifuged at 7000 rpm for 15 min at 4 ºC. Washed pellets were saved at 
-80 ºC until use.  
 
2.8 Purification of recombinant GltX 
Frozen pellets from protein expression were suspended in lysis buffer (20 mM Tris pH 8.0, 
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250 mM NaCl, 30mM imidazole, 10 mM β-mercaptoethanol, 0.2 % Triton-X 100, 10 mg/ml 
lysozyme, 1mM PMSF) and incubated on ice for 30 min. Initial lysis was carried out by four cycles 
of freeze/ thaw in dry ice/ethanol bath and 37 ºC. Lysate was passed through a 22-gauge needle 
and added to pre-chilled 2 mL screw cap tubes with 0.1 mm silica beads. Cells were lysed using a 
FastPrep-24 5G instrument (MP Biomedical) using 2 rounds of 6.5 m/s intensity for 40 secs with 
4 min incubation on ice between rounds. Lysates were cleared by centrifugation at 20,000 x g for 
30 mins at 4 ºC. Cleared lysates were incubated in Pierce 5ml columns with Ni-NTA agarose beads 
(Qiagen) at 4 ºC for 1 h. Lysate was allowed to flow through and beads were washed 10 column 
volumes of wash buffer (20 mM Tris pH 8.0, 250 mM NaCl, 30 mM imidazole, 10 mM β-
mercaptoethanol). His6-tagged protein was eluted using increasing concentrations of imidazole 
(100-500 mM) in 20 mM Tris pH 8.0, 250 mM NaCl. Elution fractions were analyzed on a 10 % 
SDS-PAGE gel and fractions containing protein were pooled and dialyzed overnight at 4 ºC using 
Slide-A-Lyzer mini dialysis device 10 K MWCO (Thermo Scientific) in GltX storage buffer (20 
mM Hepes pH 7.5, 10% glycerol , 5 mM b-mercaptoethanol). Dialyzed samples were concentrated 
using Amicon Ultra 10K centrifugal filters and assessed for purity using a 12 % SDS-PAGE gel. 
Proteins were stored at -80 ºC. 
 
2.9 Cloning and expression of YegI and YegI-NTD 
The yegI gene was PCR amplified using Phusion polymerase (Thermo Scientific) from E. 
coli REL606 genomic DNA using primers (KR58/ KR59). Sequence for an N-terminal His6 tag 
was included in the primer. The PCR product was digested with NcoI/SphI and ligated into 
similarly digested pBAD24 backbone. Ligation products were transformed in DH5α cells and 
selected on LB/ampicillin plates. The resulting plasmid pKR31 generated an N-terminal His6-
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tagged YegI fusion protein. Plasmid cloning was subsequently verified by restriction enzyme 
digest and DNA sequencing (Operon).  
The N-terminal domain of yegI gene (aa 1-390) was PCR amplified using Phusion 
polymerase (Thermo Scientific) from E. coli REL606 genomic DNA using primers (KR58/KR 
60). Sequence for N-terminal His6 tag was included in the primer. The PCR product was digested 
with NcoI/SphI and ligated into similarly digested pBAD24 plasmid backbone. Ligation products 
were transformed in DH5α cells and selected on LB/ampicillin plates. The resulting plasmid 
generated an N-terminal His6-tagged YegI-NTD fusion protein. Plasmid cloning was subsequently 
verified by restriction enzyme digest and DNA sequencing (Operon).  
The kinase domain of yegI gene (aa 1-300) was PCR amplified using Phusion polymerase 
(Thermo Scientific) from E. coli REL606 genomic DNA using primers (KR58/KR61). Sequence 
for N-terminal His6 tag was included in the primer. The PCR product was digested with NcoI/SphI 
and ligated into similarly digested pBAD24 plasmid backbone. Ligation products were 
transformed in DH5α cells and selected on LB/ampicillin plates. The resulting plasmid generated 
an N-terminal His6-tagged YegI-KD fusion protein. Plasmid cloning was subsequently verified by 
restriction enzyme digest and DNA sequencing (Operon).  
For protein expression, plasmid was transformed into either C43(DE3) cells or E. coli 
LOBSTR (Kerafast) cells and plated on LB ampicillin (100 µg/ml) agar plates. Single colonies 
were inoculated into 3 ml LB supplemented with ampicillin (100 µg/ml) for overnight cultures. 
The next day, a dilution of 1:250 in 500 ml LB was grown to an OD600 of 0.6-0.8. YegI recombinant 
protein was induced by addition of arabinose (0.2% w/v) for 3 h at 18 ºC. YegI-NTD recombinant 
protein was induced by addition of arabinose (0.2% w/v) for 3 h at 25 ºC. Cells were harvested at 
6000 xg for 15 min at 4 ºC. Pellets were washed with ice-cold 50 mM EDTA and centrifuged at 
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7000 rpm for 15 min at 4 ºC. Washed pellets were saved at -80 ºC until use.  
 
2.10 Oligonucleotide site directed mutagenesis for YegI point mutants 
Point mutation of lysine residue K39 was generated by two step overlap PCR mutagenesis 
using primer pairs (KR58/KR246) and (KR245/59) with Phusion polymerase. A second PCR was 
performed with primers (KR58/KR59) using primary PCR products as a template and the 
subsequent PCR products were digested with Nco1/Sph1 and ligated into similarly digested 
pBAD24 to generate an N-terminal His6 tagged K39D YegI fusion protein. Plasmid cloning was 
subsequently verified by restriction enzyme digest and DNA sequencing (Operon).  
Point mutation of aspartic acid residue D141 was generated by two step overlap PCR 
mutagenesis using primer pairs (KR58/ KR248) and (KR247/KR59) with Phusion polymerase. A 
second PCR was performed with primers (KR58/KR59) using primary PCR products as a template 
and the subsequent PCR products were digested with Nco1/Sph1 and ligated into similarly digested 
pBAD24 to generate an N-terminal His6 tagged D141N YegI fusion protein. Plasmid cloning was 
subsequently verified by restriction enzyme digest and DNA sequencing (Operon). 
Phosphoablative point mutants used in the study were generated using the same strategy as above 
and details of plasmid construction are described in Appendix B.   
 
2.11 Purification of recombinant YegI and YegI-NTD 
Frozen pellets were suspended in lysis buffer (50 mM Tris pH 8.0, 200 mM NaCl, 10 mM 
β-mercaptoethanol, 1 mM PMSF and 2% w/v sarkosyl) and incubated at room temperature for 
overnight lysis. Cells were subsequently lysed using sonication. Lysates were cleared by 
centrifugation at 15000 x g for 30 min at 4 ºC and incubated in Pierce 5 ml columns with Ni-NTA 
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agarose beads (Qiagen) at 4 ºC for 1 h. Lysate was allowed to flow through and beads were washed 
10 column volumes of wash buffer (50 mM Tris pH 8.0, 200 mM NaCl, 30 mM imidazole, 10 mM 
β-mercaptoethanol, 0.05% w/v sarkosyl). His tagged protein was eluted using 300 mM imidazole 
in 50 mM Tris pH 8.0, 200 mM NaCl, 10 mM β-mercaptoethanol and 0.05% w/v sarkosyl. Elution 
fractions were tested on 12% SDS-PAGE gel and fractions containing protein were pooled and 
dialyzed overnight at 4 ºC using Snakeskin dialysis tubing 10K MWCO (Thermo Scientific) in 
kinase storage buffer (20 mM Tris pH 8.0, 125 mM NaCl, 10% glycerol, 1 mM DTT). Dialyzed 
protein was assessed for purity using 12% SDS-PAGE gel and stored at -80 ºC. YegI variant 
proteins were purified using the same protocol. Proteins were stored at -80 ºC. 
 
2.12 Phosphatase assays using pNPP as a substrate 
The phosphatase activity of PphC (YegK) was determined by measuring hydrolysis of p-
nitrophenol phosphate (pNPP) to p-nitrophenol by spectrophotometry. Assays were performed in 
triplicate in a 96 well plate. Each well contained 350 nM purified PphC (WT or mutant) in assay 
buffer (10 mM Tris pH 8.0, 5 mM MnCl2). Reactions were initiated by addition of 5 mM pNPP 
(NEB) and absorbance measurements were recorded every 10 min at 405 nm for 60 min in a Tecan 
Infinite M200 plate reader. Amount of phosphate released is represented as nmol pNP/µg of protein 
and the amount of pNP was calculated using extinction coefficient of 18000 M-1cm-1. 
Metal dependence was determined by incubating 350 nM purified PphC in assay buffer 
containing either 5 mM MgCl2, 5 mM MnCl2, 5 mM CaCl2 ,5 mM ZnCl2, 5 mM NiCl2 or no metal. 
Absorbance measurements were recorded as above. To determine optimal MnCl2 concentrations, 
reactions were carried out with 350 nM purified WT PphC in assay buffer with different MnCl2 
concentrations (0-10 mM) and absorbance was measured at 405nm.  
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Sensitivity to phosphatase inhibitors was determined by measuring phosphatase activity of 
purified PphC in the presence of the following: sodium phosphate (Sigma), sodium fluoride 
(Sigma), okadaic acid (Cell Signaling), sodium orthovanadate (NEB) or EDTA (Macron 
Chemicals), sanguinarine chloride (Tocris), aurin tricarboxylic acid (Alfa Aesar) and 5,5’ 
methylene disalycilic acid (Acros Organics). Okadaic acid, sanguinarine chloride, aurin 
tricarboxylic acid and 5,5’ methylene disalycilic acid were diluted in DMSO to get a 1 mM stock. 
The remaining inhibitors were diluted to stock concentrations in sterile water pH 8. 150 nM of 
purified WT PphC was incubated in assay buffer containing indicated concentrations of inhibitor 
or DMSO/water for 5 min. Reactions were initiated by addition of 5 mM pNPP and absorbance 
was recorded every 5 min for 15 min at 30 ºC in a Tecan Infinite M200 plate reader.  
The kinetic parameters of PphC were determined by varying the pNPP concentration (0.1-
6.4 mM) in a reaction with 350 nM of purified wild type PphC from either REL606 and MG1655 
in assay buffer. Hydrolysis was monitored every 5 min for 30 min in the linear range of the 
reaction. Initial reaction velocities were calculated for every substrate concentration. To determine 
Km and Vmax values, the data was fit to a Michaelis-Menten curve and Lineweaver-Burke plot was 
derived using Graphpad Prism 7 software. 
Effect of phosphorylation by YegI-NTD on PphC phosphatase activity was assessed using 
pNPP as a substrate. Firstly, a 175 µL kinase reaction was performed using 89 nM of YegI-NTD 
and 350 nM of PphC at a kinase: substrate ratio (1:4) in kinase buffer containing 50 mM Tris pH 
7.5, 50 mM KCl, 0.5 mM DTT, 10 mM MgCl2, 10 mM MnCl2, 200 µM ATP for 45 mins at 37C 
to allow transphosphorylation. After 45 mins, phosphatase reactions were initiated by addition of 
5 mM pNPP (NEB) and absorbance measurements were recorded every 10 min at 405 nm for 60 
min in a Tecan Infinite M200 plate reader. 
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2.13 Phosphatase assays using synthetic phosphopeptides as substrates  
To assess substrate specificity, 200 µM of serine [RRApSVA], threonine [KRpTIRR] or 
tyrosine [RRLIEDAEpYAARG] phosphopeptides (Millipore) were incubated with 350 nM 
phosphatase in a 50 µl reaction containing 20 mM Tris pH 8.0 with either 5 mM MnCl2 or 5 mM 
MgCl2 for 30 min at 37 ºC. Phosphatase reaction was stopped by addition of Biomol Green reagent 
(Enzo). Reaction was incubated at room temperature for 25 min to allow color development and 
absorbance at OD620 was measured. Phosphate standard (Enzo) was used to calculate the amount 
of phosphate released.   
 
2.14 Phosphatase assays using β–casein as a substrate 
Phosphorylated β–casein (Sigma) was dissolved in 50 mM Tris pH 7.5, 150 mM NaCl to a 
final concentration of 4 mg/ml. For the phosphatase assay, 4 µg of β–casein was incubated with 
1.5 µg PphC (WT/D46N/S174A) in 20 µl of 50 mM Tris pH 8.0 with either 10 mM MnCl2 or 10 
mM MgCl2 at 37 ºC for 1 h. Reactions were stopped with 3X SDS loading dye and samples were 
heat denatured at 95 ºC for 5 min. Samples were loaded on 10% SDS- PAGE gel containing 50 
µM Phos-tag acrylamide as per manufacturer’s instructions (Wako). Gels were run at constant 
voltage of 150 V for 75 min at 4 ºC. Proteins were visualized by Coomassie staining.  
 
2.15 Dephosphorylation assays  
2.15.1 Dephosphorylation of autophosphorylated HipA  
For the dephosphorylation assay, 2 µM of recombinant HipA (60-95% phosphorylated) was 
incubated with 4 µM PphC (WT/D46N) in 20 µl of 30 mM HEPES pH 7.5 10 mM KCl, 1 mM 
DTT and 2 mM MnCl2 at 37 ºC for 1 h. Reactions were stopped with 3X SDS loading dye and 
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samples were heat denatured at 95 ºC for 5 min. Samples were loaded on 10% SDS- PAGE gel 
containing 50 µM Phos-tag acrylamide as per manufacturer’s instructions (Wako). Gels were run 
at a constant voltage of 150 V for 75 min at 4 ºC. Proteins were visualized by Coomassie staining. 
  
2.15.2 Dephosphorylation of phosphorylated GltX   
To obtain phosphorylated GltX, an in vitro kinase assay was performed in the presence of 
0.2 µM of HipA, 2 µM of GltX in a 100 µL reaction containing 30 mM HEPES pH 7.5, 10 mM 
KCl, 20 mM MgCl2, 16 µM ZnSO4, 100 mM DTT and 100 µM ATP. Reactions were incubated at 
37 ºC for 45 mins and then dialyzed in 500 ml of dialysis buffer ( 30 mM HEPES pH 7.5, 10mM 
KCl, 1 mM DTT) overnight at 4ºC using Slide-A-Lyzer mini dialysis device 10K MWCO (Thermo 
Scientific) to get rid of free unlabeled ATP. For the dephosphorylation assay, 2 mM MnCl2 was 
added to the dialyzed kinase reaction and was divided into four 20µL reactions. Buffer (HEPES 
pH 7.5) or 400U of Lambda protein phosphatase or 4 µM PphC-WT or 4 µM PphC-D46N was 
added to separate 20 µL reactions and reactions were incubated at 37 ºC for 1 h. Reactions were 
stopped with 3X SDS loading dye and samples were heat denatured at 95 ºC for 5 min. Samples 
were loaded on 10% SDS- PAGE gel containing 50 µM Phos-tag acrylamide as per manufacturer’s 
instructions (Wako). Gels were run at a constant voltage of 150 V for 75 min at 4 ºC. Proteins were 
visualized by Coomassie staining.  
 
2.15.3 Dephosphorylation of autophosphorylated YegI  
Autophosphorylation of YegI kinase was performed by addition of 5 µCi of [g-32P] ATP 
(Perkin Elmer) to 2 µM of purified YegI in 10 µl of reaction buffer containing 50 mM Tris pH 7.5, 
50 mM KCl, 0.5 mM DTT, 10 mM MgCl2, 10 mM MnCl2, 200 µM ATP. Phosphatase storage 
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buffer or PphC or PphC-D46N was added to the above reaction to a final concentration of 4 µM. 
Reactions were incubated at 37 ºC for 45 mins and were stopped using 3X Laemmli buffer and 
boiled for 5 min at 95 ºC. Samples were resolved on a 12% SDS-PAGE gel and visualized by 
staining with Coomassie dye. Radioactive gels were dried for 30 mins at 80 ºC in a gel dryer . 
Dried gel was exposed to a phosphoscreen and visualized by autoradiography using a Typhoon 
Scanner (GE Healthcare).  
 
2.16 In vitro kinase assay using PphC as a substrate 
Transphosphorylation of PphC phosphatase was performed by addition of 5 µCi of [g-32P] 
ATP (Perkin Elmer) to 0.5µM of YegI-NTD, 2µM of PphC in a 25µl of kinase reaction buffer 
containing 50 mM Tris pH 7.5, 50 mM KCl, 1 mM DTT, 10 mM MgCl2, 10 mM MnCl2, 200 µM 
ATP. Reactions were incubated at 37 ºC and reactions were stopped at different timepoints t=15, 
30, 60 mins using 3X Laemmli buffer and boiled for 5 min at 95 ºC. Samples were resolved on a 
12% SDS-PAGE gel and visualized by staining with Coomassie dye. Radioactive gels were dried 
for 30 mins at 80 ºC in a gel dryer . Dried gel was exposed to a phosphoscreen and visualized by 
autoradiography using a Typhoon Scanner (GE Healthcare).  
 
2.17 In vitro kinase assay for phosphopeptide identification 
Transphosphorylation of PphC phosphatase for mass spectrometry was performed by 
addition of 1.33 µM of YegI-NTD and 5.32 µM of PphC in a 30µl of reaction buffer containing 50 
mM Tris pH 7.5, 50 mM KCl, 1 mM DTT, 10 mM MgCl2, 10 mM MnCl2, 200 µM ATP. Reactions 
were incubated at 37 ºC for 1 h and 10 µl of reaction were stopped using 3X Laemmli buffer and 
boiled for 5 min at 95 ºC. Samples were resolved on a 12% SDS-PAGE gel and visualized by 
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staining with Coomassie dye . Remainder of sample (20 µl) was submitted for mass spectrometry 
based phosphopeptide detection.  
 
2.18 Phosphopeptide identification by Mass spectrometry ( provided by Dr. Emily Chen) 
2.18.1 In-gel protein digestion  
In vitro kinase assay samples containing YegI-NTD and PphC were resolved on 4-20% Tris-
glycine gradient gel and then stained with GelCode Blue safe Coomassie stain for 2 h followed by 
de-staining with double distilled water overnight. The resolved proteins were excised and 
processed at the HICCC Proteomics Shared Resource at Columbia University Medical Center. The 
excised gel pieces were rehydrated and digested in 80 µl of 12.5 ng/µl Trypsin Gold/50 mM 
ammonium bicarbonate at 37 °C overnight or 80 µl of 12.5 ng/ul Chymotrypsin/50 mM 
ammonium bicarbonate at room temperature overnight. After the digestion was complete, 
condensed evaporated water was collected from tube walls by brief centrifugation using the 
benchtop microcentrifuge (Eppendorf, Hauppauge, NY). The gel pieces and digestion reaction 
were mixed with 50 µL 2.5% TFA and rigorously mixed for 15 min. The solution with extracted 
peptides was transferred into a fresh tube. The remaining peptides were extracted with 80 µl 70% 
ACN/5% TFA mixture using rigorous mixing for 15 min. The extracts were pooled and dried to 
completion (1.5–2 h) in SpeedVac. The dried peptides were reconstituted in 30µl 0.1% TFA by 
mixing for 5 min and stored in ice or at −20°C prior to analysis. 
 
2.18.2 LC-MS/MS analysis 
The concentrated peptide mix was reconstituted in a solution of 2 % acetonitrile (ACN), 2 
% formic acid (FA) for MS analysis. Peptides were eluted from the column using a Dionex 
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Ultimate 3000 Nano LC system with a 10-minute gradient from 2% buffer B to 35 % buffer B 
(100 % acetonitrile, 0.1 % formic acid). The gradient was switched from 35 % to 85 % buffer B 
over 1 min and held constant for 2 min. Finally, the gradient was changed from 85 % buffer B to 
98 % buffer A (100% water, 0.1% formic acid) over 1 min, and then held constant at 98 % buffer 
A for 5 more minutes. The application of a 2.0 kV distal voltage electro sprayed the eluting 
peptides directly into the Thermo Fusion Tribrid mass spectrometer equipped with an EASY-Spray 
source (Thermo Scientific). Mass spectrometer-scanning functions and HPLC gradients were 
controlled by the Xcalibur data system (Thermo Scientific). 
 
2.18.3 Database search and interpretation of MS/MS data 
Tandem mass spectra from raw files extracted and transformed to mzXML format with MS 
convert within ProteoWizard (138). The spectra were searched against an E. coli protein database 
containing the sequences of his-tagged YegK (PphC), YegI, EF-Tu using Inspect (139) 
(proteomics.ucsd.edu). The program was instructed to look for variable phosphorylation 
modifications on Ser, Thr and Tyr, as well as variable modification for acetylation on Lys, 
oxidation on Met and fixed modification of carbamidomethylation on Cys. Instrument was set as 
FT-hybrid, with either trypsin or chymotrypsin as protease. Putative phosphorylated peptides (with 
a p-value < 0.1) were manually matched to their respective spectra to determine likelihood of 
match. If a match was able to be verified, a new experiment was conducted to target these specific 
peptides. The instrument was setup to only make MS/MS on the specific parent masses for these 
peptides. After the experiment, data was again manually verified to make sure that the peptides 
were phosphorylated. Elution traces for the specific peptides, tracing specific fragments for the 
peptides, were created within QualBrowser (Thermo Scientific). 
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2.19  Autophosphorylation assays  
2.19.1 Autophosphorylation assay using different bivalent cations 
Autophosphorylation of YegI or YegI-NTD was performed by addition of 5 µCi of [g-32P] 
ATP (Perkin Elmer) to 1 µM of purified YegI or YegI-NTD in 10 µl of reaction buffer containing 
50 mM Tris pH 7.5, 50 mM KCl, 0.5 mM DTT, 200 µM ATP. MgCl2 or MnCl2 or CaCl2 or NiCl2 
was added to a final concentration of 10 mM. Reactions were incubated at 37 ºC for 30 mins and 
were stopped using 3X Laemmli buffer and boiled for 5 min at 95 ºC. Samples were resolved on 
a 12% SDS-PAGE gel and visualized by staining with Coomassie dye. Radioactive gels were dried 
for 30 mins at 80 ºC in a gel dryer, exposed to a phosphoscreen and visualized by autoradiography 
using a Typhoon Scanner (GE Healthcare).  
 
2.19.2 Autophosphorylation assay using YegI point mutants 
Autophosphorylation of YegI and point mutants was performed by addition of 5 µCi of [g-
32P] ATP (Perkin Elmer) to 1 µM of purified YegI or YegI point mutants in 10 µl of reaction buffer 
containing 50 mM Tris pH 7.5, 50 mM KCl, 0.5 mM DTT, 200 µM ATP, 10mM MgCl2 and 10mM 
MnCl2. Reactions were incubated at 37 ºC for 30 mins and were stopped using 3X Laemmli buffer 
and boiled for 5 min at 95 ºC. Samples were resolved on a 12% SDS-PAGE gel and visualized by 
staining with Coomassie dye. Radioactive gels were dried for 30 mins at 80 ºC in a gel dryer, 
exposed to a phosphoscreen and visualized by autoradiography using a Typhoon Scanner (GE 
Healthcare). 
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2.19.3 Inhibition of autophosphorylation by staurosporine 
Staurosporine sensitivity experiments were performed using 1µM of YegI in 10 µl of 
reaction buffer containing 50 mM Tris pH 7.5, 50 mM KCl, 0.5 mM DTT, 10 mM MgCl2 and 10 
mM MnCl2. Staurosporine (Calbiochem) was dissolved in DMSO to a obtain a stock concentration 
of 10 mM. Staurosporine stock (10 mM) was diluted in DMSO and added to the above kinase 
reaction to obtain final concentrations in the range of 12.5-100 µM. DMSO was added to the no 
inhibitor control. Reactions were incubated at 25 ºC for 10mins followed by addition of 5 µCi of 
[g-32P] ATP (Perkin Elmer). Reactions were incubated for additional 30 mins at 37 ºC and were 
stopped using 3X Laemmli buffer. Samples were boiled for 5 min at 95 ºC and resolved on a 12% 
SDS-PAGE gel. Gel was visualized by staining with Coomassie dye. Radioactive dried gel was 
exposed and visualized by autoradiography using a Typhoon Scanner (GE Healthcare).  
 
2.20 Membrane topology analysis 
2.20.1 Construction of YegI PhoA-lacZα fusion and derivatives 
To study the membrane topology of YegI, I first constructed plasmid pKR72 that encodes a 
dual pho-lac reporter which is in-frame to full length YegI. The YegI-PhoA-lacZα was constructed 
by a PCR-mediated overlap extension (140). First, the yegI gene fragment encoding aa 2-646 was 
PCR amplified using Phusion polymerase (Thermo Scientific) from E. coli REL606 genomic DNA 
using primers (KR223/KR224). Alkaline phosphatase PhoA fragment (aa 21-471) and the alpha 
fragment of beta galactosidase LacZ (aa 5-60) was PCR amplified from E. coli MG1655 genomic 
DNA using primers (KR225/KR226) for phoA and (KR227/KR228) for lacZα respectively. 
Eighteen nucleotides encoding a GSGSGS linker along with eighteen nucleotides from the phoA 
DNA was introduced in the reverse primer KR224 to generate an overlapping region between yegI 
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and phoA. Similarly, eighteen nucleotides from the lacZ DNA was introduced in the reverse primer 
KR226 to generate an overlapping region between phoA and lacZ. The yegI and phoA PCR 
products were purified and used as templates for a second PCR to create a fused yegI-linker-pho 
DNA that was amplified using primers (KR229/KR226). Sequence for N-terminal His6 tag was 
included in the primer KR229. Purified PCR products yegI-linker-phoA DNA and lacZ DNA were 
used a templates for third and final round of PCR to create a fused yegI-linker-pho-lac fusion that 
was amplified using primers (KR229/KR228). The PCR product was digested with Nhe1/Kpn1 
and ligated into similarly digested pBAD24 plasmid backbone. Ligation products were 
transformed into DH5α cells and selected on LB/ampicillin plates. The resulting plasmid pKR72 
generated an N-terminal His6-tagged YegI-PhoA-lacZα fusion protein. Plasmid cloning was 
subsequently verified by restriction enzyme digest and DNA sequencing (Operon).  
Plasmid derivatives of pKR72 with pho-lac fusions were constructed in frame with different 
codons of YegI using the Q5 Site-Directed mutagenesis kit (NEB). Primers used to generate pho-
lac fusions in frame to different codons E439 (KR230/KR231), T432 (KR230/KR232), R414 
(KR230/KR233), E390 (KR230/KR234), E340 (KR230/KR235) were designed using 
NEBaseChanger. Primers were designed such that the 5’ ends were annealing back-to-back 
following manufacturer’s instructions. PCR amplification was performed using Q5 hotstart high 
fidelity master mix with respective primers and 2 ng of Plasmid pKR72 as template DNA. The 
PCR product was subsequently treated with Kinase/Ligase/Dpn1 mix for 5 mins and transformed 
in NEB5alpha competent E. coli cells (C2987). This method generated plasmids with in-frame 
pho-lac fusions to different codons of YegI at positions E439 (pKR73), T432 (pKR74), R414 
(pKR75), E390 (pKR76), E340 (pKR77). pKR78, a derivative of pKR72 lacking yegI was used 
as a control plasmid and was constructed using the same method using primers KR230/KR240. 
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Plasmid cloning was subsequently verified by colony PCR and DNA sequencing (Operon).  
 
2.20.2 Membrane topology assay 
To assess membrane topology in vivo, E. coli DH5α cells were transformed with the resulting 
pho-lac fusion plasmids and streaked on dual indicator plates containing LB agar with 5-bromo-
4-chloro-3-indolyl phosphate disodium salt (X-Phos) (Sigma) at a final concentration of 80µg/ml 
and 6-chloro-3-indolyl-β-D-galactoside (Red-Gal) (Sigma) at a final concentration of 100 µg/ml 
as indicators. L-arabinose at a final concentration of 0.1% was added as an inducer for reporter 
expression. 100µg/ml of ampicillin was added for plasmid selection. Plates were incubated at 25o 
C for 24 h and scanned using EPSON image scanner.  
 
2.21 Generation of in-frame deletion of yegI in E. coli REL606  
𝝀 red recombination system (141) was used for generation of in-frame deletions of yegI in 
E. coli REL606. pKD13 (141), which encodes kanamycin resistance, was used as the template 
plasmid in PCR reactions. FRT-Kan-FRT cassette of pKD13 was amplified with primers 
(KR176/KR177) containing 20 bases of homology to pKD13 sequence and 40 bases of homology 
upstream and downstream of yegI chromosomal sequence. Primers were designed such that PCR 
product recombines at two ends of yegI locus replacing yegI ORF from aa 9-624 with FRT-Kan-
FRT cassette. The PCR product was transformed by electroporation into strain KR103 
(REL606/pKD46) as in (141) and the deletion was verified by colony PCR and sequencing, 
resulting in strain KR154 (∆yegI::[FRT-kan-FRT]).  
The kanamycin marker was excised via Flp mediated recombination by transforming Flp 
helper plasmid pCP20 into KR154 by electroporation as in (141). Colonies were selected on 
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ampicillin plates at 30 ºC. Loss of kanamycin marker was confirmed by patching on kanamycin 
plates. The kanamycin sensitive colonies contained a single FRT scar at the desired yegI 
chromosomal site along with helper plasmid pCP20 resulting in KR156 (∆yegI::FRT/ pcp20). Flp 
helper plasmid pCP20 has a temperature sensitive origin of replication. Therefore, to cure the strain 
of helper plasmid , strain KR156 was incubated at 42 ºC resulting in KR160 (∆yegI).  
 
2.22 Generation of yegI-FRT-lacZ fusion in E. coli REL606  
KR156 (∆yegI::FRT/ pcp20) was utilized for generation of yegI-FRT-lacZ fusion using 
pCE40 as in (142). pCE40 has been used previously to convert an FRT site to translational lacZ 
fusion by site specific FLP mediated recombination event. pCE40 is a translational fusion vector 
with a single FRT site followed by lacZ sequence that lacks a translational start site. pCE40 was 
transformed by electroporation into strain KR156 and transformants were selected on kanamycin 
plates at 37 ºC . Integration of pCE40 at FRT site in correct orientation resulted in fusion of 9th 
codon of YegI in-frame with FRT scar and LacZ sequence at the C terminus. The lacZ fusion was 
verified by colony PCR and sequencing, resulting in strain KR168 (∆yegI ::[FRT-lacZY kan]).  
To avoid endogenous beta-galactosidase activity, the gene lacZ from amino acid 10-1011 
was replaced with FRT-Kan-FRT cassette amplified from pKD4 using primers (KR185/KR186) 
as described in (141). The PCR product was transformed by electroporation into KR103 
(REL606/pKD46) as in (141) and the deletion was verified by colony PCR and sequencing, 
resulting in strain KR178 (∆lacZ::[FRT-kan-FRT]). The kanamycin marker was excised by 
transformation of pCP20 into KR178 by electroporation resulting in strain KR181 (∆lacZ::FRT). 
KR181 was confirmed for loss of β-galactosidase activity by patching on LB+ 50 µg/ml Xgal 
(GoldBio) plates and sequencing. KR181 was used a control strain for β-galactosidase assays. The 
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chromosomally integrated yegI-FRT-lacZY-kan was moved from strain KR168 to strain KR181 
by P1 transduction as in (143) and selecting for kanamycin resistance. This strain was named 
KR188 (∆lacZ ∆yegI ::[FRT-lacZY kan]).  
 
2.23 β-galactosidase assay  
Assay for β-galactosidase activity was conducted as described (144). Briefly, strains KR181 
and KR188 were grown in LB lennox broth at 37 ºC until OD600~0.6 or OD600~3. 2 ml of cultures 
were chilled on ice until the desired OD was attained. 2 ml cultures pellets were resuspended in 
640µl of Z buffer (60 mM Na2HPO4 7H20, 40mM NaH2PO4, 10 mM KCl, 1 mM MgSO4 7H20, 50 
mM β-mercaptoethanol). Cells were lysed using 160µl of lysozyme (2.5 mg/ml in Z buffer) 
followed by incubation at 37 ºC for 5 mins. Samples were returned to ice and 8 µl of 10 % Triton-
X-100 was added to each of the samples. Each tube was vortexed for 10 s and samples were 
transferred to a 30 ºC water bath for 5 mins. The reaction was initiated by addition of 200 µl of 
ONPG (o-Nitrophenyl β -D-galactopyranoside) (4 mg/ml in Z buffer; Sigma) at 10 s intervals to 
each of the tubes. When yellow color develops, 400 µL of 1M Na2CO3 was added to stop the 
reaction. Time taken to develop yellow color was recorded. 1ml of reaction mixture was transferred 
to microcentrifuge tubes and centrifuged at 16000 X g for 1 min to get rid of cell debris. 150µl of 
supernatant from reaction mixture was transferred to 96 clear well Nunclon Delta surface plates 
(Thermo Scientific) and the optical density was recorded at 420 nm and 550 nm. Enzyme units of 
β-galactosidase was calculated as follows:  
1000 X (OD420-1.75 X OD550) / t X v X OD600 = units of β-galactosidase 
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Where, OD420 and OD550 are optical density measurements from the reaction mixture; OD600 
represents the cell density of cultures before the assay; t is the time of reaction in minutes and v is 
the volume of culture used in reaction mixture.  
 
2.24 Examining growth in minimal media  
Cultures for indicated strains were grown overnight in minimal A medium (144) containing 
0.4 % w/v glucose or 0.4 % v/v glycerol as a carbon source. Cultures were then diluted 1:500 into 
150 µL of the same media in each well in clear-bottom, polystyrene 96-well plate (Thermo 
scientific 167008). Cultures were incubated at 37 C with continuous shaking at medium speed in 
a Tecan infinite M200 plate reader. Growth was measured by taking optical density readings at 
600 nM every 10 mins for 20-22 h.   
 
2.25 Generation of in-frame deletion of yegI in E. coli MG1655 
In-frame deletion of yegI (JW2055-4) in E. coli BW25113 was obtained from the Keio 
collection stock center (145). P1 virion was made from JW2055-4 and transduced into recipient 
strain E. coli MG1655 and the transductants were selected on kanamycin. P1 transduction into 
recipient strain was confirmed by colony PCR resulting in strain KR60. The kanamycin marker 
was excised via FLP mediated recombination by transforming Flp helper plasmid pCP20 into 
strain KR60 by electroporation as in (141). Colonies were selected on ampicillin plates at 30 ºC. 
Loss of kanamycin marker was confirmed by patching on kanamycin plates. Strain was incubated 
at 42 ºC to cure Flp helper plasmid pCP20 resulting in strain KR257 (MG1655 ∆yegI). 
 
2.26 Antibiotic sensitivity assays 
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2.26.1  MIC determination using microtiter broth dilution method  
Antibiotics used for MIC determination by microtiter broth dilution method were as follows: 
Cefotaxime (Mpbio, 50 mg/ml in water), Ceftriaxone (Sigma, 20 mg/ml in water) , Cefoxitin 
(Sigma, 10.5 mg/ml in water), Cefipime (Sigma, 16.9 mg/ml in phosphate buffer pH 8.0), 
Fosfomycin (Sigma, 50 mg/ml in water), Kanamycin (Fisher Scientific, 50 mg/ml in water), 
Chloramphenicol (Sigma, 5 mg/ml in ethanol), Tetracycline (Sigma, 10 mg/ml in 50% ethanol), 
Ciprofloxacin (Enzo, 30 mg/ml in water), Gentamycin (Gibco, 50 mg/ml in water). Antibiotics 
were dissolved in respective solvents and diluted in sterile BBL Mueller Hinton II (MHII) broth 
(Bector Dickinson) to 2X the highest concentration desired in the test. Serial dilutions were 
prepared in MHII broth and 100 µl of 2X antibiotic solutions are added to sterile clear 96-well 
Nunclon Delta surface plates (Thermo Scientific). Bacterial colonies from a freshly streaked plate 
were suspended into 3 ml of sterile 1X phosphate buffered saline (PBS) to yield a final density of 
108 cfu/ml roughly equivalent to 0.5 Macfarland’s unit. This suspension was diluted 1:100 in MHII 
media and 100 µl is added to 96 well plates containing 100 µL of 2X antibiotic. Plates were sealed 
with parafilm and incubated without shaking at 37 ºC for 24h. Plates were scanned by eye or read 
spectrophotometrically at 600 nm to determine the minimum inhibitory concentration.  
 
2.26.2 MIC determination using Etest strips  
To determine MIC by Etest strips, I used Mueller Hinton II (MHII) agar plates prepared 
using manufacturer’s instructions. Inoculation of cultures was done by swabbing the MHII agar 
plates in all directions with a swab soaked in bacterial suspension equivalent to 0.5 Macfarland’s 
unit. Cefotaxime Etest strips (Biomerieux) (0.0002- 32 µg/ml) was placed on inoculated plates 
using sterile forceps. Plates were incubated at 37 ºC for 20 h and scanned using image scanner.  
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2.26.3 Antibiotic sensitivity  
Antibiotic sensitivity was assessed by back-diluting overnight cultures of indicated strains 
in LB to OD600 ~1. Aliquots of cultures were serially diluted 10-fold and 4 µl volumes of each of 
the dilutions were spotted on the surface of LB agar plates supplemented with antibiotics 
(Cefotaxime, 0.125 µg/ml) or (Nalidixic acid, 1 µg/ml). Plates were incubated at 37 ºC for 20-24h 
and scanned using image scanner. 
 
2.27 Complementation assays  
2.27.1 Plasmid construction for complementation assay 
Plasmids used for complementation assay were constructed using the Q5 Site-Directed 
mutagenesis kit (NEB) by using pKR31 as a template. Primers used to generate in frame deletions 
of yegI from aa 2-300 (KR274/KR275), aa 2-436 (KR276/KR275), aa 2-535 (KR287/KR288), aa 
2-565 (KR289/KR290) were designed using NEBaseChanger. Primers were designed such that the 
5’ ends annealed back-to-back following manufacturer’s instructions. PCR amplification was 
performed using Q5 hotstart high fidelity master mix with respective primers and 2 ng of Plasmid 
pKR31 as template DNA. The PCR product was subsequently treated with Kinase/Ligase/Dpn1 
mix for 5 mins and transformed into NEB5alpha competent E. coli cells (C2987). This method 
generated plasmids with different truncations of yegI in frame with N terminal His6 tag as follows: 
∆2-300 (pKR93), ∆2-436 (pKR92), ∆2-536 (pKR95), ∆2-566 (pKR96). pBAD24 was used as a 
control plasmid for complementation assays.  Plasmid cloning was subsequently verified by colony 
PCR and DNA sequencing (Operon). Plasmids were transformed in strain KR160 for 
complementation assays and selected on LB ampicillin plates.  
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2.27.2 Complementation assay 
Overnight cultures of indicated strains were grown in LB carbenicillin and were back-diluted 
in fresh LB to OD600 ~1. Aliquots of cultures were serially diluted 10-fold and 4 µl volumes of 
each of the dilutions were spotted on the surface of LB agar plates supplemented with antibiotics. 
Wherever indicated, arabinose (0.2% w/v) and carbenicillin (100 µg/ml) were added for induction 
of protein expression and maintenance of plasmid respectively.   
 
2.28 UV sensitivity assay 
Overnight cultures of indicated strains were grown in LB and were back-diluted in fresh LB 
to OD600 ~1. Aliquots of cultures were serially diluted 10-fold and 4 µl volumes of each of the 
dilutions were spotted on the surface of LB agar plates. Spotted plates were exposed to different 
doses of UV (0, 5, 10, 20, 40, 60 J/m2) using UV crosslinker (Stratagene). Plates were covered in 
aluminum foil, incubated at 37 ºC for 20-24h and scanned using image scanner. 
 
2.29 Generation of in-frame deletion of tolC in E. coli REL606 
𝝀 red recombination system (141) was used for generation of in-frame deletions of tolC in 
E. coli REL606. pKD13, which encodes kanamycin resistance was used as the template plasmid 
in PCR reactions (141). FRT-Kan-FRT cassette of pKD13 was amplified with primers 
(KR299/KR300) containing 20 bases of homology to pKD13 sequence and 40 bases of homology 
upstream and downstream of the tolC chromosomal sequence. Primers were designed such that 
PCR product recombines at two ends of tolC locus replacing tolC ORF from aa 10-475 with FRT-
Kan-FRT cassette. The PCR product was transformed by electroporation into strain KR103 
(REL606/pKD46) as in (141) and the deletion was verified by colony PCR and sequencing, 
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resulting in strain KR329 (∆tolC::[FRT-kan-FRT]). The kanamycin marker was excised via FLP 
mediated recombination by transforming Flp helper plasmid pCP20 by electroporation as in (141). 
Colonies were selected on ampicillin plates at 30 ºC. Loss of kanamycin marker was confirmed by 
patching on kanamycin plates. Strain was incubated at 42 ºC to cure Flp helper plasmid pCP20 
resulting in strain KR337 (REL606 ∆tolC). 
To generate ∆tolC in ∆yegI background, P1 virion was made from KR329 (∆tolC::[FRT-
kan-FRT]) and transduced into recipient strain KR160 (∆yegI), selecting on kanamycin. P1 
transduction into recipient strain was confirmed by colony PCR resulting in strain KR336 
((∆tolC::[FRT-kan-FRT] ∆yegI). The kanamycin marker was excised using pCP20 by 
electroporation as in (141). Colonies were selected on ampicillin plates at 30 ºC. Loss of 
kanamycin marker was confirmed by patching on kanamycin plates. Strain was incubated at 42 ºC 
to cure Flp helper plasmid pCP20 resulting in strain KR338 (REL606 ∆yegI ∆tolC). 
 
2.30 Comparative phosphoproteomics (In collaboration with Dr. Ljiljana Pasa-Tolic) 
2.30.1 Growth conditions 
E. coli REL606 (JDE2735) and REL606 ∆yegI (KR160) were grown overnight at 37 ºC in 
minimal A medium (144) containing 0.4 % w/v glucose as a carbon source. Cultures were grown 
in triplicates and then diluted 1:500 into 1 L of the same media in Erlenmeyer flasks . Cultures 
were incubated at 37 ºC with continuous shaking and cells were harvested by centrifugation at 
OD600 of 0.8 (log phase) and OD600 of 2.5 (stationary phase). Cell pellets were washed with 100 
mM ammonium bicarbonate pH 8.0 and shipped to our collaborator Dr. Ljiljana Pasa-Tolic at 
PNNL, WA. Protein extraction, phosphopeptide enrichment and data analysis were performed by 
Dr. Jared Shaw (Pasa-Tolic Lab).  
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2.30.2 Protein extraction and digestion (Provided by Dr. Jared Shaw) 
Each cell pellet was diluted in 2-5 mL of 8 M urea in 100 mM ammonium bicarbonate, pH 
8. 1 mL was transferred to 2 mL snap-cap centrifuge tubes (Eppendorf) with 0.1 mm zirconia beads 
and bead beat in a bullet Blender (Next Advance) at speed 8 for 3 minutes at 4°C. After bead 
beating, the lysate was spun into a 15 mL Falcon tube at 2000 xg for 10 minutes at 4°C. The 
supernatant (200 µl) was removed to a clean tube and a bicinchoninic acid (BCA) assay (Thermo 
Scientific) was performed to determine protein concentration. Following the assay, 10 mM 
dithiothreitol (DTT) was added to the samples and incubated at 60°C for 30 minutes with constant 
shaking at 800 rpm followed by the addition of 40 mM iodoacetamide (IAA) with 30 minutes of 
room temperature incubation in the dark. Samples were then diluted 8-fold for preparation for 
digestion with 100 mM NH4HCO3, 1 mM CaCl2 and sequencing-grade modified porcine trypsin 
(Promega, Madison, WI) was added to all protein samples at a 1:50 (w/w) trypsin-to-protein ratio 
for 3 h at 37˚C. Digested samples were desalted using a 4-probe positive pressure Gilson GX-274 
ASPEC™ system (Gilson Inc.) with Discovery C18 100 mg/1 mL solid phase extraction tubes 
(Supelco), using the following protocol: 3 mL of methanol was added for conditioning followed 
by 2 mL of 0.1 % trifluoroacetic acid (TFA) in H2O. The samples were then loaded onto each 
column followed by 4 mL of 95:5:H2O:Acetonitrile , 0.1% TFA. Samples were eluted with 1mL 
acetonitrile 80:20 Acetonitrile :H2O, 0.1% TFA. The samples were concentrated down to ~100 µL 
using a Speed Vac and a final BCA was performed to determine the peptide concentration. The 
sample volumes were calculated to contain 500 µg each and aliquoted into new low-protein 
binding 1.5 mL centrifuge tubes. For the pooled channel, 83 µg of each sample within each set 
were combined to make 500 µg. All the volumes were brought up using 0.5M triethylammonium 
bicarbonate (TEAB) to 75 µl. The pH of each sample was measured and brought to over pH 8 
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using 1M TEAB. Each vial of 8-plex iTRAQ reagent (AB Sciex) was brought to room temperature. 
The reagents were pulse spun to ensure the contents were collected at the bottom and 60 µl of 
isopropanol was added to each reagent vial. The reagents were thoroughly vortexed, spun down 
and 5 vials of each reagent were added to the appropriate 500 µg sample. Each sample was 
vortexed and spun down to incubate at room temperature for 2 hours at which time 100µl of 
nanopure water was added to hydrolyze the sample and incubated for an additional 30 minutes. 
The samples were partially dried down in a speed vac to remove the organic solvent and then 
pooled together to obtain 3 samples each containing all 7 of the iTRAQ labels and C18 cleaned 
again as described above followed by another BCA assay to determine the final peptide mass for 
phosphopeptide enrichment. Peptides were brought up to a concentration of 0.5 µg/µL in 80:20 
Acetonitrile :H2O, 0.1% TFA and used for phosphopeptide enrichment. 
 
2.30.3 Phosphopeptide enrichment using IMAC and phosphopeptide desalting 
Immobilized metal affinity chromatography (IMAC) columns by prepared by first prepared 
by pretreating Ni-NTA superflow agarose beads with 100 mM EDTA to strip beads of the nickel. 
Beads were washed with HPLC water and then activated with 10 mM iron (III) chloride aqueous 
solution for 30 mins at RT. Beads were then treated with 1:1:1 acetonitrile:methanol:0.01% acetic 
acid to make a slurry of 1:1:1 beads: acetonitrile :methanol:0.01% acetic acid. IMAC beads were 
then incubated with prepared peptide solution and incubated for 30 mins at RT on a shaker at 1000 
rpm. Beads/peptide solution was spun to remove supernatant and then brought up to 200 µL 
volume in 80:20 Acetonitrile :H2O, 0.1% TFA to get phosphoenriched beads. For desalting step, 
2-plug C18 stage tips were prepared using Empore C18 extraction disks. Stage tips were 
conditioned with methanol and centrifuged at 3000Xg for 3 mins to discard any liquid from the 
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collection vial. Stage tips were washed with 50 % acetonitrile in 0.1% formic acid twice and then 
equilibrated in 1% formic acid. The phosphoenriched beads loaded onto the stage tip and 
centrifuged at 3000Xg for 3 mins to discard any liquid from the collection vial. Beads were 
subsequently washed with 80:20 Acetonitrile :H2O, 0.1% TFA twice followed by wash with 1% 
formic acid. Peptides were eluted off the beads and onto the C18 plugs using 500 mM potassium 
phosphate buffer ( 1M monobasic + 1M dibasic potassium phosphate). C18 plugs were washed 
with 1 % formic acid and then peptides were eluted off C18 plugs with 50 % acetonitrile in 0.1% 
formic acid. Eluate was transferred to an HPLC vial, freeze dried, reconstituted in 2% 
acetonitrile/0.1 % formic acid and analyzed by LC-MS/MS as described (146).  
 
2.31 Cloning and expression of E. coli enolase   
The E. coli eno gene encoding enolase was PCR amplified using Phusion polymerase 
(Thermo Scientific) from REL606 genomic DNA using primers (KR211/KR212). The PCR 
product was digested with Nde1/BamHI and ligated into similarly digested pETPhos plasmid 
backbone (147). Ligation products were transformed into DH5α cells and selected on LB 
ampicillin plates. The resulting plasmid pKR71 generated an N-terminal His6-tagged Eno fusion 
protein.  
Point mutation of serine residue S400 was generated by two step overlap PCR mutagenesis 
using primer pairs (KR211/KR250) and (KR249/KR212) with Phusion polymerase. A second PCR 
was performed with primers (KR211/KR212) using primary PCR products as a template and the 
subsequent PCR products were digested with Nde1/BamHI and ligated into similarly digested 
pETphos to generate plasmid pKR85 expressing an N-terminal His6 tagged S400A enolase fusion 
protein. Plasmid cloning was subsequently verified by restriction enzyme digest and DNA 
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sequencing (Operon).  
For protein expression, plasmid pKR85 was transformed into BL21(DE3) cells and plated 
on LB ampicillin (100 µg/ml) agar plates. Single colonies were inoculated into 3 ml LB 
supplemented with ampicillin (100 µg/ml) for overnight cultures. The next day, 400 ml cultures 
were diluted 1:200 and grown to an OD600 of 0.6-0.8. Recombinant protein was induced by 
addition of IPTG (1mM) for 3h at 25 ºC. Cells were harvested at 6000 x g for 15 min at 4 ºC. 
Pellets were washed with ice-cold 50 mM EDTA and centrifuged at 7000 rpm for 15 min at 4 ºC. 
Washed pellets were saved at -80 ºC until use.  
 
2.32 Purification of recombinant enolase  
Frozen pellets from protein expression were suspended in lysis buffer (20 mM Tris pH 7.5, 
300 mM NaCl, 30mM imidazole, 10 mM β-mercaptoethanol, 0.2 % Triton-X 100, 10 mg/ml 
lysozyme, 1mM PMSF) and incubated on ice for 30 min. Initial lysis was carried out by four cycles 
of freeze/ thaw in dry ice/ethanol bath and 37 ºC. Lysate was passed through a 22-gauge needle 
and added to pre-chilled 2 mL screw cap tubes with 0.1mm silica beads. Cells were lysed using a 
FastPrep-24 5G instrument (MP Biomedical) using 2 rounds of 6.5 m/s intensity for 40 secs with 
4 min incubation on ice between rounds. Lysates were cleared by centrifugation at 20,000 xg for 
30 mins at 4 ºC. Cleared lysates were incubated in Pierce 5ml columns with Ni-NTA Agarose 
beads (Qiagen) at 4 ºC for 1 hr. Lysate was allowed to flow through and beads were washed 10 
column volumes of wash buffer (20 mM Tris pH 7.5, 300 mM NaCl, 30 mM imidazole, 10 mM 
β-mercaptoethanol). His6-tagged protein was eluted using 300 mM imidazole in 20 mM Tris pH 
7.5, 300 mM NaCl. Elution fractions were analyzed on a 12 % SDS-PAGE gel and fractions 
containing protein were pooled and dialyzed overnight at 4 ºC using Snakeskin dialysis tubing 
 58 
10K MWCO (Thermo Scientific) in enolase storage buffer (20 mM Tris pH 7.5, 50 mM NaCl, 100 
mM KCl, 10 % glycerol 1 mM DTT, 1 mM MgSO4). Dialyzed samples were concentrated and 
assessed for purity using a 12 % SDS-PAGE gel. The S400A variant was purified using the same 
protocol. Proteins were stored at -80 ºC. 
 
2.33 In vitro kinase assay using enolase as a substrate 
Transphosphorylation of His-Eno was performed by addition of 5 µCi of [g-32P] ATP (Perkin 
Elmer) to 0.5 µM of YegI-NTD, 2 µM of His-Eno in a 25µl of kinase reaction buffer containing 
50 mM Tris pH 7.5, 50 mM KCl, 1 mM DTT, 10 mM MgCl2, 10 mM MnCl2, 200 µM ATP. 
Reactions were incubated at 37 ºC for 1h and stopped using 3X Laemmli buffer and boiled for 5 
min at 95 ºC. Samples were resolved on a 12% SDS-PAGE gel and visualized by staining with 
Coomassie dye. Radioactive gels were dried for 30 mins at 80 ºC in a gel dryer. Dried gel was 
exposed to a phosphoscreen and visualized by autoradiography using a Typhoon Scanner (GE 
Healthcare).  
 
2.34 Cloning and expression of E. coli elongation factor-Tu (EF-Tu)   
The E. coli tufB gene encoding Elongation factor-Tu (EF-Tu) was PCR amplified using 
Phusion polymerase (Thermo Scientific) from MG1655 genomic DNA using primers 
(KR145/KR146). The PCR product was digested with BamHI/Xho1 and ligated into similarly 
digested pGEX-6p1 plasmid backbone. Ligation products were transformed into DH5α cells and 
selected on LB ampicillin plates. The resulting plasmid pKR61 generated an N-terminal GST-
tagged EF-Tu fusion protein.  
For protein expression, plasmid was transformed into BL21(DE3) cells and plated on LB 
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ampicillin (100 µg/ml) agar plates. Single colonies were inoculated into 3 ml LB supplemented 
with ampicillin (100 µg/ml) for overnight cultures. The next day, 250 ml cultures were diluted 
1:125 and grown to an OD600 of 0.6-0.8. Recombinant protein was induced by addition of IPTG 
(1mM) for 3h at 25 ºC. Cells were harvested at 6000 x g for 15 min at 4 ºC. Pellets were washed 
with ice-cold 50 mM Tris pH 7.5, 150 mM NaCl, 1 mM DTT and centrifuged at 7000 rpm for 15 
min at 4 ºC. Washed pellets were saved at -80 ºC until use.  
 
2.35 Purification of recombinant EF-Tu  
Purification of GST-EF-Tu was adapted from (148). Briefly, frozen pellets were suspended 
in lysis buffer (50 mM Tris pH 7.5, 100 mM NaCl, 2 mM β-mercaptoethanol, 1 mM PMSF, 0.5 
mM MgCl2, 0.2 mM GDP, 1% v/v Triton-X-100) and incubated on ice for 15 mins. Cells were 
subsequently lysed using sonication. Lysates were cleared by centrifugation at 15000 x g for 30 
min at 4 ºC and incubated in Pierce 5 ml columns with prepared immobilized glutathione beads 
(Pierce) at 4 ºC for 1 h. Immobilized glutathione beads were prepared by washing five times with 
five column volumes of lysis buffer. Lysate was allowed to flow through and beads were washed 
10 column volumes of wash buffer (50 mM Tris pH 7.5, 100 mM NaCl, 2 mM β-mercaptoethanol, 
0.5 mM MgCl2, 0.2 mM GDP). GST-tagged protein was eluted using 10 mM reduced glutathione 
(Calbiochem) prepared in wash buffer. Elution Fractions were tested on 12% SDS-PAGE gel and 
fractions containing protein were pooled and dialyzed overnight at 4 ºC using Snakeskin dialysis 
tubing 10K MWCO (Thermo Scientific) in 2X translation factor storage buffer (20 mM Tris pH 
7.5, 100 mM KCl, 1 mM MgCl2,10 mM β-mercaptoethanol, 0.4 mM GDP). Dialyzed protein was 
assessed for purity using 12% SDS-PAGE gel, glycerol was added to a final concentration of 50 
% and stored at -80 ºC.  
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2.36 In vitro kinase assay using EF-Tu as a substrate 
Transphosphorylation of GST-EF-Tu was performed by addition of 5 µCi of [g-32P] ATP 
(Perkin Elmer) to 2 µM of YegI-NTD, 2 µM of GST or GST-EF-Tu in a 25µl of kinase reaction 
buffer containing 50 mM Tris pH 7.5, 50 mM KCl, 0.5 mM DTT, 10 mM MgCl2, 10 mM MnCl2, 
200 µM ATP. Reactions were incubated at 37 ºC for 45 mins and stopped using 3X Laemmli buffer 
and incubated for 5 min at 95 ºC. Samples were resolved on a 12% SDS-PAGE gel and visualized 
by staining with Coomassie dye. Radioactive gels were dried for 30 mins at 80 ºC in a gel, exposed 
to a phosphoscreen and visualized by autoradiography using a Typhoon Scanner (GE Healthcare). 
  
2.37 Phosphorylation of EF-Tu in vivo  
2.37.1 Construction of pETDuet-1 co-expressing EF-Tu and tagless YegI-NTD.  
E. coli EF-Tu was phosphorylated in vivo by co-expression of tagless YegI N-terminal 
domain (YegI-NTD) and His6-tagged EF-Tu from a pETDuet-1 derived plasmid. The E. coli tufB 
gene encoding EF-Tu was first PCR amplified using Phusion polymerase (Thermo Scientific) from 
MG1655 genomic DNA using primers (KR293/KR294). The PCR product was digested with 
BamHI/Not1 and ligated into multiple cloning site (MCS-1) of similarly digested pETDuet-1 
plasmid backbone. Ligation products were transformed into DH5α cells and selected on LB 
ampicillin plates. The resulting plasmid pKR103 generated an N-terminal His6-tagged EF-Tu 
fusion protein with no co-expressing kinase.  
Derivative of pKR103 co-expressing a tagless YegI-NTD was constructed by PCR 
amplifying YegI-NTD (aa 1-390) using Phusion polymerase (Thermo Scientific) from REL606 
genomic DNA using primers (KR62/KR64). The PCR product was digested with BglII/Xho1 and 
ligated into multiple cloning site (MCS-2) of similarly digested pKR103 plasmid backbone. 
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Ligation products were transformed into DH5α cells and selected on LB ampicillin plates. The 
resulting plasmid pKR105 generated an N-terminal His6-tagged EF-Tu fusion protein co-expressed 
with tagless YegI-NTD.  
 
2.37.2 Expression and purification of phosphorylated EF-Tu 
For protein expression, plasmids (pKR103 or pKR105) were transformed into BL21(DE3) 
cells and plated on LB ampicillin (100 µg/ml) agar plates. Single colonies were inoculated into 3 
ml LB supplemented with ampicillin (100 µg/ml) for overnight cultures. The next day, 200 ml 
cultures were diluted 1:100 and grown to an OD600 of 0.6-0.8. Recombinant protein was induced 
by addition of IPTG (1 mM) for 3h at 25 ºC for plasmids pKR103 and pKR105 whereas for 
pKR104 recombinant protein was induced by addition of IPTG (1 mM) for 3h at 18 ºC. Cells were 
harvested at 6000 x g for 15 min at 4 ºC. Pellets were washed with ice-cold 50 mM EDTA and 
centrifuged at 7000 rpm for 15 min at 4 ºC. Washed pellets were saved at -80 ºC until use.  
Frozen pellets were suspended in lysis buffer (50 mM Tris pH 7.5, 300 mM NaCl, 10 mM 
β-mercaptoethanol, 10 mM imidazole, 2 mM PMSF, 0.5 mM MgCl2, 0.2 mM GDP, 1 mg/ml 
lysozyme, Halt phosphatase inhibitor cocktail (Thermo scientific) and incubated on ice for 5 mins. 
Cells were lysed using a FastPrep-24 5G instrument (MP Biomedical) using 2 rounds of 6.5 m/s 
intensity for 40 secs with 4 min incubation on ice between rounds. Lysates were cleared by 
centrifugation at 15000 x g for 30 min at 4 ºC . Cleared lysates were incubated in Pierce 5ml 
columns with Ni-NTA Agarose beads (Qiagen) at 4 ºC for 1 hr. Lysate was allowed to flow through 
and beads were washed 10 column volumes of wash buffer (50 mM Tris pH 7.5, 300 mM NaCl, 
10 mM β-mercaptoethanol, 30 mM imidazole, 0.5 mM MgCl2, 0.2 mM GDP, Halt phosphatase 
inhibitor cocktail (Thermo scientific). His6-tagged protein was eluted using 300 mM of imidazole 
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in 50 mM Tris pH 7.5, 300 mM NaCl, 0.5 mM MgCl2, 0.2 mM GDP. Elution fractions were 
analyzed on a 12 % SDS-PAGE gel and fractions containing protein were pooled and dialyzed 
overnight at 4 ºC using Snakeskin dialysis tubing 10K MWCO (Thermo Scientific)  in translation 
factor storage buffer (10 mM Tris pH 7.5, 50 mM KCl, 5 mM β-mercaptoethanol, 0.5 mM MgCl2, 
0.2 mM GDP). Dialyzed protein was assessed for purity using 12% SDS-PAGE gel and glycerol 
was added to a final concentration of 10 %. Protein was concentrated to 2 µg/µl using Amicon 
Ultra 10K centrifugal filters and stored at -80 ºC. 
 
2.38 In vitro translation of CotE-FLAG 
In vitro translation assay was carried out using a modified PURExpress system (New 
England Biolabs) following manufacturer’s instructions to transcribe and translate a C-terminal 
flag tagged CotE protein. A plasmid expressing a ~21kda CotE-FLAG protein has been previously 
used as a template for in vitro translation assay (133). The modified PURExpress system contains 
all the necessary components for synthesis of CotE-FLAG except elongation factor Tu (EF-Tu). 
170 ng of CotE-FLAG expressing plasmid (pSFP234) was added to a 5µl reaction ( 2.4 µl of 
Solution A + 1.56 µl of Solution B (-EF-Tu) + 0.7µl of sterile water). Translation reaction was 
initiated by addition of unphosphorylated or phosphorylated EF-Tu to a final concentration of 2 
µg. Reaction was incubated at 37 ºC for 10 mins and reactions were stopped using 30 µl of 3X 
Laemmli buffer and boiled for 5 min at 95 ºC. Samples were resolved on a 12% SDS-PAGE gel 
and transferred to a PVDF membrane at 4 ºC at 300 mA for 90 mins. PVDF membrane was 
subsequently blocked with 3 % BSA in PBS-T for 1h at room temperature. After blocking, 
membrane was probed with α-FLAG-HRP antibody (Sigma, 1:25000) and then detected using 
Super signal West Pico PLUS chemiluminescent substrate ( Thermo Scientific).  
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CHAPTER 3 
Identification and biochemical characterization of a novel PP2C-like Ser/Thr phosphatase 
in Escherichia coli 
 
This chapter is adapted from: 
 
Rajagopalan K, Dworkin J (2018). Identification and biochemical characterization of a novel 
PP2C-like Ser/Thr phosphatase in Escherichia coli. Journal of Bacteriology, JB.00225-18. 
 
This study was initiated to identify PP2C-like serine/threonine phosphatases in E. coli. I 
contributed to all the figures in the paper. I designed and performed all the experiments for the 
biochemical characterization of the phosphatase. I wrote the first draft of the manuscript and 
participated in the subsequent rounds of editing. 
 
3.1 Introduction 
Reversible protein phosphorylation is an important regulatory mechanism in eukaryotes and 
prokaryotes (149). In eukaryotes, signaling phosphorylation typically occurs on serine, threonine 
or tyrosine residues and is mediated by the combined action of kinases and phosphatases. In 
prokaryotes, signaling phosphorylation has been thought to occur largely on histidine and aspartate 
residues mediated by histidine kinases of two-component systems (14). However, mass 
spectrometry based-phosphoproteomic analyses over the past decades have identified numerous 
Ser/Thr/Tyr phosphorylated proteins in many bacteria (30, 113, 150), including Escherichia coli 
(114, 119, 123, 146). Some of these phosphoproteins and the specific phosphosites are conserved 
in divergent species (114) suggesting that this regulation may be physiologically relevant.   
Ser/Thr kinases from phylogenetically diverse bacteria have been described (30). For 
example, in E. coli, YeaG plays a role in nitrogen starvation (70), YihE is involved in the Cpx 
stress response (80) and cell death pathways (82) and HipA regulates bacterial persister formation 
by phosphorylating a tRNA synthetase (78, 79). However, both the authentic in vivo substrates of 
these kinases and/or their proximal activating stimuli are largely uncharacterized, complicating 
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efforts to understand their precise physiological role.   
Phosphorylation on serine or threonine residues is more stable than phosphorylation on 
histidine or aspartate residues and is subject to additional regulation by Ser/Thr phosphatases. 
Analysis of phylogenetically diverse bacterial genomes revealed the presence of genes encoding 
proteins (88, 89, 151) which bear significant resemblance to eukaryotic Ser/Thr PP2C 
phosphatases (89, 137) hence they are referred to as eukaryotic-like Ser/Thr phosphatases (eSTPs). 
Some of these proteins have been characterized biochemically and structurally, with these studies 
confirming their general similarity to their eukaryotic counterparts.  Eukaryotic Ser/Thr protein 
phosphatases are divided into two classes, either phosphoprotein phosphatases (PPP) or metal- 
dependent protein phosphatases (PPM), according to structure, presence of signature motifs, metal 
ion dependence and sensitivity to inhibitors (152). PPM phosphatases require Mg2+/Mn2+ to 
mediate dephosphorylation of phospho-serine or phospho-threonine residues. A well-studied 
member of the PPM phosphatase family is human protein phosphatase 2C (PP2C) (94) which bears 
a striking resemblance to bacterial PPM phosphatases. PPM/PP2C phosphatases are characterized 
by the presence of 11 signature motifs with 8 absolutely conserved residues (89, 152).  
While several bacterial PPM-type phosphatases have been biochemically characterized (100, 
101, 107, 153-157), PPM-type phosphatases have not been identified in E. coli despite strong 
evidence of Ser/Thr phosphorylation. Here, I characterize a previously undescribed ORF, yegK, 
that is present in both E. coli B and K strains. This ORF encodes a ~28 kDa protein which bears 
sequence similarity to PP2C-type phosphatases. We designate this gene pphC and its protein 
product as PphC. Recombinant PphC was purified and its enzymatic properties characterized. 
Despite some differences in sequence conservation as compared to other bacterial eSTPs, PphC 
resembles PP2C-type phosphatases in various biochemical assays. Furthermore, we show that 
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PphC dephosphorylates autophosphorylated YegI (a previously undescribed Ser/Thr kinase) which 
is encoded in the same operon as pphC. To our knowledge, this is the first report of the 
identification and biochemical characterization of an E. coli PP2C-like phosphatase.  
 
3.2 Results  
3.2.1 YegK is an atypical PP2C-like phosphatase 
To identify PP2C-like phosphatases in E. coli, I performed a homology-based BLAST search 
using Bacillus subtilis PrpC, a well-characterized PP2C-like phosphatase (100), as the query. This 
analysis revealed a previously uncharacterized 762 bp ORF, yegK, which encodes a putative 253 
amino acid polypeptide. Sequence analysis and domain prediction of YegK revealed that amino 
acids 11-232 have homology to a PP2C domain (Fig.3.1A). PP2C phosphatases include 11 
conserved signature motifs (29, 89). Multiple sequence alignment of YegK with known PP2C 
phosphatases from other Gram-negative bacteria shows presence of these 11 motifs but with low 
overall sequence similarity. However, unlike other bacterial PP2C homologs (107, 154, 155, 157, 
158), YegK contains only six of the eight absolutely conserved residues that are involved in metal 
binding, coordination and catalysis (Fig.3.1B). In particular, the amino acid sequence alignment 
clearly shows that YegK lacks the conserved glycine residue in motif VI and the aspartic acid 
residue in motif VIII (Fig. 3.1B). 
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Figure 3.1 YegK is an atypical PP2C-like phosphatase. 
(A) Domain architecture of YegK. Metal binding site D46 is highlighted in black. (B) Amino acid 
sequence alignment of YegK with bacterial PP2C-like phosphatases. YegK (Ec: Escherichia coli) was 
aligned to PP2C homologs from Gram-negative bacteria using T-coffee (159) and Boxshade. Identical 
residues are shaded in black and similar residues are shaded in gray. The eight absolutely conserved 
residues found in bacterial PP2Cs are depicted with asterisks. The conserved residues absent in YegK are 
indicated by arrows. Signature motifs seen in most bacterial PP2Cs are denoted as roman numerals based 
on Shi et al. (89). The aspartic acid residue involved in metal binding is depicted with open triangle. Te: 
Thermosynechococcus elongatus tPphA; Pa: Pseudomonas aeruginosa Stp1; Mx: Myxococcus xanthus 
Pph1; Se: Salmonella enterica serovar Typhi PrpZ (aa 1-260); Ct: Chlamydia trachomatis CTL0511 (Cpp1).  
 
 
Ec    1 MSWR----------------------LVYASAVGTSHISADLPCQDACQMQVAWLND--- 
Te    1 MD------------------------VAGLTDCGLIR----KSNQD------AFYID--- 
Pa    1 MQRT------------------EPWRSAARTDRGKVR----ARNED------AFL-D--- 
Mx    1 MRI----------------------EVAGSTHVGMKR----NHNED------NFL-M--- 
Se    1 MFTERLARWLARSSAKSGINRPEDLNAVLSTDIGLVR----AENQD------LIAAIRVN 
Ct    1 MIVA-------------------DFEYFGLSDVGLVR----HNNED------FWQVN--- 
 
 
Ec   36 -----QQPLLVMFLADGAGSVSQGGEGAKLAVNEAMAFMVQKVQDGEL--G--------- 
Te   24 -----EKHQRFFIVADGMGGHAGGEEASRLAVDHIRQYLETHLEDLQH-----------D 
Pa   29 -----CPDRGLWAVADGMGGHQAGDLASRMIVTSLAELPARAGFDERL------------ 
Mx   25 -----LPEEFLFCVADGMGGHSSGEIASRIAVDELGEFYKLTSKDQDYTWPFKMDKTRNY 
Se   51 TPSNVGNPFFAMALLDGMGGMQDGKQCATIALSTLFYSLIKFRSDPPE------------ 
Ct   29 ------YDSQLIAIADGMGGHRAGAVASYEAVGNLMQLVDLHKVDLER-FGD-----E-Q 
 
 
Ec   80 LNDVLATNMVLTIRQRLFAEAEAKALAV--RDFACTFLGLIS--S-ANGTLIMQIGDGGV 
Te   68 PVTLLRQAF-LAANHAIVEQQR-QNSAR--ADMGTTAVVILLDEK-GDRAWCAHVGDSRI 
Pa   72 --NAMRQCL-HWLNRRLGEELT-LSAERGDRIIGSTVVALVV--E-GSRAACVWVGDSRC 
Mx   80 DENRLATGV-KLANARIFEKAC-SESKY--KGMGTTIVTVHF--S-QSAVYVGHVGDSRV 
Se   99 --SRLLKAT-LEANSVVYD------YAK--GHGGSTLSAVII--ENGSAPVIVNVGDSRI 
Ct   76 YKESIKTIV-SEVNLLIYRQGL-SNEEF--KGMGTTLSCMQF--R-RGKAWLFHVGDCRV 
 
 
Ec  135 VVDFGR-GLELPLTPMVGEYANMTHFISDED-AVSRLETFTSTERAHKVAAFTDGIQRLA 
Te  123 YRWRKD-QLQ----QITSDHTWIAQAVQLGSLTIEQARQHPWRHVLSQCLGRED---LSQ 
Pa  125 YLWRGQ-RLY----QLSRDHSLLQRLIDERRMDIEQARAYPSARALTRAVGASE---QLV 
Mx  133 YYFRGG-ALK----QVTEDHSLLNDYLKAKKLSPEEIENFPHKNVIVRALGMKE---NVQ 
Se  146 YSFSLDCGLT----AISSDDSLEALGGR--------------GRGLLQFIGMG---ESIK 
Ct  129 YRLRNK-MLE----RLTEDHSLANHLASRYGLSKQSVKRYPGRNVLTNVLGSR---PHVS 
 
 
Ec  193 LNMLDNSPHVP-FFTPFFNGLA-AAT----QEQLDLLPELLK--QFLSSPAVNERTDDDK 
Te  175 IDIQPIDLEPGDRLLLCSDGLTEELTDDVISIYLS-EPNVQKAAAALVDAAKTHGGRDNV 
Pa  177 LDVLELEVHPGDVFLLCSDGLYEELSADALGRALS-LASPQVAVERLFDGALSGAARDNL 
Mx  185 VDVSRVEPQEDDVFLLCSDGLSGMVTDAQMQEILQRTPELEKACSQLIDMANAAGGNDNV 
Se  185 PHINILDKNHK-NIILTSDGTH-FISHSAFEELLSHSSDFSTSAQRIAQYVQWCGAKDNA 
Ct  181 LDIREMSYEKEDLFVFCSDGLTSAVSDHDMLDILTQTTTLEEGGNILISLANSRGGRDNA 
 
 
Ec  245 TLALALWLP--------- 
Te  234 TVVVIS---V-------- 
Pa  236 TAVVIR---Q-------- 
Mx  245 TCVLARYHAA-------- 
Se  243 SFGIINCNDIENSLNSHK 
Ct  241 TVILVRMR---------- 
 
 
 
I
*II III
* IV V
* *Va Vb VIIVI
*VIII
**
IX X
*XI
PP2C like domain 
1 25311 232
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A
A
B
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A predicted structure of YegK using Phyre2 algorithm (Fig. 3.2B) closely resembles the 
published structure of the bacterial PP2C-like phosphatase PphA (Fig.3.2A) from 
Thermosynechococcus elongatus (95) consisting of β-sheets and a catalytic core in the center 
surrounded by exterior alpha helices. In addition, yegK is located immediately upstream of yegI, 
an ORF which encodes a protein with homology to eukaryotic-like Ser/Thr kinases, consistent 
with the observation that bacterial Ser/Thr kinases and phosphatases are often located in operons 
(30). Taken together, these observations suggest that, despite the absence of two highly conserved 
residues, yegK likely encodes a PP2C-like phosphatase.  
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Figure 3.2 Predicted structure of YegK (PphC) resembles crystal structure of eSTP 
Thermosynechococcus elongatus PphA.  
(A) Crystal structure of Thermosynechococcus elongatus PphA (PDB ID 2J86) (95). (B) Predicted structure 
of E. coli YegK (PphC). The Phyre2 algorithm (160) was used to predict structural model of YegK (PphC). 
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3.2.2 Biochemical characterization of YegK  
To demonstrate that yegK encodes a functional protein phosphatase, the 762 bp fragment 
was cloned in frame with an N-terminal six-histidine tag into the pBAD24 vector (161). The 
plasmid was transformed into E. coli C43 (DE3) and following protein expression, the cell lysate 
was subjected to affinity purification using Ni2+-NTA resin and subsequent analysis by SDS-
PAGE. The protein migrated at an apparent molecular mass of ~25 kDa, similar to the calculated 
molecular mass of 28.18 kDa (Fig 3.3A). The phosphatase activity of purified YegK was 
determined using an absorbance-based assay which measures the hydrolysis of p-nitrophenyl 
phosphate to p-nitrophenol. Formation of p-nitrophenol detected at an absorbance of 405 nm is 
directly proportional to the phosphatase activity which is expressed as nmol of pNP formed/µg 
protein. Consistent with the alignment (Fig. 3.1B), YegK displayed a time-dependent increase in 
phosphatase activity (Fig. 3.3B)  suggesting that it is an active protein phosphatase. We have 
therefore renamed YegK as PphC (Protein phosphatase C) following the nomenclature of two 
previously characterized E. coli protein phosphatases PphA and PphB (162) and the bacterial 
PP2C-like phosphatase PphA from T. elongatus (95) 
To further confirm the bioinformatic identification of PphC as a PP2C-like phosphatase, the 
aspartic acid residue (D46) in motif II was mutated to asparagine. A similar approach was used in 
the analysis of the PP2C-like phosphatase Cpp1 from Chlamydia trachomatis (154). The mutant 
protein (PphC-D46N) was purified as above and phosphatase activity was compared to wild-type 
PphC. PphC-D46N displays no hydrolysis of pNPP suggesting that the aspartic acid residue is 
essential for catalytic activity (Fig. 3.3B). To ensure that the loss of activity of PphC-D46N was 
not a consequence of improper folding, PphC and PphC-D46N were subjected to size exclusion 
chromatography. The gel filtration elution profile shows that PphC-D46N eluted as a single peak 
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and at the same retention volume as PphC indicating that the loss of phosphatase activity observed 
with the PphC-D46N mutant is most likely due to a loss of catalytic activity (Fig. 3.3C).  
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Figure 3.3 YegK is an active phosphatase.  
(A) Coomassie brilliant blue stained 10% SDS-PAGE gel. Purified WT and D46N PphC (2 μg) migrate at 
an apparent molecular mass of ~25Kda. (B) Assessment of phosphatase activity of YegK using pNPP 
as substrate. Reactions were performed at 37 ºC for 60 mins with 350 nm of phosphatase (WT/D46N 
mutant), 5mM pNPP substrate in phosphatase assay buffer (20mM Tris pH 8.0 and 5mM MnCl2). (C) Size 
exclusion chromatography profile of WT and D46N YegK. His6-tagged protein (10nmol) was loaded on 
a Superdex 75 size exclusion column and eluted in 20 mM Tris pH 8.0, 50 mM NaCl, 1 mM DTT, 1 mM 
MnCl2.  
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PP2C phosphatases belong to the PPM family of metal-dependent Ser/Thr phosphatases that 
require either Mg2+ or Mn2+ for activity (29, 152). The requirement for a divalent cation for PphC 
phosphatase activity was assessed by measuring hydrolysis of pNPP in the presence of either 
MgCl2/MnCl2/CaCl2/ZnCl2/NiCl2. Since pNPP hydrolysis was only observed in the presence of 
MnCl2 but not MgCl2,CaCl2, ZnCl2, NiCl2, PphC is a Mn2+ dependent phosphatase (Fig. 3.4A,B). 
This result is consistent with the requirement for Mn2+ ion for previously characterized bacterial 
PP2Cs (101, 153-157). The concentration dependence of PphC phosphatase activity on Mn2+ was 
measured and the optimal MnCl2 concentration was determined to be between 1-2 mM (Fig. 3.4C) 
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Figure 3.4 PphC (YegK) is a Manganese dependent PP2C-like phosphatase.  
Metal dependency of PphC phosphatase was tested using pNPP as a substrate. (A) Reactions were 
carried out at 37 ºC for 60 min in buffer containing 350 nM phosphatase, 5 mM pNPP substrate  with either 
5 mM MgCl2/ MnCl2/CaCl2/NiCl2/ZnCl2. (B) Reactions were carried out at 37 ºC for 60 min in buffer 
containing 350 nM phosphatase, either 5mM MgCl2 or 5mM MnCl2, or both, with 5mM pNPP substrate. (C) 
Effect of Mn2+ concentration on PphC catalytic activity using pNPP as a substrate. Reactions were 
carried out at 37 ºC for 30 min in assay buffer containing 350 nM phosphatase, 5 mM pNPP substrate and 
different concentrations of MnCl2.  
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The effect of different classes of protein phosphatase inhibitors on PphC phosphatase activity 
was tested using pNPP as a substrate (Table 3.1). PphC activity dramatically decreased in the 
presence of general protein phosphatase inhibitor sodium phosphate and was slightly affected by 
sodium fluoride (~30% decrease at 100 mM). Okadaic acid, a known inhibitor of PP1 family of 
phosphatases (163), did not inhibit PphC activity. PphC activity was also unaffected by sodium 
orthovanadate, a known tyrosine phosphatase inhibitor. Aurin tricarboxylic acid and 5,5’ 
Methylene disalycilic acid which were previously reported to inhibit Staphylococcus aureus Stp1 
(99, 164) had little effect on PphC phosphatase activity. Similarly, sanguinarine chloride an 
inhibitor of Human PP2Ca (165) did not affect phosphatase activity. However, a ~60% decrease 
in activity was detected in the presence of bivalent metal chelator EDTA confirming that PphC is 
a metal dependent phosphatase. Together, these data are consistent with the characterization of 
PphC as a PP2C-like phosphatase.  
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Table 3.1. Effect of inhibitors on PphC activitya. 
Sr.No. Inhibitors (Concentration) % Relative activityb 
1 No inhibitor 100 
2 Sodium phosphate (5 mM) 13 
 Sodium phosphate (10 mM) 6 
3 Sodium fluoride (10 mM) 81 
 Sodium fluoride (100 mM) 70 
4 Sodium orthovanadate (5 µM) 87 
 Sodium orthovanadate (50 µM) 95 
5 Okadaic acid (0.1 µM) 91 
 Okadaic acid (1 µM) 88 
6 EDTA (1 mM) 63 
 EDTA (2 mM) 38 
7 Aurin tricarboxylic acid (25 µM) 82 
 Aurin tricarboxylic acid (50 µM) 66 
 Aurin tricarboxylic acid (100 µM) 52 
8 5,5’ Methylene disalycilic acid (25 µM) 100 
 5,5’ Methylene disalycilic acid (100 µM) 87 
9 Sanguinarine chloride (50 µM) 98 
 
a Reactions were carried out at 30 ºC for 15 min in buffer containing 150 nM phosphatase with 5 mM pNPP 
in the presence or absence of inhibitors. 
b Relative activity was calculated as a percentage of phosphatase activity in the presence of inhibitor versus 
activity in absence of inhibitor.  
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3.2.3 PphC phosphatase activity is different in closely related E.coli strains.                  
 I identified striking differences in the genetic architecture surrounding the pphC (yegK) 
locus in E. coli K and B strains. Specifically, in the E. coli B strain REL606, pphC (yegK) is 
immediately upstream of yegI, an ORF encoding a putative Ser/Thr kinase, whereas in the E. coli 
K strain MG1655, yegJ, a putative ORF, is located between the pphC (yegK) and yegI genes facing 
the opposite direction (Fig. 3.5A). This different genomic organization is conserved in other K and 
B strains, suggesting that it pre-dates the divergence of these lineages (166). A reasonable 
prediction is that pphC and/or yegI expression would be affected by the presence of the divergently 
oriented yegJ, but as I have not identified conditions under which we can robustly detect pphC 
expression, it has not been possible to evaluate this prediction. 
In addition to this difference in the genetic architecture around the pphC locus, multiple 
sequence alignment of pphC from a K strain (MG1655) and a B strain (REL606) revealed that 
only ~92 % of the PphC sequence is conserved (Fig. 3.5B). This is in contrast to the extremely 
high degree of sequence identity typically observed for the E. coli proteome: more than half the 
proteins in MG1655 have 100 % sequence identity with the corresponding protein in REL606 
(166).   
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Figure 3.5 PphC locus and amino acid sequence differs in closely related E. coli strains.  
(A) Genetic map of yegK/yegI operon from E. coli B strain REL606 and K strain MG1655: Thick arrows 
denote ORFs. The genes yegL, yegK and yegI encode a von Willebrand factor type A, a PP2C-like 
phosphatase and an eukaryotic-like Ser-Thr kinase respectively. The gene mdtA encodes a  subunit of a 
multidrug efflux pump and yegD encodes an actin family protein.  The yegJ gene encodes a protein of 
unknown function.  (B) Amino acid sequence alignment of PphC from E. coli B strain REL606 and K 
strain MG1655. Identical residues are shaded in black and similar residues are shaded in gray. Signature 
motifs seen in bacterial PP2C phosphatases are depicted as Roman numerals based on (89). The aspartic 
acid residue involved in metal binding is conserved and indicated by open triangle. The conserved residues 
found in bacterial PP2Cs are depicted with arrows.  
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To determine whether these differences in amino acid sequence affect phosphatase activity, 
the gene product of yegK from E. coli MG1655 was over-expressed and purified by the same 
method used to purify REL606 PphC. The enzyme kinetics of the two proteins was compared 
using the pNPP assay (Fig. 3.6A). Phosphatase activity (pmol pNP/min/µg) was determined with 
increasing concentrations of pNPP and Km and Vmax values were calculated (Fig. 3.6B). Since the 
Km and Vmax of Rel606 PphC is lower than those of MG1655 PphC (Fig. 3.6C), it reaches a 
maximum velocity at a lower substrate concentration. Similarly, the Kcat values were calculated to 
be 0.2089 s-1 and 0.093s-1 for REL606 and MG1655 PphC, respectively. Previously reported 
kinetic values for known bacterial PP2Cs range from 0.35 mM to 5.7 mM pNPP for Km, 0.1-
4.5µmole/min/mg for Vmax and 0.1 to 7.4 s-1 for Kcat (96, 100, 101, 154-156, 167-170), indicating 
that PphC has relatively low phosphatase activity in vitro as compared to previously characterized 
bacterial PP2C-like phosphatases.  
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Figure 3.6 PphC phosphatase activity differs in closely related E. coli strains. (A and B) Enzyme 
kinetics of PphC from REL606 and MG1655 strains. Substrate-dependent activity was assessed using 
different concentrations of pNPP (0.1-6.4 mM) in assay buffer containing 350 nm phosphatase and 5 mM 
MnCl2. Data were fitted to a Michaelis-Menten curve (A) and a Lineweaver-Burk plot (B). The Lineweaver-
Burk plot was used to determine Km, Vmax and Kcat values (C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
A B
Parameters REL606 PphC [B strain] MG1655 PphC [K strain]
Km 0.2750 ± 0.04009mM 0.2119 ± 0.03647mM
Vmax 223.3± 7.896 pmol/min/µg 99.85± 3.833 pmol/min/µg
Kcat 0.2089 s-1 0.093s-1
Kcat/Km 0.759*103 M-1s-1 0.440*103 M-1s-1
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3.2.4 Substrate specificity of PphC 
The results of the pNPP assay suggested that PphC has phosphatase activity. Therefore, I 
investigated whether PphC is capable of dephosphorylating a protein substrate. β-casein is 
phosphorylated on five serine residues at the N-terminus (171) and was used as a model protein in 
our assay. Using Mn2+-Phos-tag/SDS-PAGE to monitor phosphorylation state (172), untreated β-
casein migrated at an apparent molecular mass of 30 kDa (Fig. 3.7A, lane 1), but β-casein that had 
been pre-incubated with PphC in MnCl2 buffer exhibited a mobility shift (Fig. 3.7A, lane 2). Since 
such a change is indicative of a loss in phosphorylation, PphC likely dephosphorylated the serine 
residues of β -casein. Further, this mobility shift was not detected following incubation of β-casein 
with the catalytic mutant PphC-D46N (Fig. 3.7A, lane 4). Dephosphorylation of β-casein by PphC 
and not PphC-D46N was also observed in MgCl2 buffer (Fig.3.7B). However, the extent of 
dephosphorylation was 2-fold lower in comparison to MnCl2 buffer. These results indicate that 
PphC is capable of acting as a serine phosphatase in a Mn2+ or a Mg2+ dependent manner. 
The substrate specificity of PphC was further examined using commercially available 
phosphopeptides. Previously characterized PP2Cs have demonstrated preferential specificity to 
phosphoserine/threonine peptides over phosphotyrosine peptides (154, 155, 158, 167). 
Phosphatase assays were performed with phosphoserine RRA(pS)VA, phosphothreonine 
KR(pT)IRR and phosphotyrosine RRLIEDAE(pY)AARG peptide substrates (Fig. 3.7C). In 
MnCl2 buffer, PphC released two-fold and six-fold more phosphate in the presence of the 
phosphotyrosine peptide as compared to the phosphothreonine peptide and phosphoserine peptide, 
respectively. In comparison to MnCl2 buffer, PphC activity in MgCl2 buffer towards all 
phosphopeptides was substantially lower further confirming that PphC is a Mn2+ dependent 
phosphatase. To confirm that the phosphopeptides are capable of being dephosphorylated, I used 
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a known PP2C-like phosphatase (B. subtilis PrpC) as a positive control. As expected, PrpC 
dephosphorylated both serine and threonine residues and had minimal activity to tyrosine (Fig. 
3.7D). Thus, since PphC had overall minimal activity on phosphopeptides in comparison to PrpC, 
they may not be ideal substrates for PphC.  
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Figure 3.7 Effect of bivalent cations on PphC phosphatase activity using β-casein and 
phosphopeptides as substrates. Dephosphorylation reactions were carried out at 37 ºC for 60 min in 
buffer containing 50 mM Tris pH 8, 4 μg phosphorylated β-casein, 1.5 μg (9 µM) phosphatase in the 
presence of 10 mM MnCl2 (A) or 10 mM MgCl2 (B) and examined on Mn2+ Phostag/SDS-PAGE (C) 
Comparison of synthetic phosphopeptide specificity of E. coli PphC (WT and D46N) in MgCl2 or 
MnCl2 buffer.  Dephosphorylation reactions were carried out at 37 ºC for 30 min in assay buffer containing 
350 nM PphC phosphatase and 200 μM phosphopeptide. Amount of free phosphate was measured using 
malachite green assay. (D) Synthetic phosphopeptide specificity of B. subtilis PrpC phosphatase.  
Dephosphorylation reactions were carried out at 37 ºC for 30 min in assay buffer containing 350 nM PrpC 
phosphatase and 200μM phosphopeptide. Amount of free phosphate was measured using malachite green 
assay. B. subtilis PP2C-like phosphatase PrpC was purified as previously described (105). 
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3.2.5 Identification of a PphC substrate 
Ser/Thr phosphatases can regulate reversible phosphorylation by dephosphorylating a 
Ser/Thr kinase or by dephosphorylating a substrate protein. Three genes encoding  Ser/Thr kinases 
yihE, hipA and yeaG have been identified in E.coli,  but their physiological substrates are largely 
unknown. The exception is HipA, an atypical Ser/Thr kinase that has similarity to the 
phosphatidylinositol-3/4 kinase family. HipA overexpression results in cell growth arrest and 
autophosphorylation of Ser-150 is crucial for this arrest in cell growth suggesting that kinase 
activity plays an important role in maintaining cell growth arrest (73). hipA was first identified for 
its role in bacterial persistence, a non-inherited epigenetic state which allows a subpopulation of 
slow growing cells to survive in the presence of antibiotics (75, 76). More recently, the molecular 
mechanism by which HipA mediates bacterial persistence has been characterized (78, 79). HipA 
phosphorylates glutamyl tRNA synthetase (GltX) at Ser-239 and thereby inhibits GltX function. 
Since phosphorylated GltX is unable to aminoacylate tRNA, uncharged tRNAs accumulate at the 
ribosome and this accumulation results in the activation of the stringent response and subsequent 
cell growth arrest. This growth arrest is thought to be essential for persister cell formation since 
non-growing cells are phenotypically tolerant to many antibiotics. However, the advantages gained 
by this state would be lost if the cells are unable to re-initiate growth at some future time. Thus, 
how is HipA or GltX phosphorylation reversed? Since phosphorylation on Ser/Thr residues is a 
stable modification, a dedicated phosphatase is required to reverse this modification. Therefore, I 
hypothesized that PphC is the Ser/Thr phosphatase responsible for dephosphorylation of HipA 
and/or GltX.  
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To test if HipA is a PphC substrate, I first expressed and purified N-terminal His6-tagged 
HipA recombinant protein from BL21(DE3) cells using Ni2-NTA chromatography. It has been 
previously reported that recombinant HipA when purified from E.coli, is about 65-90% 
phosphorylated on Ser150 (73, 173). Using Mn2+-Phos-tag/SDS-PAGE to monitor 
phosphorylation state (172), purified untreated HipA migrated ~55kda (Fig. 3.8A, lane 1) but HipA 
that had been preincubated with a non-specific lambda protein phosphatase in MnCl2 displayed a 
mobility shift (Fig. 3.8A, lane 2). Since faster mobility on Phos-tag containing SDS-PAGE is 
indicative of loss of phosphorylation, this confirmed previous observations that HipA is 
phosphorylated during purification. However, when HipA was preincubated with PphC-WT (Fig. 
3.8A, lane 3) or with PphC-D46N (Fig. 3.8A, lane 4), there was no difference in mobility as 
compared to untreated HipA suggesting that HipA is not a PphC substrate. 
To test if phosphorylated GltX is a substrate for PphC, I first expressed and purified N-
terminal His6-tagged GltX recombinant protein from BL21(DE3) cells using Ni2+-NTA 
chromatography. Following an in vitro kinase reaction with HipA and GltX in the presence of cold 
ATP , I examined GltX phosphorylation state using Mn2+-Phos-tag/SDS-PAGE. Consistent with 
previous reports (78, 79), I was able to detect the phosphorylated form of GltX that migrated 
~60kDa, as compared to unphosphorylated form (~50kda) (Fig. 3.8B, lane 1).  Although HipA 
migrates close to ~50kDa, I was unable to visualize HipA due to the low concentrations used in 
the reaction (~0.2 µM). After the kinase reaction, I dialyzed the samples to remove free unlabeled 
ATP. I observed a mobility shift when phosphorylated GltX was preincubated with the non-
specific Lambda protein phosphatase (Fig. 3.8B, lane 2), but I was unable to see any mobility shift 
when preincubated with PphC-WT(Fig. 3.8B, lane 3), or with PphC-D46N(Fig. 3.8B, lane 4). 
Taken together, these results suggest that neither HipA nor GltX is a substrate for PphC.  
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Figure 3.8 Effect of PphC on HipA kinase and phosphorylated GltX  
(A) Effect of PphC on HipA kinase. Dephosphorylation reactions contained  2 µM of phosphorylated HipA 
and 4 µM PphC (WT or D46N) in reaction buffer as described in materials and methods. For control reaction, 
400 U of Lambda protein phosphatase (LPP) was used in reaction buffer. Reactions were stopped at t=1 h 
and analyzed on Mn2+-Phostag/SDS-PAGE. Molecular weights are denoted on the right as kDa.  
(B) Effect of PphC on phosphorylated GltX. Kinase reactions contained 0.2 µM HipA and 2 µM GltX in 
reaction buffer for 45 mins. Dialyzed kinase reactions were used to setup dephosphorylation reactions at 
37 ºC with either 400 U of LPP or 4 µM PphC-WT or 4µM of PphC-D46N.   Dephosphorylation reactions 
were stopped at t=1 h and analyzed on Mn2+-Phostag/SDS-PAGE. Molecular weights are denoted on the 
right as kDa. 
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Bacterial PP2C-like phosphatases are often present in the same operon as a Ser/Thr kinase 
(30) and the kinase is often itself a substrate of the phosphatase (100-102, 157). As noted above, 
pphC(yegK) is located immediately adjacent to yegI, a 1947 bp ORF encoding a 648 amino acid 
protein with homology to eukaryotic-like Ser/Thr kinases (Fig. 3.5A). (30). Thus, to examine if 
YegI could serve as a substrate for PphC, autophosphorylated YegI kinase (Fig. 3.9, lane 1) was 
incubated in the presence of wild type or D46N mutant PphC and assayed for loss of 
phosphorylation. While wild type PphC dephosphorylates YegI kinase, as indicated by the loss of 
the radiolabeled band (Fig. 3.9, lane 2), this effect is not seen following incubation with the 
catalytic mutant PphC-D46N (Fig. 3.9, lane 3). Interestingly, while PphC-D46N is 
phosphorylated, phosphorylation of wild type PphC is not observed (Fig. 3.9, lane 2), suggesting 
that either PphC can dephosphorylate itself or that inactivation of the YegI kinase by PphC could 
result in decreased phosphorylation of PphC-WT.  
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Figure 3.9 Effect of PphC on YegI kinase. 
(Left panel) Effect of PphC on YegI kinase. Dephosphorylation reactions were carried out at 37 ºC with 2 
µM of phosphorylated YegI and 4 µM PphC in reaction buffer as described in materials and methods. 
Reactions were stopped at t=45mins and run on 12% SDS-PAGE followed by autoradiography. Molecular 
weights are denoted as kDa. (Right panel) Percent relative 32P incorporation was calculated by 
densitometry analysis using FIJI software. Data represents the mean +/- SE of five independent 
experiments. Statistical analysis used unpaired T-test ( *** P value<0.0001).  
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3.2.6 Phosphorylation of PphC by co-encoded kinase 
In these assays, a weak phosphorylation product of ~25kDa corresponding to PphC-D46N 
was observed (Fig. 3.9, lane 3), suggesting that YegI could transphosphorylate PphC. Low levels 
of phosphorylation of PphC could be due to weak transphosphorylation potential of YegI. In order 
to obtain more robust phosphorylation of PphC, we expressed and purified the N-terminal region 
of YegI (aa 1-390) which includes the predicted kinase domain (aa1-300). The purified protein is 
annotated as YegI-NTD. Firstly, I tested if PphC serves as a substrate for YegI-NTD. Using 
radioactive kinase assay, I observed autophosphorylation of YegI-NTD (Fig. 3.10, lane 1) 
suggesting that the purified N-terminal domain of YegI is an active kinase. Furthermore, I observed 
of robust phosphorylation of PphC by YegI-NTD in a time dependent manner (Fig. 3.10, lane 3-5) 
validating PphC as a potential substrate for YegI-NTD.  
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Figure 3.10 Phosphorylation of PphC by YegI-NTD. 
Phosphorylation reactions were carried out at 37 ºC with 0.5 µM of YegI-NTD alone (lane 1) or 2 µM PphC 
alone (lane 2) or both (lane 3-5) in kinase assay reaction buffer as described in materials and methods. 
Reactions were stopped after addition of [𝜸-32P]ATP at indicated times and run on 12% SDS-PAGE followed 
by autoradiography. Molecular weights are denoted as kDa. 
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Since PphC phosphorylation was more robust with YegI-NTD as compared to YegI, 
subsequent phosphopeptide detection using mass spectrometry was performed using in vitro kinase 
assay sample of PphC that has been incubated with/without YegI-NTD (Fig. 3.11A). Samples were 
submitted to the Columbia University Medical Center Herbert Irving Cancer Center Proteomics 
Center. To identify the phosphorylation site(s) of PphC, Dr. Emily Chen performed mass 
spectrometry analysis. She identified one phosphopeptide corresponding to serine residue at 
position 174 (Fig. 3.11B, C).  
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Figure 3.11 YegI-NTD phosphorylates PphC on Ser-174. 
(A) Phosphorylation reactions were carried out at 37 ºC with 5.32 µM of PphC alone (lane 1) or 5.32 µM 
PphC in the presence of 1.33µM of YegI-NTD (lane 2) in kinase assay reaction buffer for mass spectrometry 
as described in materials and methods. 10µl of sample was run on 12% SDS-PAGE to verify sample 
homogeneity. (B) Amino acid sequence of PphC. Residues will full coverage are shown in black color and 
residues with no coverage are indicated in gray color. Phosphorylated residue Ser-174 is indicated by red 
circle. N-terminal his tag used for purification of PphC is underlined. (C) Representative MS/MS spectra of 
phosphopeptide obtained after trypsin digestion of PphC.  
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To examine if PphC phosphorylation on serine 174 has any impact on phosphatase activity 
in vitro, I purified a mutant protein where I replaced the serine residue at position 174 to an alanine 
residue (PphC-S174A). Although I observed robust phosphorylation of PphC on Ser-174 using 
mass spectrometry data, I was unable to demonstrate any effect of this modification on PphC 
activity in vitro (Fig.3.12). Using β-casein as a substrate, PphC-S174A dephosphorylated β-casein 
similarly to PphC-WT (Fig. 3.12A). While a slight difference in the rate of dephosphorylation as 
compared to the wildtype was observed, this difference was not statistically significant suggesting 
that Ser174 residue may be not be important for phosphatase activity, at least in vitro. To test if 
phosphorylation of PphC affects phosphatase activity, I modified the pNPP assay by first 
performing an in vitro kinase reaction of PphC (WT or S174A) and YegI-NTD to obtain P~PphC 
followed by addition of pNPP. Using pNPP as a substrate, I observed no difference in phosphatase 
activity between unphosphorylated PphC and phosphorylated PphC (P~PphC) (Fig.3.12B). 
Similar to the β-casein result, I observed a slight decrease in phosphatase activity of PphC-S174A 
as compared to PphC-WT;  however, this difference was also not statistically significant. Together, 
these results show that phosphorylation of PphC at Ser-174 has no significant impact on 
phosphatase activity in vitro.  
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Figure 3.12 S174A mutation of PphC does not impact phosphatase activity . 
(A) β-casein as a substrate: Dephosphorylation reactions were carried out at 37 ºC for indicated timepoints 
in buffer containing 50 mM Tris pH 8, 4 μg phosphorylated β-casein, 1.5 μg (9 µM) phosphatase in the 
presence of 10 mM MnCl2. (B) Effect of phosphorylation on phosphatase activity of PphC using pNPP as 
substrate. In vitro kinase reactions were performed with 350nM of phosphatase ( WT/S174A mutant) in the 
presence or absence of 89 nM YegI-NTD for 45 mins at 37 ºC in reaction buffer as described in materials 
and methods. 5 mM pNPP was added and absorbance at 405nM was recorded for 60 mins. 
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3.3 Discussion 
Mass spectrometry-based phosphoproteomic analysis has revealed that many Ser/Thr/Tyr 
residues undergo phosphorylation in phylogenetically diverse species. In most cases, the kinases 
and phosphatases responsible for these modifications have not been identified, although the 
presence of homologs of eukaryotic Ser/Thr kinases and phosphatases in most (if not all) bacterial 
species suggest that they could play a role. These so-called eukaryotic-like Ser/Thr kinases and 
their partner PP2C-like Ser/Thr phosphatases have extensive structural and biochemical similarity 
with their eukaryotic counterparts (30). In E. coli, extensive Ser/Thr phosphorylation has been 
observed, with several studies reporting >75 phosphorylated proteins (114, 119, 123, 146). 
However, the kinases and phosphatases responsible for making or removing these modifications 
are not known. Here, I have described biochemical analysis of PphC, a protein product of a 
previously undescribed E. coli ORF, yegK, that encodes the first reported PP2C-like Ser/Thr 
phosphatase in E. coli. 
   PphC contains all of the 11 conserved motifs present in PPM/PP2C phosphatases (29, 89, 
151, 152). However, unlike bacterial PP2C-like phosphatases from other Gram-negative bacteria, 
PphC has only 6 out of the 8 absolutely conserved residues involved in metal co-ordination and 
catalysis (95, 96, 98). Specifically, PphC lacks a conserved glycine residue in motif VI and a 
conserved aspartate residue in motif VIII (Fig. 3.1B). The aspartate residue in motif VIII is 
important for metal ion co-ordination in bacterial PP2C-like phosphatases (95, 96, 98). Despite 
these differences in amino acid sequence, PphC effectively hydrolyzed the chromogenic substrate 
pNPP, suggesting that the requirement of all 8 residues as a criterion for assessing the likelihood 
that an ORF encodes a PP2C-like phosphatase may be too stringent. 
The regulation of PP2C-like phosphatases has been studied in a number of contexts including 
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Mycobacterium tuberculosis PstP whose activity is stimulated by phosphorylation on multiple Thr 
residues by two eukaryotic-like Ser/Thr kinases (174). Although I observed that PphC is 
phosphorylated at residue Ser 174 by its partner Ser/Thr kinase YegI (Fig. 3.11), I was unable to 
detect any effect of on PphC activity using phosphoablative mutant (Fig. 3.12). Another regulatory 
mechanism occurs in the B. subtilis SpoIIE protein, a PP2C-like phosphatase that plays an essential 
role during sporulation. A single residue in SpoIIE (Val-697) mediates an alpha-helical switch that 
changes the coordination of a metal ion in the active site and thereby activates the phosphatase 
(175). However, since this residue is not conserved in PphC, a similar regulatory mechanism is 
probably not operating in the context of PphC function. 
Bacterial PP2C-like phosphatases are known to dephosphorylate pSer/pThr containing 
peptides (154-156). PphC was initially identified using a homology search using B. subtilis PrpC 
but unlike PrpC (Fig. 3.7D), PphC displayed low preference for pSer/pThr/pTyr peptides (Fig. 
3.7C). This minimal activity against phosphopeptides is in contrast to the ability of PphC to 
dephosphorylate the pSer containing protein substrate b-casein. A possible explanation could be 
that PphC may require additional residues for substrate recognition and/or binding that are not 
present in the phosphopeptides. However, this is not likely to be a sufficient explanation as b-
casein is a generic substrate that would not be expected to contain specificity determinants for 
PphC. Alternatively, this result suggests that there may be limits to using phosphopeptide 
dephosphorylation as an accurate assay of PP2C-like phosphatase function.  
Bacterial eukaryotic-like Ser/Thr kinases and PP2C-like phosphatases are often encoded in 
the same operon and in many cases the kinase is a substrate for the phosphatase (100, 101, 153, 
157). Similarly, in the E. coli B strain REL606, the ORF yegI encodes a putative eukaryotic-like 
Ser/Thr kinase and is located immediately downstream of pphC. My data demonstrate that YegI is 
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a substrate of PphC (Fig. 3.8). However, in E. coli K strain MG1655, there is a putative intervening 
ORF, yegJ, located between the yegI and pphC genes and that is transcribed divergently (Fig. 
3.5A), suggesting potential regulatory differences between the two strains. I have been unable to 
observe transcription of the pphC locus under any conditions, so we do not know if yegJ has an 
effect on expression of this locus. Interestingly, mutations in yegI, the gene encoding the partner 
kinase of PphC, repeatedly emerge in long-term evolution experiments (176), suggesting that this 
kinase/phosphatase pair may have significant fitness effects. Consistently, the presence of the 
potentially disruptive yegJ locus in the K lineage may be also reflect these effects. However, at 
present, in the absence of a deeper understanding of the physiological role of YegI/PphC pair, these 
effects remain mysterious.  
In addition to the differences in the genome organization around pphC in the E. coli B and 
K lineages, the amino acid sequence of PphC differs between the two strains, with several non-
conservative substitutions. This observation is intriguing given that half of the proteome is 
identical between these two strains (166). Although these differences are not in residues that are 
absolutely conserved among bacterial PP2C-like phosphatases (95, 96, 98), they may have 
functional consequences since the two proteins exhibited modest differences in enzyme kinetics 
(Fig. 3.6). Future work will be aimed at identifying the impact of specific substitutions in the 
residues that differ on the relative activity of the different PphC alleles. 
Finally, PP2C phosphatases play important roles in cellular regulation in more complex 
systems including mammals (152). One issue in investigating PP2C function in these in vivo 
contexts is that specific chemical inhibitors do not exist. Thus, the bacterial homologs such as 
PphC may be useful in identifying cell-permeable inhibitors, both because of the technical 
tractability of the organism as well as the presence of only a single PP2C-phosphatase gene in the 
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genome. 
In summary, this study provides the first evidence for the existence of a PP2C-like 
phosphatase in E. coli. Despite some differences in sequence conservation as compared to other 
PP2Cs, PphC is an active PP2C-like phosphatase, albeit with lower Km and Vmax values than other 
bacterial PP2Cs. Future studies will be required to identify physiological substrates of PphC and 
to ascertain its physiological role in vivo. I expect that further characterization of PphC’s partner 
kinase, YegI (see Chapter 4), will greatly facilitate these efforts. 
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CHAPTER 4 
Characterization of a novel membrane Ser/Thr kinase in Escherichia coli 
 
 
4.1 Introduction 
Protein phosphorylation on Ser/Thr residues was widely assumed to be present only in 
eukaryotes and absent in prokaryotes. This assumption was challenged by phosphoproteomic 
analysis of phylogenetically diverse bacterial species that identified numerous proteins to be 
phosphorylated on Ser/Thr residues. For example, phosphoproteomic studies of the Gram-negative 
bacterium Escherichia coli identified ~100 proteins modified on Ser/Thr residues (114). However, 
the enzymes responsible for this phosphorylation in E. coli have not been identified to date.  
Bacterial Ser/Thr kinases can be divided into two classes based on their structure and 
sequence homology: eukaryotic-like Ser/Thr kinases (eSTKs) and atypical Ser/Thr  kinases. 
eSTKs bear striking resemblance in structure and function to Hanks family Ser/Thr kinases from 
eukaryotes (30). Unlike eSTKs, atypical Ser/Thr kinases lack any sequence homology to 
eukaryotic kinases. So far, three genes (hipA, yeaG, yihE) encoding Ser/Thr kinases have been 
reported in E.coli of which HipA and YihE are atypical Ser/Thr kinases while YeaG is an eSTK.  
HipA resembles a eukaryotic phosphatidyl inositol 3/4-kinase and was found to be involved 
in bacterial persistence (73). Bacterial persistence is an epigenetic state exhibited by a 
subpopulation of slow growing cells that display enhanced survival in the presence of antibiotics. 
This state is temporary and can be readily reversed by removal of antibiotic treatment. HipA 
regulates bacterial persistence by phosphorylating a substrate protein glutamyl tRNA synthetase 
(GltX) on a single serine residue. Phosphorylated GltX can no longer aminoacylate tRNA, leading 
to accumulation of uncharged tRNAs at the ribosome which in turn inhibits translation, induces 
the stringent response and thereby results in persistence. (78, 79).  
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YihE was identified as an atypical Ser/Thr kinase that shares significant structural homology 
to eukaryotic choline kinases but lacks several of the absolutely conserved residues in the catalytic 
loop (80). While the transphosphorylation of YihE has not been shown with physiological 
substrates, it transphosphorylates the generic protein substrate myelin basic protein (MBP) (82). 
YihE was shown to play a role in regulating stress response leading to programmed cell death in 
E. coli (82) although little mechanistic insight is available. YeaG was the first eSTK to be reported 
in E. coli (66). YeaG functions in modulating transcription of methionine biosynthetic genes, 
facilitating adaptation of cells to sustained nitrogen stress (70, 71). 
      Although these Ser/Thr kinases have been shown to be active in the cell and participate in 
regulating various cellular physiological processes, the substrates for these kinases have not been 
characterized in vitro except in the case of HipA. Similarly the Ser/Thr kinases/phosphatases 
responsible for the Ser/Thr phosphorylation of proteins reported in E.coli phosphoproteomics 
studies are not known(114, 119, 177).  
I recently reported the identification and characterization of a PP2C-like Ser/Thr 
phosphatase PphC in E.coli (178) (Chapter 3). PphC is the first PP2C-like phosphatase to be 
characterized in E.coli. In our efforts to identify a substrate for PphC, we noted an adjacent gene, 
yegI, that encodes a putative Ser/Thr kinase. In this chapter, I describe the biochemical 
characterization of YegI, an integral membrane Ser/Thr kinase with two Helix-hairpin-Helix 
(HhH) motifs in the C-terminal domain. Additionally, I show that a strain carrying a deletion of 
yegI exhibited decreased susceptibility of cells to the β-lactam antibiotic cefotaxime and to the 
DNA damage inducing agent nalidixic acid.  
Using comparative phosphoproteomics and an in vitro kinase assay, I identify the glycolytic 
enzyme enolase as a substrate for YegI. Finally, I demonstrate that elongation factor Tu (EF-Tu) 
 100 
is a target for YegI in vitro and this phosphorylation inhibits the function of EF-Tu in protein 
synthesis.  
 
4.2 YegI is a novel eukaryotic-like Ser/Thr kinase  
Analysis of the genome of  E. coli strain REL606 revealed the presence of a 1941bp orf yegI 
which encodes a 646 amino acid protein YegI predicted to be a Ser/Thr kinase. In E. coli REL606 
and in several pathogenic strains such as E. coli O157:H7 EDL933, yegI occurs in the same 
putative operon as a PP2C-like phosphatase pphC (yegK) with a four nucleotide overlap (ATGA) 
at the 5’ end suggesting that the genes could be cotranscribed. Alternatively, in E. coli K strains 
(e.g., MG1655/W3110), the yegI-pphC operon is disrupted by yegJ, encoding a protein of 
unknown function (Fig. 4.1A). Amino acid sequence analysis and alignment of YegI with bacterial 
eSTKs (Fig. 4.1B) revealed the presence of Hanks signature motifs (I-XI) suggesting that YegI is 
an authentic eukaryotic-like Ser/Thr kinase (eSTK) (13). Although YegI contains all the Hanks 
signature motifs, it contains only seven out of the ten absolutely conserved residues that are 
commonly found in eSTKs. For example, in motif III, YegI has an aspartic acid residue instead of 
the conserved glutamic acid (Fig.4.1B). The conserved glutamic acid residue which contacts Lys-
39 in Motif II for stable binding of α and β phosphates of ATP (35). YegI also lacks the conserved 
asparagine (replaced by serine) in motif VI that together with catalytic site Asp-141 and Asp-159 
is important for stability of Mg2+ ion binding (35).  Lastly, YegI lacks a conserved arginine 
(replaced by glycine) in motif XI that is important for stabilizing the substrate-protein interactions 
(Fig.4.1B).  
In order to identify how these sequence changes affect the structure, I created a homology 
model of the YegI kinase domain (aa1-300) with the crystal structure of M. tuberculosis eSTK 
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PknB (PDB 1MRU) as a template using Swiss-model (179). Despite the absence of three 
conserved residues, the predicted structure of the YegI kinase domain shows all the structural 
features seen in M. tuberculosis eSTK PknB (Fig.4.1C) suggesting that YegI is an eSTK. 
Specifically, YegI adopts the canonical bilobed structure seen in eSTKs. The N-terminal lobe of 
the YegI kinase domain contains the ATP binding P-loop and the helix C structure (See Fig.4.1B, 
C) which is responsible for proper orientation of active site with substrate protein. The C-terminal 
lobe includes the catalytic loop which contains all the residues required for catalysis and an 
activation loop which is important for kinase activation by autophosphorylation. Although overall 
the YegI sequence is only ~20% identical to PknB (Fig.4.1B), the predicted structure of YegI is 
very similar to solved structure of PknB (Fig.4.1D), strongly suggesting that YegI is an eukaryotic-
like Ser/Thr kinase.     
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Figure 4.1 YegI is a novel eukaryotic-like ser/thr kinase  
(A)Genome organization of yeg operon in different E. coli strain backgrounds. Thick arrows denote 
orfs. Genes yegL, pphC, yegI encode a predicted Von Willebrand factor, a PP2C-like phosphatase and an 
eukaryotic-like Ser/Thr kinase respectively. The yegJ gene encodes a protein of unknown function. E. coli 
strain backgrounds are indicated on the right.  
(B) Amino acid sequence alignment of YegI with bacterial eSTKs. YegI (Escherichia coli) was aligned 
to bacterial eSTKs PrkC (Bacillus subtilis), PknB (Mycobacterium tuberculosis) and PpkA (Pseudomonas 
aeruginosa) using T-coffee (159). Alignment was visualized using Jalview. Absolutely conserved residues 
are shaded in dark blue whereas residues conserved in three out of the four kinases are shaded in light 
blue. The ten absolutely conserved residues found in bacterial eSTKs are depicted with arrows. Hanks 
conserved domains are depicted on top of the sequence as roman numerals (I-XI). YegI (aa 1- 303), PrkC 
(aa 1-269), PknB (aa 1-275) and PpkA (aa 1-265) which includes the kinase domain was used for alignment. 
Structurally and functionally important motifs are indicated below the sequence. 
(C) Predicted structure of YegI kinase domain (aa 1-302). The Phyre2 algorithm (160) was used to 
predict structural model of YegI kinase domain. Structurally important motifs such as P-loop (pink),  Helix 
C (green), Catalytic loop (red), activation loop( yellow) and P+1 loop (black) are indicated in structure. 
Corresponding amino acid sequences are depicted in (B).  
(D) Structural overlay of predicted structure of YegI kinase domain (blue) and Mycobacterium tuberculosis 
eSTK PknB (pink) (Protein data bank PDB:1MRU). Mg2+ ion is represented as a grey sphere. 
 
4.3 Biochemical properties of YegI  
4.3.1 Expression and Purification of YegI  
Although the predicted structure of YegI revealed striking similarities to the structure of M. 
tuberculosis eSTK PknB, three of the ten absolutely conserved residues of the Hanks family STKs 
were absent raising the question of whether YegI is an active kinase. Domain prediction of YegI 
revealed the presence of a Ser/Thr catalytic domain (aa 13-300), two transmembrane domains (aa 
391-411, 414-436) and a C-terminal domain (aa 436-646). To directly test if YegI exhibits kinase 
activity, I first expressed and purified either recombinant His6-tagged YegI or a His6-tagged 
fragment of YegI that includes the entire N-terminal fragment encompassing the Ser/Thr kinase 
domain and 90 residues of the linker to the transmembrane helix (YegI-NTD) (Fig. 4.2A). 
Plasmids expressing YegI and YegI-NTD were transformed in C43(DE3) cells and expression was 
confirmed by western blot analysis with an α-his antibody (Fig.4.2B). I detected a 72 kDa and a 
43.5 kDa band, likely corresponding to YegI and YegI-NTD respectively post induction with 
arabinose confirming that both proteins were expressed. Since YegI has two predicted 
transmembrane domains, lysis and purification was carried out in the presence of anionic detergent 
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N-lauryl sarcosine to facilitate solubilization and purification. N-lauryl sarcosine has been shown 
to help with cell lysis as well as protein solubility of membrane bound proteins (180). Using N-
lauryl sarcosine, I was able to successfully purify both the full length form (Fig.4.2C) and the N-
terminal domain of YegI (Fig.4.2D). However, SDS-PAGE analysis showed the presence of an 
equally abundant protein at 25 kDa. This co-purifying protein could be one of two possibilities: a 
potential interacting protein which forms a complex with YegI or a his-tag affinity purification 
contaminant. To examine these possibilities, purified protein samples were submitted to the 
Columbia University Medical Center Herbert Irving Cancer Center Proteomics Center. Dr. Emily 
Chen performed MALDI Peptide Mass Fingerprinting of the 25kDa gel band. She identified that 
the 25kDa protein was indeed a common his-tag affinity purification contaminant,  peptidyl-prolyl 
cis/trans-isomerase (SlyD), thus ruling out the possibility of co-purification of an interacting 
partner. To avoid co-purification of SlyD, YegI and YegI-NTD were expressed in a SlyD mutant 
strain LOBSTR (181) which lacks the histidine-rich region of SlyD thereby preventing SlyD from 
binding to Ni2+-NTA beads. As expected, expression of YegI and YegI-NTD in the LOBSTR 
strain eliminated the 25kDa contaminating SlyD to yield pure protein (Fig. 4.2E,F).  
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Figure 4.2 Expression and purification of His-YegI and His-YegI-NTD 
(A) Graphical representation of domain architecture of YegI. Amino acids corresponding to different 
domains are indicated at the top. TM: Transmembrane domain. Amino acid boundaries for YegI (aa 1-
646) and YegI-N terminal domain YegI-NTD (1-390) are indicated.  
(B) Western blot analysis using α-HIS antibody to confirm expression of His-YegI and His-YegI-
NTD. Molecular weights (kDa) are indicated on the left. U represents Uninduced culture at OD600:0.8. 1 
and 2 represents samples taken at 1h and 2h post induction with 0.2% arabinose respectively.  
(C) Purification of YegI from C43(DE3) using Ni-NTA resin. Sample after elution from Nickel beads 
was verified by gel electrophoresis. A 25kDa band corresponding to Peptidyl-prolyl cis/trans-isomerase 
(SlyD), a common his contaminant that co-purifies with YegI is indicated.  
(D) Purification of Yeg-NTD from C43(DE3) using Ni2+-NTA resin. Sample after elution from Nickel 
beads was verified by gel electrophoresis.  
(E) Purification of YegI from LOBSTR using Ni2+-NTA resin. U: Uninduced sample, I: Induced fraction, 
TL: Total lysate after sonication and overnight lysis with 2% sarkosyl, SF: Soluble fraction, FT: Flow 
through after Ni-NTA binding , 1-5: Elutions with 300mM imidazole.  
(F) Purification of YegI-NTD from LOBSTR using Ni2+-NTA resin: same as in (E) 
 
4.3.2 YegI is an active kinase  
Despite the absence of three of the ten absolutely conserved residues (Fig. 4.1B), I 
demonstrated that His-YegI is indeed an active kinase capable of autophosphorylation (Chapter 3, 
Fig.3.9) (178). YegI contains a conserved lysine at position 39 and a conserved aspartic acid site 
at position 141, both of which are known to play a crucial role in ATP binding and catalysis 
respectively (28). To confirm that the kinase activity depends on both these residues, I generated 
lysine to aspartic acid (K39D), lysine to alanine (K39A) and aspartic acid to asparagine (D141N) 
mutations in YegI. Single point mutants were expressed and purified in the same manner as the 
WT YegI. Kinase activity was demonstrated using an in vitro radioactive kinase assay using 
radiolabeled 𝜸-[32P] ATP. Mutation of either Lys-39 or Asp-141 resulted in complete loss of 
autophosphorylation activity of YegI as compared to WT indicating that both residues are essential 
for kinase activity (Fig.4.3A).  
Staurosporine is widely used as a small molecule inhibitor for Ser/Thr kinases (182) . 
Eukaryotic Ser/Thr protein kinases are sensitive to staurosporine with IC50 in the nM range (183). 
Sensitivity of the YegI kinase to staurosporine was assessed by incubating YegI with increasing 
µM concentrations of staurosporine. In comparison to eukaryotic protein kinases, YegI shows an 
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IC50 of 50 µM (Fig.4.3B). This is comparable to  the  Enterococcus faecalis eSTK IreK which has 
an IC50 of 150 µM (53) and the Staphylococcus epidermis eSTK Stk  which has as  IC50 of 320 
µM (184).   
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Figure 4.3 YegI is an active kinase  
(A) Kinase activity of YegI: Autophosphorylation reactions were carried out at 37 ºC with 0.2 µM of YegI 
(WT or K39D, D141N or K39A) in kinase buffer (50 mM Tris pH 7.5, 50 mM KCl, 1 mM DTT, 10 mM MgCl2, 
10 mM MnCl2, 200 µM cold ATP and 5 µCi 𝜸-[32P]ATP. Reactions were stopped at t=30 mins and run on 
12 % SDS-PAGE followed by autoradiography. Molecular weights (kDa) are indicated on the right of the 
gel.  
(B) Sensitivity to staurosporine: Autophosphorylation reactions were carried out at 37 ºC with 1 µM of 
YegI (WT) in kinase buffer without cold ATP. Different concentrations of staurosporine (µM) was added to 
the reaction at indicated concentrations. Reactions were stopped at t=30 mins and run on 12% SDS-PAGE 
followed by autoradiography. Molecular weights are indicated on the right of the gel.  
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4.3.3 Metal ion requirement of YegI  
Bacterial eSTKs require the presence of bivalent cations for activity (34, 101, 153, 185). To 
test the effect of different bivalent cations on YegI activity, radioactive kinase assays were 
performed in the presence of either MgCl2/MnCl2/CaCl2/NiCl2. Similar to many eSTKs, YegI and 
YegI-NTD catalyzed autophosphorylation only in the presence of MgCl2 and MnCl2, albeit to 
different levels. Both YegI (Fig.4.4A) and YegI-NTD (Fig.4.4B) displayed much higher 
autophosphorylation in the presence of Mn2+ ion than Mg2+ ion suggesting that YegI is a Mn2+ 
dependent kinase.  
The structures of eukaryotic kinases indicate that the DFG motif present in domain VII 
coordinates Mg2+ ion binding (33, 186). However, YegI does not contain the DFG sequence which 
is instead replaced by the residues DSD (Fig.4.1B). To examine if addition of the DFG motif to 
YegI alters preference to MgCl2, I generated point mutations to replace the DSD motif with DFG: 
serine to phenylalanine at position 160 and aspartic acid to glycine at position 161 (S160F, 
D161G). Point mutants were expressed and purified in the same manner as the WT YegI and kinase 
activity in the presence of MgCl2/MnCl2 was assessed. Surprisingly, replacement of DSD to DFG 
completely inactivated the kinase (Fig.4.4C) indicating that the DSD motif is indispensable for 
YegI autophosphorylation.  
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Figure 4.4 YegI is Mn2+ ion dependent kinase  
(A) Requirement of bivalent cations: Autophosphorylation reactions were carried out at 37 ºC with 1 µM 
of YegI (WT) in kinase buffer with either 10 mM of MgCl2/ MnCl2, CaCl2/ NiCl2. Reactions were stopped at 
t=30 mins and run on 12% SDS-PAGE followed by autoradiography  
(B) Requirement of bivalent cations: Autophosphorylation reactions were carried out at 37 ºC with 1 µM 
of YegI-NTD (WT) in kinase buffer as described in (A) 
(C) Requirement of  DFG motif: Autophosphorylation reactions were carried out at 37 ºC with 0.2 µM of 
YegI (WT or S160FD161G or D161G) in kinase buffer with either 10 mM of MgCl2/ MnCl2 as described in 
(A) 
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4.3.4 Autophosphorylation of YegI 
Autophosphorylation is a common model for activation of eukaryotic kinases (33), therefore 
identifying the sites of autophosphorylation can provide insight into how these kinases are 
activated. To map the sites of autophosphorylation, phosphopeptide detection using mass 
spectrometry was performed using His-YegI that had been subjected to an in vitro kinase reaction. 
Samples were submitted to the Columbia University Medical Center Herbert Irving Cancer Center 
Proteomics Center. To identify the autophosphorylation site(s) of YegI, Dr. Emily Chen performed 
mass spectrometry analysis and identified two phosphopeptides that each included a serine residue: 
at position 602 and 644 at the C-terminus of YegI (Fig. 4.5A). To confirm the sites of 
autophosphorylation, I mutated both serine residues to alanine (S602AS644A). The mutant protein 
was expressed and purified in the same manner as WT and assessed for loss of autophosphorylation 
using a radioactive kinase assay. I observed that mutation of both Ser-602 and Ser-644 led to a 
decrease in autophosphorylation but not a complete loss suggesting that there are additional sites 
of autophosphorylation (Fig.4.5B).  
Since eSTKs have previously been shown to undergo autophosphorylation on serine or 
threonine residues particularly in the activation loop of the kinase domain (41, 111, 187, 188), the 
lack of observable autophosphorylation in this region of YegI was surprising. Therefore, we 
repeated the mass spectrometry analysis using in vitro phosphorylation samples with the His-YegI-
NTD protein instead to identify phosphorylation sites primarily in the kinase domain. Dr. Emily 
Chen identified three phosphopeptides corresponding to serine residues at position 153, 160 and 
162 in the kinase domain (Fig.4.5A). Ser-153, Ser-160 and Ser-162 are located between Motif VI 
and VII in close proximity to the catalytic loop and activation loop and therefore I hypothesized 
that these residues could be important for kinase activity.  
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To characterize the functional role of the autophosphorylation sites of YegI-NTD, I mutated 
all three serine residues to alanine (S153A, S160A, S162A). The triple mutant protein was 
expressed and purified in the same manner as the WT and assessed for loss of autophosphorylation. 
In contrast to full-length YegI, I observed that mutating all three residues (S153A, S160A, S162A) 
in YegI-NTD lead to complete loss of autophosphorylation (Fig. 4.5C), suggesting that 
phosphorylation of Ser-153, Ser-160 and Ser-162 residues could be play an important role in 
activation of YegI kinase. The impact of individual phosphoablative mutants on YegI activation 
is yet to be assessed.  
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Figure 4.5 YegI autophosphorylation occurs on Ser residues in the catalytic loop and at the C-
terminus 
(A)Graphical representation of YegI and YegI-NTD: Domain structure depicting phosphorylation sites 
following mass spectrometry analysis of autophosphorylation. Phosphorylated residues are indicated by 
red circles.  
(B) Sites of autophosphorylation on YegI: Reactions were carried out at 37 ºC with 1 µM of YegI (WT or 
S602AS644A) in kinase buffer. Reactions were stopped at t=30 mins and run on 12 % SDS-PAGE followed 
by autoradiography. Molecular weights (kda) are indicated on the right of the gel.  
(C) Sites of autophosphorylation on YegI-NTD: Reactions were carried out at 37 ºC with 1 µM of YegI-
NTD (WT or S153AS160AS162A) in kinase buffer. Reactions were stopped at t=30 mins and run on 12 % 
SDS-PAGE followed by autoradiography. Molecular weights (kDa) are indicated on the right of the gel.  
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4.4  Topology and domain organization of YegI  
4.4.1 YegI is an inner membrane protein  
Recombinant protein purification of YegI required the presence of the anionic detergent N-
lauryl sarcosine suggesting that YegI could be a membrane protein. Additionally, examination of 
the protein sequence using the domain prediction algorithm Phobius (189) predicted that YegI 
protein has two transmembrane domains joined by a short periplasmic loop and with both the N- 
and the C-terminus of the protein in the cytosol (Fig. 4.6A).  
To test if YegI is a membrane bound protein, I utilized the PhoAlacZα dual reporter system 
to experimentally validate the predicted topology of YegI. The PhoAlacZα dual reporter system 
has been widely used to examine the topology of membrane proteins (190-193). Specifically, a 
reporter with mature alkaline phosphatase (PhoA, aa 21-471) lacking the periplasmic localization 
signal is fused in frame with the α-fragment of E. coli β-galactosidase (LacZα, aa 5-60).  PhoA is 
active only in the bacterial periplasm whereas LacZ is only active in the cytoplasm. Therefore 
when the protein of interest fused with PhoAlacZα is targeted to the periplasm or to the membrane, 
the reporter fusion displays high phosphatase activity but no β-galactosidase activity. On the 
contrary, if the protein of interest fused with PhoAlacZα is targeted to the cytoplasm, then reporter 
fusion displays high β-galactosidase activity with no phosphatase activity. PhoAlacZα reporter 
fusions can be assessed using dual indicator plates with PhoA or LacZ specific chromogenic 
substrates that allow identification of periplasmic or cytoplasmic fusions (192). Cells expressing 
PhoAlacZα protein fusions with high levels of phosphatase activity are able to process the X-phos 
(5-bromo-4-chloro-3-indolyl phosphate) substrate resulting in blue colored colonies, while cells 
expressing PhoAlacZα protein fusions with high levels of β-galactosidase activity enzymatically 
process the Red-gal (6-chloro-3-indolyl-β-D-galactoside) substrate to yield red colored colonies. 
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  I constructed in-frame C-terminal pho-lac fusions expressing E. coli alkaline phosphatase 
fragment (PhoA, aa 21-471) in frame with the α-fragment of E. coli lacZ (aa 5-60) in an arabinose 
inducible pBAD24 plasmid. C-terminal pho-lac fusions were made to YegI at amino acid positions 
340, 390, 414, 432, 439 and 646 (Fig. 4.6A). E. coli DH5α cells have low endogenous phosphatase 
activity (∆phoA) and are capable of β-galactosidase α-complementation (E. coli LacZ∆M15), 
therefore DH5α cells were used for the expression of pho-lac fusions. DH5α cells expressing just 
the empty backbone vector pBAD24 (shown as (C) in Fig.4.6.B) was used as a negative control, 
while DH5α cells expressing phoAlacZα without YegI (shown as phoAlacZα in Fig.4.6.B) was 
used as a positive control. The resulting transformants were streaked on dual indicator plates 
containing chromogenic substrates X-phos and Red-gal. As expected, cells expressing pBAD24 
(negative control) formed colorless colonies on dual indicator plates, while cells expressing 
PhoALacZα without YegI yielded red/pink colonies indicative of cytoplasmic location (Fig.4.6B). 
Consistent with the in silico prediction, PhoAlacZα fusions of YegI at amino acid positions 340, 
390, 439 and 646 yielded red/pink colored colonies on indicator plates suggestive of high β-
galactosidase activity and cytoplasmic localization (Fig.4.6B,C). In contrast, PhoAlacZα fusions 
of YegI at amino acid positions 414, 432 yielded blue colored colonies on indicator plates 
suggestive of high alkaline phosphatase activity and periplasmic/TM localization. (Fig.4.6 B,C).  
In summary, the PhoAlacZα reporter fusions confirmed the bioinformatic prediction that YegI is 
an integral inner membrane protein containing two TM domains connected by a short periplasmic 
loop, with both the N- and C-terminus located in the cytosol. 
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Figure 4.6 YegI is an inner membrane protein  
(A) Predicted topology of YegI using Phobius. Amino acid positions at which phoA-lacZα reporters are 
fused are indicated along with associated phenotypes. Phenotypes of phoAlacZα fusions due to LacZ 
activity are denoted as red ellipses while PhoA activity are denoted as blue ellipses. Predicted 
transmembrane domains ( I and II) are depicted as grey rectangles.  
(B) Membrane topology analysis: DH5α transformed with different phoAlacZα reporters were streaked 
on an LB plate containing 5-bromo-4-chloro-3-indolyl phosphate disodium salt (X-Phos, 80µg/ml), 6-chloro-
3-indolyl-β-D-galactoside (Red-Gal, 100 µg/ml, 0.1 % w/v arabinose and 100 µg/ml of ampicillin. C: control 
strain expressing pBAD24 empty vector, phoAlacZα: strain expressing phoAlacZα in pBAD24 without YegI. 
Amino acid positions at which phoAlacZα reporters are fused are indicated.  
(C) Localization of different phoAlacZα reporter fusions.  
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4.4.2 YegI contains two predicted Helix-hairpin-Helix motifs in the C terminal domain  
Sequence analysis and domain prediction revealed that the YegI cytoplasmic C-terminal 
domain contains two predicted Helix-hairpin-Helix (HhH) motifs corresponding to aa 516-535 and 
aa 546-565 respectively (Fig.4.7A). The HhH motif is a 20 amino acid nonspecific DNA binding 
motif which forms a hydrogen bond with DNA phosphate groups through the backbone protein 
nitrogen atoms. The HhH motif is formed by two antiparallel α- helices that are connected by a 
short hairpin loop (194). Sequence alignment of the two HhH motifs (HhH1 and HhH2) in YegI 
with known HhH containing proteins showed an absolute conservation of glycine residues at 
position 8 and 10 forming the GXG motif where X corresponds to a hydrophobic residue 
(Fig.4.7B). GXG motif is responsible for the hairpin formation as well as binding to DNA. 
Furthermore, positions 3, 6, 9, 17 and 18 in YegI show the presence of small hydrophobic residues 
(VILMFYWA) which is crucial for orientation of α-helices.  
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Figure 4.7 YegI contains two Helix-hairpin-helix motifs at the C-terminus. 
(A) Graphical representation of domain architecture of YegI with 2 HhH motifs. Amino acids 
corresponding to different domains are indicated at the top. HhH: Helix hairpin helix motif  
(B) Amino acid sequence alignment of YegI HhH motifs and known HhH containing proteins. 
Absolutely conserved residues are indicated in dark blue and highlighted by dotted red box. Partially 
conserved residues ( four out of seven motifs) are shaded in light blue. Pol_B1 and Pol_B2: HhH1(aa 59-
74)and HhH2 (aa 100-115) from Rat Polymerase β1, Pol_1: T.aquaticus polymerase I, Endo: HhH from E. 
coli Endonuclease III (aa 111-126), AlkA: HhH from E. coli AlkA (aa 209-224)  
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4.5 YegI expression 
Gene reporter fusions have been widely used to study transcriptional and translational 
regulation (195). For example, expression of a gene of interest that is translationally fused to the 
lac operon (lacZY) can be determined by β-galactosidase assays. To determine when YegI is 
expressed in E. coli REL606, I generated a yegI in-frame deletion strain in E. coli REL606 where 
I removed  aa 9-624 using Lambda red recombination as described (141). Using FLP/FRT 
recombinase system, I then constructed a translational fusion of yegI to lacZ from ∆yegI-FRT 
using pCE40 as described (142) such that yegI (aa1-8) fused to FRT site is in-frame with a 
translational lacZ fusion. I confirmed the conversion of the FRT site in ∆yegI-FRT generated from 
pKD13 (141) to a translational lacZ fusion by sequencing. The translational yegI::lacZ fusion was 
made in a ∆lacZ background to prevent background β-galactosidase activity due to endogenous E. 
coli LacZ. I observed a slight increase in β-galactosidase activity from yegI::lacZ only in stationary 
phase cultures of LB (24h) as compared to strain lacking the translational fusion (Fig. 4.8) 
suggesting that YegI might be expressed only in stationary phase. However, the expression was 
very low (0.01 β-galactosidase Miller units) when to compared endogenous LacZ levels which 
usually corresponds to 1-2 β -galactosidase miller units in log phase suggesting that when grown 
in LB,  endogenous YegI protein levels are very low.  
 
 
 120 
 
Figure 4.8: YegI is expressed in stationary phase albeit at low levels. 
Expression of YegI-lacZ translational fusion was determined using β-galactosidase assay. Strains KR181 
(∆lacZ) and KR188 (∆lacZ yegI::lacZ) were grown at 37 ºC in LB to log and stationary phase and β -
galactosidase activity (miller units) was calculated. 
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4.6 Phenotypic analysis of YegI  
4.6.1 yegI is not essential for growth in minimal media 
To determine the physiological role of yegI, I used the yegI in-frame deletion strain in E. coli 
REL606 where I removed aa 9-624 using Lambda red recombination (141). The resulting strain 
was confirmed by colony PCR and sequencing. Deletion of eSTKs in B. subtilis (106), S. pyogenes 
(170), E. faecalis (196) showed significant defects in cell growth. To test if ∆yegI also displayed 
a growth defect, WT and ∆yegI strains were grown in chemically defined minimal media (MinA) 
with glucose or glycerol as a carbon source (144). However, I did not observe any significant 
difference in growth in minimal media between the WT strain and the ∆yegI strain (Fig. 4.9A,B)  
suggesting that deletion of yegI did not have any impact on growth in minimal media. 
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Figure 4.9 Deletion of yegI does not affect growth of E. coli in minimal media. 
(A) Strains WT (JDE2735) and ∆yegI (KR160) were grown in MinA medium with 0.4% w/v glucose for 20h 
in a plate reader and OD600 was measured every 10 mins. 
(B) Strains WT (JDE2735) and ∆yegI (KR160) were grown in MinA medium with 0.4% w/v glycerol for 20h 
in a plate reader and OD600 was measured every 10 mins.  
 
 
 
 
 
 
 
 
A
B
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4.6.2 Antibiotic susceptibility  
In Gram-positive bacteria, deletion of genes encoding eSTKs results in increased sensitivity 
to cell wall targeting antibiotics. For example, E. faecalis eSTK IreK kinase activity is required 
for increased resistance to cell wall targeting antibiotics such as cephalosporins (52). Similarly 
deletion of the S. aureus eSTK STK resulted in a marked increase in sensitivity to cephalosporins 
and carbapenems (49). Based on the rationale that alteration of eSTKs could affect antibiotic 
susceptibility, I compared E. coli REL606 WT and ∆yegI strains to screen for differences in 
susceptibility to ten antibiotics of different classes (listed in Table 4.1).  
I used the microtiter broth dilution method for determination of Minimum inhibitory 
concentrations (MICs) (197). Briefly,  bacterial cultures (equivalent to 106 cfu/ml) were inoculated 
into Mueller Hinton Broth containing 2X of the actual concentration of antibiotics tested in a 96 
well microplate. The lowest dilution that exhibits minimal inhibition of growth represents the MIC. 
I observed that the ∆yegI strain displayed decreased sensitivity to cell wall targeting antibiotics 
belonging to the cephalosporin class of β-lactam antibiotics (Table 4.1).  Specifically, I observed 
an 8-16 fold difference in sensitivity to 3rd generation cephalosporins (cefotaxime, ceftriaxone) 
and a 4-fold decrease in sensitivity to cefoxitin (2nd generation) and cefipime (3rd generation). WT 
and ∆yegI showed little or no difference in susceptibility to inhibitors of protein synthesis 
(tetracycline, chloramphenicol, gentamycin and kanamycin) or of nucleic acid synthesis 
(ciprofloxacin). The decreased susceptibility of ∆yegI to cephalosporins is in stark contrast to 
increased antibiotic sensitivity phenotypes seen with E. faecalis ∆ireK and S. aureus ∆stk strains, 
suggesting that the mechanism of regulating antibiotic sensitivity in ∆yegI is different from those 
seen with Gram-positive eSTKs.  
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Table 4.1 Antibiotic susceptibility  
Median Minimum inhibitory concentrations (MIC) for E. coli WT and ∆yegI strains 
 
 
 
 
 
 
 
No. Antibiotic Target WT
(µg/ml) 
∆yegI
(µg/ml)  
1 Cefotaxime Cell wall 0.0078-0.015 0.125
2 Ceftriaxone Cell wall 0.0078 0.125
3 Cefoxitin Cell wall 4 16
4 Cefipime Cell wall 0.03125 0.125
5 Fosfomycin Cell wall 4 16
6 Tetracycline Protein synthesis 1 4
7 Chloramphenicol Protein synthesis 2 4
8 Ciprofloxacin Nucleic acid 0.03125 0.03125
9 Gentamycin Protein synthesis 0.5 0.5
10 Kanamycin Protein synthesis 4 4
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Since the difference in MICs between WT and ∆yegI strains were the highest for cefotaxime, 
I investigated the mechanistic basis of the reduced cefotaxime sensitivity observed in ∆yegI.  To 
validate the differential susceptibility to cefotaxime observed in WT and ∆yegI, I used Etest strips 
containing gradients of cefotaxime as an alternate approach to calculate MICs. Consistent with 
MIC values obtained by Microtiter broth dilution (Table 4.1),  I observed striking differences in 
the MICs of E. coli REL606 WT and ∆yegI (Fig. 4.10).  In the E. coli REL606 B strain, yegI is 
contiguous with pphC while in the E. coli K-12 strain MG1655, an unknown gene, yegJ, is found 
between yegI and pphC (Fig. 4.1A). I hypothesized that the different genome organization could 
result in differential sensitivity to antibiotics. To test this hypothesis, I obtained an in-frame 
deletion strain of yegI (∆aa 2-640) in K-12 BW255113  from the Keio collection (145) and 
transduced this mutation into K-12 MG1655 by P1-mediated transduction. I used cefotaxime Etest 
strips to calculate MICs of WT and ∆yegI to test for differences between B and K strain 
backgrounds. Since, I observed no difference in sensitivity to cefotaxime between WT and ∆yegI 
in MG1655 (Fig.4.10) there could be differences in the regulation of the yeg operon between the 
closely related E. coli K and B strains.  
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Figure 4.10 Deletion of yegI decreases sensitivity to cefotaxime in an E. coli B strain but not in a K 
strain. 
Determination of MIC of cefotaxime using Etest strips. For E. coli B strain WT (JDE2735), ∆yegI 
(KR160) were used while for E. coli K strain WT (KR01), ∆yegI (KR60) strains were used to calculate MICs 
using Cefotaxime Etest strips (0.0002-32 µg/ml). E strips were placed on Mueller Hinton II agar plates that 
were swabbed with bacterial suspension cultures from indicated strains. Plates were incubated at 37 ºC for 
20h and MIC were determined by eye. MIC values for B and K strains are indicated in µg/ml.  
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To confirm that the decreased sensitivity to cefotaxime was indeed due to yegI, I transformed 
both the WT and ∆yegI strains in REL606 background with a control vector (pBAD24) or plasmid 
expressing YegI under control of an arabinose inducible promoter and examined sensitivity to 
cefotaxime. As expected, I saw a complete restoration of sensitivity to cefotaxime only when 
expression of YegI-WT was induced in ∆yegI strain suggesting that the YegI may play a role in 
modulating cefotaxime sensitivity (Fig.4.11). To test if the kinase activity of YegI was required for 
this phenotype, I expressed a ATP binding mutant YegI-K39D or the catalytic mutant YegI-D141N 
in ∆yegI strain. Surprisingly, mutation of K39D or D141N, both which result in an inactive kinase, 
still restored sensitivity to cefotaxime suggesting that kinase activity of YegI is not required for 
sensitivity to cefotaxime. As shown in (Fig. 4.2.A) YegI is a 646aa protein with an N-terminal 
kinase domain (aa 13-300), two TM domains (aa 391-436) and a 210aa C-terminal domain with 
two HhH motifs. Thus, the TM domains or the C-terminal domain may be involved in restoring 
cefotaxime sensitivity.  
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Figure 4.11 Kinase activity of YegI is not required for decreased sensitivity to cefotaxime.  
To test if YegI kinase activity is required for decreased sensitivity to cefotaxime, strains KR199: WT 
(pBAD24), KR200: ∆yegI (pBAD24), KR206: ∆yegI (pYegI), KR247: ∆yegI (pYegI K39D) and KR250: ∆yegI 
(pYegI D141N) were grown at 37 ºC in LB with carbenicillin overnight. Cultures of strains expressing 
plasmids were serially diluted 10-fold and spotted from right to left (100-10-5) on LB plates containing 
indicated concentrations of either cefotaxime or arabinose or both. Carbenicillin (100 µg/ml) was used for 
plasmid selection. Plasmids used are indicated in parentheses. pBAD24: backbone vector used for 
complementation. pYegI:  pBAD24 expressing WT-YegI, pYegI K39D: pBAD24 expressing K39D-YegI and 
pYegI D141N:  pBAD24 expressing D141N-YegI.  
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To identify the domain required for restoring cefotaxime sensitivity of ∆yegI, I generated 
pBAD24 derivatives expressing either full-length YegI or truncated versions of YegI (Fig. 4.15A) 
under the control of an arabinose inducible promoter. YegI protein sequence boundaries for 
truncation were determined based on secondary structure and domain predictions from InterPro 
(198). I transformed ∆yegI strains with different truncations corresponding to various regions of 
YegI and examined sensitivity to cefotaxime in the presence of arabinose. Similar to Fig. 4.11,  I 
observed complete restoration of cefotaxime sensitivity when full length protein (pYegI) was 
induced (Fig 4.12B). Consistent with a kinase independent role of YegI, I did not see any 
restoration of  sensitivity to cefotaxime when the N-terminal domain of YegI alone was expressed 
(pYegI 1-390, pYegI 1-300) suggesting that the C-terminal domain is involved. Expression of just 
the C-terminal domain (pYegI 301-646) restored sensitivity to cefotaxime further validating a 
kinase independent role of YegI. Furthermore, expression of the pYegI 436-646 truncation that 
lacks the TM domains also restored cefotaxime sensitivity suggesting that TM domains are not 
required for restoration of cefotaxime sensitivity. However, expression of pYegI 536-646 or pYegI 
566-646 lacking one or both HhH motifs respectively failed to restore cefotaxime sensitivity. 
These results suggest that the HhH motifs in YegI (436-646) are important for restoration of 
cefotaxime sensitivity to ∆yegI strains, although the molecular mechanism of how the HhH motifs 
affect sensitivity to cefotaxime remains unclear.  
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Figure 4.12 HhH motifs in the C-terminal domain are important for decreased sensitivity to 
cefotaxime  
(A) Domain organization: Graphical representation of YegI and various truncation mutants used to 
determine which domain is required for complementation of cefotaxime resistance. Amino acid boundaries 
are domains included in WT and truncation mutants are indicated. depicting phosphorylation sites following 
mass spectrometry analysis of autophosphorylation. 
(B) Strains KR199: WT (pBAD24), KR200: ∆yegI (pBAD24), KR206: ∆yegI (pYegI), KR230: ∆yegI (pYegI 
1-390), KR231: ∆yegI (pYegI 1-300), KR292: ∆yegI (pYegI 301-646),  KR295: ∆yegI (pYegI 437-646), 
KR309: ∆yegI (pYegI 536-646) and KR311: ∆yegI (pYegI 566-646) were grown at 37 ºC in LB with 
carbenicillin overnight. Cultures of strains expressing plasmids were serially diluted 10-fold and spotted 
from right to left (100-10-5) on LB plates containing indicated concentrations of either cefotaxime or 
arabinose or both. Carbenicillin (100 µg/ml) was used for plasmid selection. Plasmids used are indicated in 
parentheses. 
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4.6.3 Sensitivity to DNA damaging agents  
The C-terminal domain of YegI contains two predicted HhH motifs (Fig.4.7A,B). 
Interestingly,  HhH motifs are commonly present in DNA repair proteins (199, 200). For example, 
E. coli DNA-3-methyl adenine glycosylase (AlkA)  is a base excision repair glycosylase that 
contains HhH motifs that likely to mediate DNA affinity during base excision repair of alkylated 
bases (194, 201, 202). Therefore, YegI could play a role in DNA damage response or repair. To 
test this hypothesis, I used a deletion strain of yegI to test sensitivity to DNA damage caused by 
UV radiation. The E. coli DH5α strain which lacks the HhH containing DNA repair protein 
recombinase A (recA-) displays increased sensitivity to UV and was therefore used as a positive 
control. Unlike DH5α, both the WT and ∆yegI showed no sensitivity to UV radiation even at high 
UV exposure (60J/m2) (Fig.4.13) demonstrating that deletion of yegI does not affect sensitivity to 
UV radiation.  
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Figure 4.13 Deletion of yegI doesn’t affect sensitivity to UV radiation  
WT (JDE2735), ∆yegI (KR160) and recA- (JDE12) strains were grown at 37 ºC in LB overnight. Cultures 
were serially diluted 10-fold and spotted from right to left (100-10-5) on LB plates. Plates were exposed to 
indicated doses of UV using UV crosslinker.  
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I then examined if deletion of YegI affected the response to DNA damage induced by a 4-
quinolone antibiotic nalidixic acid. Nalidixic acid inhibits DNA synthesis by directly forming a 
cleavage complex with DNA gyrase causing DNA damage and activation of the bacterial SOS 
response (203).  Mutations in HhH motif-containing nucleotide excision proteins such as UvrB 
and UvrC result in decreased sensitivity to nalidixic acid (204, 205). Therefore, I hypothesized 
that deletion of yegI might affect sensitivity to nalidixic acid. To test this hypothesis, I used the 
same approach as that for assessing cefotaxime sensitivity. First,  I determined any differences in 
sensitivity to nalidixic acid between WT and ∆yegI from both REL606 and MG1655 backgrounds. 
Deletion of yegI in REL606 decreased sensitivity by 2-log to nalidixic acid at 1 µg/ml as compared 
to WT (Fig.4.14A). However I saw no difference between WT and ∆yegI in MG1655 suggesting 
differential response of ∆yegI in these closely related E. coli strains.  
To ensure that decreased sensitivity to nalidixic acid was due to yegI, I transformed WT and 
∆yegI strains with either an empty vector (pBAD24) or a plasmid expressing YegI (pYegI). I 
observed that expression of WT-YegI restored partial sensitivity to nalidixic acid (Fig.4.14B). To 
test if kinase activity is required for restoration of nalidixic acid sensitivity, I expressed YegI 
mutant proteins carrying inactivating mutations (pYegI-K39D or pYegI-D141N) in a ∆yegI strain. 
Similar to the cefotaxime results, expression of a catalytically inactive kinase still restored 
sensitivity to nalidixic acid similar to YegI-WT (Fig.4.14B). Thus, the kinase activity of YegI is 
not important for restoring nalidixic acid sensitivity.  
To identify the domain required for increasing nalidixic acid sensitivity of ∆yegI, I expressed 
full length YegI or truncated versions of YegI in a ∆yegI strain as described previously (Fig.4.12). 
Similar to cefotaxime results, I observed restoration of nalidixic acid sensitivity in ∆yegI strains 
only when full length YegI, or the YegI 301-646, YegI 436-646 truncations were expressed 
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(Fig.4.14C). Deletion of one or both HhH motifs failed to restore nalidixic acid sensitivity. Thus,  
the C-terminal domain (aa 436-646) containing the HhH motifs is likely required for restoration 
of sensitivity to nalidixic acid.  
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Figure 4.14 Deletion of yegI decreases sensitivity to nalidixic acid 
(A) Susceptibility of B and K strains to nalidixic acid. E. coli REL606 (B strain) and MG1655 (K strain) 
were used to determine differences in nalidixic acid sensitivity \. B strains WT (JDE2735), ∆yegI (KR160) 
and K strains WT (KR01), ∆yegI (KR60) were used to calculate sensitivity to nalidixic acid. Strains were 
grown at 37 ºC in LB overnight. Cultures were serially diluted 10-fold and spotted from right to left (100-10-
5) on LB plates with or without nalidixic acid ( 1µg/ml).  
(B) Kinase activity is not required for sensitivity to nalidixic acid. Strains KR199: WT (pBAD24), 
KR200: ∆yegI (pBAD24), KR206: ∆yegI (pYegI), KR247: ∆yegI (pYegI K39D) and KR250: ∆yegI (pYegI 
D141N) were grown at 37 ºC in LB with carbenicillin overnight. Cultures of strains expressing plasmids 
were serially diluted 10-fold and spotted from right to left (100-10-5) on LB plates containing indicated 
concentrations of either nalidixic acid or arabinose or both. Carbenicillin (100 µg/ml) was used for plasmid 
selection. Plasmids used are indicated in parentheses. pBAD24: backbone vector used for 
complementation. pYegI:  pBAD24 expressing WT-YegI, pYegI K39D: pBAD24 expressing K39D-YegI and 
pYegI D141N:  pBAD24 expressing D141N-YegI.  
(C) Indicated strains were grown at 37 ºC in LB with carbenicillin overnight. Cultures of strains expressing 
plasmids were serially diluted 10-fold and spotted from right to left (100-10-5) on LB plates containing 
indicated concentrations of either nalidixic acid or arabinose or both. Carbenicillin (100 µg/ml) was used for 
plasmid selection. Plasmids used are indicated in parentheses.  
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So far, my results indicate that deletion of yegI in E. coli REL606 decreases sensitivity to 
cefotaxime and nalidixic acid and expression of YegI in a ∆yegI strain restored sensitivity. 
However, the mechanism by which yegI regulates sensitivity to these antibiotics is unclear. One 
possibility for decreased sensitivity to nalidixic acid or cefotaxime could be due to changes in 
membrane permeability. In Gram-negative bacteria, membrane permeability can be affected by 
altering expression of genes encoding outer membrane porin proteins that form channels, efflux 
pumps or multidrug transporters. Proteomic studies in E. coli revealed that expression of multidrug 
transporters and efflux pumps were enhanced in nalidixic acid resistant strains (206). Specifically, 
expression of the outer membrane protein TolC, which forms protein complexes with multidrug 
transporters, is upregulated in nalidixic acid resistant E. coli strains.  
Therefore, I asked if decreased sensitivity of ∆yegI strain to nalidixic acid or cefotaxime is 
affected by the presence or absence of tolC. I constructed an in-frame deletion of tolC using 𝝀	red 
recombination (141) and confirmed the strain construction by sequencing. I introduced this 
mutation into a ∆yegI strain using P1-mediated transduction to get a double mutant strain ∆yegI 
∆tolC	and examined sensitivity of this strain to nalidixic acid and cefotaxime. In case of nalidixic 
acid, I observed that deletion of tolC in a ∆yegI background completely restored sensitivity to both 
cefotaxime and nalidixic acid. However, deletion of tolC alone also showed increased sensitivity 
to nalidixic acid suggesting that deletion of tolC is a dominant effect and therefore cannot explain 
the decreased sensitivity phenotype of ∆yegI to nalidixic acid (Fig.4.15). A similar effect of the 
tolC deletion was observed in the case of cefotaxime. Future experiments aimed at determining 
the expression of tolC or determining the transcriptome profiles in WT and ∆yegI strains may 
provide a better explanation for decreased susceptibility to nalidixic acid/cefotaxime.  
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Figure 4.15 Deletion of tolC abolishes decreased sensitivity phenotype of ∆yegI  
WT (JDE2735), ∆yegI (KR160), ∆tolC (KR337) and ∆yegI∆tolC (KR338) strains were grown at 37 ºC in LB 
overnight. Cultures were serially diluted 10-fold and spotted from right to left (100-10-5) on LB plates in the 
absence or presence of indicated antibiotics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 µg/ml 
Nalidixic acid
WT
∆yegI
∆yegI ∆tolC
LB
∆tolC
0.125 µg/ml 
cefotaxime
 138 
4.7 Potential physiological substrates for YegI  
4.7.1 Comparative phosphoproteomics shows enolase as a substrate of YegI  
Phosphoproteomic studies have been widely used to identify phosphorylated proteins in 
bacteria (113). Recent studies with bacterial eSTKs have used comparative phosphoproteomics to 
identify targets that are specific to the kinase of interest by comparing phosphoproteomes of a 
kinase null strain is compared to a control strain with intact kinase (136, 207). To identify the 
substrates of YegI kinase at a more global scale, we performed comparative phosphoproteomics 
in collaboration with the laboratory of Dr. Ljiljana Pasa-Tolic at Pacific Northwest National 
Laboratories, WA who has reported successful enrichment of phosphopeptides in E. coli using 
immobilized metal affinity chromatography (IMAC) (146).  
I used an in  frame deletion strain of yegI (∆aa 9-624) in E. coli REL606. Both WT and ∆yegI 
strains were grown in defined minimal medium MinA with 0.4% glucose (144) and samples were 
collected at either log or stationary phase (Fig. 4.16A). Frozen pellets (in triplicates) were 
submitted to Dr. Pasa-Tolic for subsequent lysis and enrichment of phosphopeptides using IMAC 
(Fig. 4.16B). Although  1700-2000 proteins were identified in each of the samples, only 38 
phosphopeptides corresponding to 34 phosphoproteins were detected,  a yield of phosphoproteins 
much lower than what has been previously reported (~100 phosphoproteins) in E. coli 
phosphoproteomic studies (114, 123, 146). Of the 34 phosphoproteins detected, differential 
phosphorylation was observed only in the case of the glycolytic enzyme enolase, that catalyzes the 
conversion of 2-phosphoglycerate to phosphoenolpyruvate. We observed a growth phase 
dependent increase in enolase phosphorylation at Ser-400 in stationary phase (Fig.4.16C). 
Interestingly, this increase in phosphorylation was not observed in a ∆yegI strain suggesting that 
enolase could be a target for yegI in vivo. However, since enolase phosphorylation was only 
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detected in one of the three replicates that were used for phosphoproteomic analysis, this result 
may not be representative.  
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Figure 4.16 Comparative phosphoproteomics shows enolase as a substrate for YegI in vivo.  
(A) Growth curves of control strain WT (JDE2735) and ∆yegI (KR160). For comparative 
phosphoproteomics, cultures were grown in triplicates in minimal media (MinA) with 0.4% glucose for 24 h 
at 37 ºC with aeration in baffled flasks. Growth was monitored by measuring optical density (OD) at 600nm. 
Samples were collected at a log OD:0.8 (L) and stationary phase OD:2.3-2.5 (S) as denoted by red arrows.  
(B) Experimental scheme for comparative phosphoproteomics Immobilized metal affinity 
chromatography (IMAC) was used for phosphopeptide enrichment.  
(C) Comparative phosphoproteomics showed differential phosphorylation of enolase. Change in 
phosphorylation levels of enolase is calculated relative to WT under log phase. Data represented is from 
one of the three replicates.  
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Although enolase phosphorylation was observed in only one of the three replicates, we were 
encouraged by the results as enolase has been reported to be phosphorylated in several global E. 
coli phosphoproteomic studies (114, 119, 123). Although phosphorylation on Ser-400 has not been 
reported, enolase was shown to be phosphorylated on Thr-322, Ser-369, Ser-372, Thr-375, Thr-
379, depending on the specific study.  To validate our phosphoproteomics finding and show 
directly that enolase is a substrate of YegI, I expressed and purified an N-terminal His tagged 
enolase (Eno) using Ni2+- affinity chromatography. To confirm the phosphorylation site at Ser-
400, I generated a serine to alanine point mutation at position 400 (S400A) and purified it in the 
same manner as WT. Using radioactive in vitro kinase assay, I observed robust phosphorylation 
of Eno-WT in the presence of YegI-NTD (Fig. 4.17,  lane 3) as compared to a reaction without 
YegI-NTD (Fig. 4.17, lane 2). However, I observed phosphorylation of Eno-S400A to a similar 
extent (Fig. 4.17, lane 4) suggesting that Ser-400 is not the only phosphorylation site.  
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Figure 4.17 Enolase is phosphorylated by YegI in vitro.  
Reactions were carried out at 37 ºC with 4 µM of Eno (WT or S400A) in the absence or presence of 2 µM 
of YegI-NTD as indicated on the top of the gel. Reactions were carried out in kinase buffer and stopped at 
t=60 mins. Samples were resolved on 12% SDS-PAGE followed by autoradiography. Molecular weights 
(kDa) are indicated on the right of the gel.  
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4.7.2 YegI regulates protein translation via phosphorylation of elongation factor-Tu  
The GTPase elongation factor-Tu (EF-Tu) is one of the most abundant proteins in the cell 
and plays an essential role in the elongation step of protein translation. In its GTP-bound form, 
EF-Tu binds aminoacyl tRNA and delivers it to the ribosome. Upon correct codon-anticodon 
matching, the ribosome activates the GTPase activity of EF-Tu thereby allowing release of EF-
Tu-GDP from the ribosome, resulting in peptide elongation. The elongation step in eukaryotic cells  
is a tightly controlled process and is subject to both transcriptional and translational regulation 
(208). Several bacterial phosphoproteomics studies, including in E. coli, have reported 
phosphorylation of EF-Tu in vivo (114, 115, 207, 209, 210), suggesting that phosphorylation of 
EF-Tu in bacteria is physiologically relevant. 
       EF-Tu is phosphorylated in vitro by the M. tuberculosis eSTK PknB at multiple threonine 
residues distributed across the full length of EF-Tu. Phosphorylation of Thr-118 resulted in  
decreased binding affinity to GTP which could impact protein synthesis (132) although whether 
this modification occurs in vivo is not known. More recently, a study from Dworkin lab showed 
that the B. subtilis eSTK YabT phosphorylates EF-Tu on multiple Ser/Thr residues including Ser-
11, Thr-63, Ser-300, Ser-385 with Thr-63 being the primary site of phosphorylation. Interestingly 
phosphorylation of B. subtilis Thr-63 (corresponds to E. coli Thr-62) inhibits GTP hydrolysis and 
translation elongation (133). Since YegI is also an eSTK, I hypothesized that EF-Tu could be a 
YegI substrate.  
I used a radioactive in vitro kinase assay to test if YegI phosphorylates EF-Tu. YegI-NTD 
was used in the kinase assay instead of YegI since transphosphorylation of substrates (PphC, 
Chapter 3) was more robust than YegI. YegI-NTD and EF-Tu migrate at the same molecular weight 
(~45kDa), so to distinguish between the two proteins, I expressed and purified a GST-tagged EF-
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Tu which migrates at ~70kDa ensuring separation on SDS-PAGE. I used GST alone without EF-
Tu as a control. Different concentrations of YegI-NTD were used to identify ideal kinase::substrate 
ratio. Robust phosphorylation of GST-EF-Tu was observed in the presence of equimolar 
concentrations of YegI-NTD (Fig.4.18A, lane 7) as compared to the no kinase control (Fig.4.18A, 
lane 6). Phosphorylation levels dropped with lower kinase concentrations (Fig.4.18A, lane 8-10). 
However, I also observed robust phosphorylation of GST tag in the presence of YegI-NTD 
(Fig.4.18A, lane 2-5) indicating that YegI-NTD might be phosphorylating the GST tag alone or 
both the GST tag and EF-Tu.  
To determine the site(s) of phosphorylation of GST-EF-Tu, in vitro kinase assay sample of 
GST-EF-Tu that has been incubated with YegI-NTD was submitted to the Columbia University 
Medical Center Herbert Irving Cancer Center Proteomics Center. Dr. Emily Chen performed mass 
spectrometry analysis and identified three phosphopeptides corresponding to threonine residue at 
position 94 and serine residues at position 198 and 220 (Fig. 4.18B)  of which Ser-220 has been 
observed in global phosphoproteomic studies in E. coli. (114, 123) Consistent with the in vitro 
kinase assay (Fig.4.18A), Dr. Emily Chen also identified two phosphoserine residues in the GST 
tag and in the PreScission cleavage site located between the GST tag and EF-Tu.  
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Figure 4.18 YegI phosphorylates elongation factor Tu (EF-Tu) in vitro. 
(A)  Reactions were carried out at 37 ºC with 2 µM of GST(lane 1-5) or GST-EF-Tu(lane 6-10) in the absence 
(lane 1 and lane 6) or presence of different concentrations of YegI-NTD as indicated on the top of the gel. 
Reactions were carried out in kinase buffer and stopped at t=60 mins. Samples were resolved on 12 % 
SDS-PAGE followed by autoradiography. Molecular weights (kda) are indicated on the right of the gel.  
(B) Graphical representation of phosphorylation sites on GST-EF-Tu following mass spectrometry analysis 
of in vitro kinase assay with YegI-NTD. Phosphorylated residues are indicated by red circles. PC: 
PreScission cleavage site is located between GST and EF-Tu.  
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To test the impact of YegI-dependent phosphorylation of EF-Tu on protein synthesis, I 
expressed and purified His-tagged EF-Tu in the absence or presence of tagless YegI-NTD in a 
pETDUET vector to yield an in vivo phosphorylated form of EF-Tu. Purified protein was resolved 
on SDS-PAGE to assess purity (Fig. 4.19A) and was used in the in vitro PURExpress 
transcription/translation assay which contains all the necessary components except EF-Tu as 
described (133).  Briefly, the in vitro transcription/ translation reaction was performed in the 
presence of recombinant EF-Tu or EF-Tu coexpressed with YegI-NTD and all the reconstituted E. 
coli components required for translation. A plasmid expressing a B. subtilis spore coat protein 
carrying a C-terminal FLAG tag (cotE-FLAG) was used as a template for the in vitro transcription/ 
translation assay (133).  CotE-FLAG synthesis was assayed using western blot with α-flag 
antibody. Synthesis of CotE-flag decreased (~70%) in the presence of EF-Tu purified from a strain 
co-expressing YegI-NTD (Fig. 4.19B, lane 2) as compared to EF-Tu purified from a strain 
expressing EF-Tu by itself (Fig. 4.19B,lane 1) indicating that EF-Tu that had been phosphorylated 
by YegI inhibits protein translation.  
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Figure 4.19 Phosphorylation of EF-Tu by YegI inhibits protein translation in vitro. 
(A) Purification of His6-EF-Tu and His6-EF-Tu coexpressed with YegI-NTD. Lanes 1-4 indicate samples 
after elution from Ni2+-beads using 300 mM imidazole.  Samples were resolved on 12% SDS-PAGE 
followed by Coomassie staining. Molecular weights (kDa) are indicated on the right of the gel.  
(B) In vitro synthesis of CotE-FLAG in the presence of EF-Tu. PURExpress reactions were carried out 
at 37 ºC for 10 mins with 2 µM of EF-Tu alone (lane 1) or EF-Tu co-expressed with YegI-NTD (lane 2). 
Synthesis of CotE-FLAG was detected by anti-flag antibody using Western blot analysis. Coomassie 
stained gel indicates the amount of EF-Tu added to each reaction. 
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4.8 Discussion 
Ser/Thr phosphorylation is an important post translational modification that is capable of 
regulating protein function both in eukaryotes (211) and prokaryotes (150). Advent of genomic 
sequencing of several prokaryotic genomes have identified several open reading frames that 
encode serine/threonine kinases and cognate protein phosphatases that are responsible for 
reversible phosphorylation indicating widespread prevalence of Ser/Thr phosphorylation in 
bacteria (30). Although Ser/Thr phosphorylation in the Gram-negative bacterium Escherichia coli 
has been known for >10 years, little is known about the enzymes responsible for this reversible 
modification and their specific substrates. In this chapter, I have described the characterization of 
a novel Ser/Thr kinase YegI in E. coli and the identification of several potential substrates  
In silico analysis revealed that YegI belongs to the class of eukaryotic-like Ser/Thr kinases 
(eSTKs) that contain all the 11 key structural subdomains that are characteristic of eukaryotic 
protein kinases (28). Homology search using YegI kinase domain revealed that it was similar to 
kinase domains of several bacterial eSTKs (Fig.4.1D). Unlike other bacterial eSTKs, however 
YegI includes only seven of the ten absolutely conserved residues responsible for ATP binding, 
catalysis, and substrate recognition (13, 28) (Fig.4.1B). Despite the absence of these conserved 
residues, YegI encodes an active protein kinase (Fig. 4.3) that undergoes autophosphorylation 
primarily on serine residues (Fig.4.5A) Similar to most bacterial eSTKs, autophosphorylation of 
YegI on serine residues in the activation loop is critical for catalytic activity of YegI (Fig. 4.5B). 
A notable feature of YegI is that it lacks the conserved DFG loop which is important for Mg2+ 
binding. The orientation of DFG loop with respect to the activation loop dictates active or inactive 
conformation of the kinase and susceptibility to kinase inhibitors (212). I speculated that addition 
of DFG loop could help kinase activation. However, since I observed that replacing the DSD loop 
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with DFG completely abolished YegI activity (Fig.4.4C), the DSD motif is likely important for 
YegI activity.  
Unlike Gram-positive eSTKs, YegI lacks a C-terminal extracellular sensing domain and 
instead has a cytoplasmic domain at the C-terminus (Fig.4.6). This suggests that the kinase senses 
a cytoplasmic signal. Since sequence analysis revealed the presence of two conserved non-specific 
DNA binding Helix-hairpin-Helix motifs (Fig.4.7A,B) which is commonly found in DNA repair 
proteins, I hypothesized that YegI plays a role in DNA repair. Consistently, I found that deletion 
of YegI decreases sensitivity to DNA damaging agent nalidixic acid (Fig.4.14). This is the first 
example of an eSTK with HhH motifs. The only other example of an eSTK directly interacting 
with DNA is B. subtilis YabT which contains a putative DNA binding site characterized by stretch 
of lysine-arginine residues (213). Understanding the possible role of HhH motif in activation of 
YegI will help understand the physiological role of YegI.   
An interesting feature of the genome organization of yegI is that it differs in closely related 
E. coli strains (Fig.4.1.A). In most pathogenic strains and lab B strains of E. coli, yegI occurs 
immediately downstream of pphC, a PP2C-like phosphatase with a four nucleotide overlap while 
in K strains this locus is disrupted by unknown protein yegJ suggesting potential regulatory 
differences between strains. Interestingly, deletion of yegI in REL606 (B strain) displayed reduced 
sensitivity to cell wall acting antibiotic cefotaxime as compared to WT strain (Fig.4.10). However 
this was not observed in an MG1655 (K strain) background allowing us to speculate that yegI 
kinase expression in K strain background might resemble a kinase null mutant. In REL606 strains, 
yegI expression was detected only in stationary phase but at very low levels (Fig.4.8). However, 
the absence of physiological stimulus that initiates yegI expression and activation makes it difficult 
to interpret the functional implications of the altered gene locus.  
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Although Ser/Thr kinases have been previously identified in E. coli and impact various 
cellular processes like antibiotic persistence and the stress response, the physiological targets for 
these kinases have largely not been identified. One of the main aims of this study was to identify 
physiological substrates of YegI. Using comparative phosphoproteomics (Fig.4.16) and an in vitro 
kinase assay (Fig.4.17), I identified enolase as a potential substrate for YegI kinase. Enolase has 
been previously reported to be phosphorylated on multiple Ser/Thr/Tyr residues (114, 123) 
consistent with my results. Identification of the sites of phosphorylation and their effect on enolase 
function would help to understand the possible role of phosphorylation in the regulation of enolase. 
In addition to its function in glycolysis, enolase also forms a part of the RNA degradosome 
assembly complex that is responsible for degradation of mRNAs. The function of enolase in the 
RNA degradosome is not well studied although enolase can mediate degradation of glucose 
transporter mRNA in response to phosphosugar stress (126). Therefore, phosphorylation of 
enolase could affect either its role in glycolysis or in the RNA degradosome.  
In vivo, E. coli elongation factor-Tu is phosphorylated on multiple Ser/Thr residues (114, 
134, 146) but the specific E. coli kinase responsible for this modification is not known. Recent 
studies have shown that phosphorylation of EF-Tu at a single site Thr 383 by the P1 phage encoded 
Doc kinase inactivates EF-Tu (214, 215). I found that phosphorylation of EF-Tu by YegI impaired 
EF-Tu function in protein synthesis (Fig.4.19B) consistent with previous findings in E. coli (134). 
However, the mechanistic basis for this effect remains unclear. Mass spectrometry analysis 
revealed that YegI phosphorylated EF-Tu at residues Thr-94, Ser-194 and Ser-220 (Fig.4.18). Lys-
89 and Asp-90 have been previously shown to be important for amino acyl tRNA binding and 
mutation of either of these residues leads to loss of tRNA binding (216). Thus, phosphorylation of 
Thr-94 could impact tRNA binding. Similarly, Gly-223 is involved in ribosome dependent 
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activation of GTPase activity of EF-Tu since mutation of this residue, which contacts the ribosome, 
inhibits GTP hydrolysis and subsequently protein synthesis (217, 218). Therefore, phosphorylation 
of EF-Tu at Ser-220, a nearby residue, could indirectly affect GTP hydrolysis. 
In summary, this chapter presents the first report of an integral membrane Ser/Thr kinase in 
E. coli. Additionally, I showed that activation of YegI requires autophosphorylation of serine 
residues near the activation loop. Furthermore, I have demonstrated that YegI phosphorylates EF-
Tu and inhibits its function in protein translation. YegI also phosphorylate enolase in vitro however 
the sites of phosphorylation and the effect of phosphorylation on enolase function are yet to be 
investigated. I found that YegI contains two HhH motif and the presence of HhH motif was 
essential for sensitivity to cell wall antibiotic cefotaxime and DNA synthesis inhibitor nalidixic 
acid. Further studies will be required to fully understand how YegI mediates sensitivity to cell wall 
acting antibiotics and DNA damaging agents. 
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CHAPTER 5 
Summary and Future Directions  
5.1 General summary  
The work presented in this thesis has identified and characterized novel enzymes that  
mediate Ser/Thr phosphorylation in E. coli. First, I identified a gene yegK(pphC) encoding a PP2C-
like Ser/Thr phosphatase in E. coli using a homology based search. I then biochemically 
characterized PphC and showed that it is an active Ser/Thr phosphatase. This is the first report of 
a PP2C-like Ser/Thr phosphatase in E. coli. Additionally, I identified a downstream gene, yegI, 
that encodes a putative integral membrane eukaryotic-like Ser/Thr kinase with two helix-hairpin-
helix motifs. I showed that YegI is an active kinase in vitro and identified two substrates. 
Phosphorylation of one of these substrates, the essential elongation factor-Tu (EF-Tu), appears to 
inhibit its activity in protein translation, suggesting that this Ser/Thr kinase/phosphatase pair may 
be involved in regulating protein synthesis. 
 
5.1.1 PphC (YegK) is a novel PP2C-like Ser/Thr phosphatase in E. coli 
Chapter 3 describes the characterization of a novel PP2C-like Ser/Thr phosphatase encoded 
by the gene yegK that I have reannotated as pphC. Despite the presence of only six of the eight 
key conserved residues associated with PP2C-like phosphatases (Fig.3.1), I found that PphC was 
an active phosphatase (Fig.3.3). PphC was able to effectively dephosphorylate Ser residues on 
phosphorylated β-casein substrate suggesting that PphC is a serine phosphatase (Fig.3.7). 
Consistent with the observation that the primary substrate for PP2C phosphatases are partner 
kinases that are often encoded in the same operon, I observed PphC-dependent dephosphorylation 
of YegI, a putative Ser/Thr kinase encoded by a gene adjacent to pphC (Fig.3.9). 
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5.1.2 YegI is a novel eukaryotic-like Ser/Thr kinase in E. coli 
Chapter 4 of this thesis describes the characterization of a novel eukaryotic-like Ser/Thr 
kinase encoded by yegI located downstream of pphC. Consistent with previous reports from other 
bacteria (30, 150), eukaryotic-like Ser/Thr kinases and their cognate phosphatase are often 
encoded in the same operon and the kinase activity is regulated by the phosphatase. YegI differs 
in amino acid sequence with previously characterized eSTKs especially in conserved residues in 
both the catalytic loop and the metal binding loop (Fig.4.1B). However, my biochemical analysis 
revealed that YegI is an active kinase (Fig.4.3) which requires the bivalent cations Mg2+/Mn2+ for 
activity (Fig.4.4). Similar to previously characterized eSTKs, YegI undergoes 
autophosphorylation of residues in the activation loop which is absolutely essential for YegI kinase 
activity (Fig.4.5). Unlike previously identified Ser/Thr kinases in E. coli, YegI is an integral 
membrane protein with both the N-terminal kinase domain and the C-terminus located in the 
cytoplasm (Fig.4.6). Interestingly, the C-terminal domain contains non-specific DNA binding 
helix-hairpin-helix motifs (Fig.4.7). Phenotypic analysis revealed that deletion of yegI resulted in 
decreased sensitivity to cell wall antibiotic cefotaxime (Fig.4.10) and DNA synthesis inhibitor 
nalidixic acid (Fig.4.14), and that the DNA binding domain of YegI was required for this decreased 
sensitivity (Fig.4.12, Fig.4.14). Finally, phosphoproteomic analysis and in vitro kinase assays 
reveal two potential substrates for YegI kinase: enolase (Fig.4.16) and elongation factor-Tu 
(Fig.4.18).  
 
5.2 Future Directions 
5.2.1 Differences in activity of PphC between closely related E. coli strains 
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Results in Chapter 3 showed a significant difference in phosphatase activity of PphC when 
purified from closely related E. coli strains (B and K strains) (Fig. 3.6) despite ~92% amino acid 
sequence identity (Fig. 3.5). Interestingly, all of the absolutely conserved residues that dictate 
catalysis and metal coordination in bacterial PP2Cs are 100% identical between REL606 and 
MG1655 PphC. However, there are differences in non-conserved residues that are broadly 
distributed throughout the protein. I speculate that these changes in amino acid sequence could 
reflect the difference in phosphatase activity. Generating amino acid substitutions in MG1655 
PphC in these non-conserved regions such that it resembles REL606 PphC and assessing 
phosphatase activity could give us additional insight into the biochemical differences between the 
closely related phosphatases. Since the differences are in residues not currently known to impact 
catalytic activity, this work could help in understanding the role of non-canonical residues that 
contribute to activity.   
 
5.2.2 How is PphC activity regulated?  
Unlike other classes of Ser/Thr phosphatases (e.g., PPP), PP2C-like phosphatases are metal 
dependent phosphatases that do not contain additional regulatory motifs raising the question of 
how these enzymes are regulated (152). One possibility is regulation at the transcriptional level; 
however, in most cases both the eSTK and eSTP occur in same operon indicating probable co-
transcription. Therefore, regulation of PP2C activity may be more complex. So far, two 
mechanisms of regulation of bacterial PP2C activity have been proposed: phosphorylation by 
partner eSTKs in the case of M. tuberculosis PstP (174) or regulation by dimer induced 
conformational change in the broadly conserved switch region as seen in the B. subtilis PP2C-like 
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phosphatase SpoIIE (175). However, PphC shows poor conservation in the switch region 
indicating that this mechanism may not be relevant  
YegI phosphorylates PphC on Ser-174 (Fig.3.11), reminiscent of previous findings in M. 
tuberculosis, where the PP2C-like phosphatase PstP is phosphorylated by eSTK PknA and PknB 
(174). To test whether Ser-174 phosphorylation has a role in regulating phosphatase activity, I 
generated a phosphoablative mutant (PphC-S174A). This mutation however did not have a 
significant impact on phosphatase activity against pNPP or phosphorylated β-casein (Fig.3.12). 
Furthermore, phosphorylating PphC with YegI in vitro and subsequent analysis of phosphatase 
activity against pNPP showed no difference in activity as compared to unphosphorylated PphC 
(Fig.3.12). It is possible that in vitro phosphorylation may not yield a sufficiently high 
stoichiometry of phosphorylated PphC to impact enzyme kinetics. Co-expression of the kinase and 
putative substrate in pETDuet-1 systems have been successfully utilized to understand the 
dynamics of kinase-substrate interaction and phosphorylation in E. coli (133, 174, 219, 220). 
Therefore, co-expression of PphC with YegI followed by phosphoenrichment could be used to 
generate in vivo phosphorylated PphC which might serve as a better candidate for testing impact 
of phosphorylation on PphC activity.  
 
5.2.3 Autophosphorylation-mediated regulation of YegI  
Although the predicted structure of YegI closely resembled the structure of the bacterial 
eSTK PknB (Fig. 4.1D), the YegI sequence shows striking deviations in the conserved regions 
particularly in the catalytic loop and the Mg2+-binding DFG loop (Fig. 4.1B). Specifically, the 
YegI sequence contains the catalytic loop VGDXXQXS as opposed to the canonical catalytic loop 
HRDXXPXN found in almost all other bacterial eSTKs. The conserved histidine residue in the 
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catalytic loop is crucial for binding both the carbonyl group of catalytic aspartate in the catalytic 
loop and making a hydrophobic contact with the phenylalanine in the DFG loop. Additionally, 
YegI lacks the highly conserved DFG (aspartate-phenylalanine-glycine) loop in motif VII which 
recognizes the Mg2+-bound ATP (221). Instead, YegI contains a DSD (aspartate-serine-aspartate) 
sequence suggesting either that YegI might be an inactive kinase or that the DFG loop is not 
essential for every kinase. My results suggest the latter, since, despite these differences in highly 
conserved residues, YegI is an active kinase (Fig.4.3) that requires bivalent cations Mg2+/Mn2+ for 
activity with increased preference to Mn2+ ion (Fig.4.4A, B). Replacing the DSD loop in YegI with 
the canonical DFG loop failed to increase activity or preference for Mg2+ ion and instead 
completely abolished activity (Fig.4.4C). This result suggests that the presence of a serine and an 
aspartic acid residue in the DSD loop might be critical for activity and could affect YegI 
autophosphorylation. Consistently, I observed that the serine residue in the DSD loop is one of the 
three serine residues that undergoes autophosphorylation and is required for activity of the kinase 
(Fig.4.5A). Substitution of all three serine residues with alanine residues 
(Ser153ASer160ASer162A) abolished YegI kinase activity indicating that these residues are 
important for autophosphorylation of YegI (Fig.4.5C). In the future, generating single 
phosphoablative mutants of these autophosphorylated serine residues will help uncover the 
contribution of each site to the activity of YegI.  
 
5.2.4 Impact of DNA binding on YegI activity 
The typical domain architecture of membrane eSTKs comprises of a cytoplasmic N-terminal 
kinase domain connected to a single transmembrane domain and an extracellular C-terminal 
domain responsible for ligand recognition and binding (30). However, unlike membrane eSTKs, 
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YegI lacks an extracellular C-terminal domain. Instead, membrane topology analysis of YegI 
revealed the presence of two transmembrane domains with both the N-terminal kinase domain and 
C-terminus located in the cytosol (Fig. 4.6). Interestingly, I observed that the YegI C-terminus 
contains two predicted helix-hairpin-helix (HhH) motifs (Fig. 4.7A,B) that in other proteins are 
responsible for non-specific DNA binding (194). This observation raises an important question: Is 
DNA binding important for the function of YegI? More specifically, could binding to DNA serve 
as a signal for activation of YegI kinase? To test this, I will first test DNA binding of YegI by 
using YegI and YegI-NTD protein that lacks the transmembrane and C-terminal domain and 
examine the effect of DNA binding on YegI autophosphorylation and transphosphorylation. DNA 
binding could alter the conformation of YegI which may favor an active/inactive conformation. 
Therefore, dissecting the function of these HhH motifs in YegI could possibly provide clues about 
the functional role of YegI in E. coli.  
 
5.2.5 Phenotypic characterization of yegI  
Similar to other bacterial eSTKs, YegI is a non-essential protein. Phenotypic evaluation of 
∆yegI strain revealed no significant difference in growth in minimal media as compared to WT 
strain (Fig.4.9). I observed decreased susceptibility of ∆yegI strain to cell wall antibiotic 
cefotaxime (Table 4.1, Fig.4.10) as well as to the DNA gyrase inhibitor nalidixic acid (Fig.4.14). 
This difference in susceptibility was seen only in the B strain REL606 and not in the K strain 
MG1655 suggesting potential regulatory differences in the yegI locus between the closely related 
E. coli strains (Fig.4.10, Fig.4.14A). While the kinase activity did not account for this reduced 
susceptibility (Fig.4.11, Fig.4.14B), the C-terminal domain including the HhH motifs were 
required to restore sensitivity to both antibiotics (Fig.4.12B, Fig.4.14C). This observation is in 
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marked contrast to previously reported roles of eSTKs in antibiotic resistance. For example, 
deletion of the E. faecalis eSTK IreK resulted in increased susceptibility to cephalosporins and 
this susceptibility was dependent on the kinase activity of IreK (52). Similarly, deletion of the S. 
aureus eSTK Stk increased susceptibility to cephalosporins (49). Thus, why are ∆yegI strains less 
susceptible to antibiotics?  
Common mechanisms of antibiotic resistance include increased efflux of antibiotics, 
decreased membrane permeability or decreased affinity of target to antibiotics (222). Membrane 
permeability and antibiotic efflux are regulated by outer membrane proteins. Furthermore, 
overexpression of outer membrane proteins including the multidrug efflux pump TolC, were 
observed in nalidixic acid resistant strains (206). Interestingly, the operon adjacent to the yeg locus 
encodes multidrug transporters (MdtA, MdtB, MdtC) (Fig.3.5) which forms a complex with TolC 
to mediate efflux of antibiotics (223, 224). Thus, I hypothesized that deletion of yegI could affect 
TolC levels either by direct regulation or by an indirect mechanism. I therefore examined if there 
were differences in antibiotic susceptibility between WT and ∆yegI strains in a ∆tolC background. 
However, deletion of tolC completely sensitized both WT and ∆yegI strains to the indicated 
concentrations of antibiotics therefore making it not possible to determine differences in sensitivity 
(Fig.4.15). In future experiments, I will test if the reduced susceptibility of ∆yegI is a result of high 
TolC levels by examining expression of tolC mRNA using qRT-PCR in WT and ∆yegI in the 
absence or presence of antibiotics. Identifying this mechanism of decreased susceptibility to 
antibiotics could help understand the role of YegI in maintaining antibiotic sensitivity. 
 
5.2.6 Potential YegI substrates 
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Comparative phosphoproteomics of WT and ∆yegI strains revealed differential 
phosphorylation of enolase, a key glycolytic enzyme, at Ser-400 (Fig.4.16C). Glycolysis breaks 
down glucose into pyruvate which is used to generate ATP and NADH and is therefore essential 
for maintaining optimal growth and production of various biomolecules. During glycolysis, 
enolase catalyzes the interconversion between 2-phosphoglycerate to phosphoenol pyruvate. 
Previously published global phosphoproteomes from phylogenetically diverse bacteria also report 
Ser/Thr phosphorylation of enolase (114, 115, 117, 122, 123). Consistent with the comparative 
phosphoproteomics analysis, I observed YegI-dependent in vitro phosphorylation of enolase 
(Fig.4.17). However, since YegI still phosphorylated the phosphoablative mutant enolase-S400A, 
there are likely additional sites of phosphorylation. Mass spectrometry analysis of enolase 
phosphorylation by YegI will help identify these sites of phosphorylation.  
The more pertinent question is whether phosphorylation of enolase affects its function. The 
lack of a commercially available substrate 2-phosphoglycerate makes the study of the impact of 
phosphorylation on enolase glycolytic activity challenging. Alternatively, in addition to its role in 
glycolysis, enolase is part of the multicomponent RNA degradosome complex that is responsible 
for regulating half-life of RNA transcripts (124). Although its exact role in RNA degradation is 
unknown, the presence of enolase in the RNA degradosome complex is required for degradation 
of glucose transporter ptsG mRNA levels under phosphosugar stress (126). Rapid degradation of 
ptsG mRNA was observed only when glycolytic pathway was blocked early on by deletion of 
phosphoglucose isomerase pgi. Pgi mediates the interconversion of glucose-6-phosphate to 
fructose-6-phosphate and deletion of pgi leads to accumulation of glucose-6-phosphate in cells 
resulting in phosphosugar stress. However how enolase in the RNA degradosome complex 
stimulates rapid degradation is still unknown. It is possible that phosphorylation could affect 
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protein-protein interactions between enolase and degradosome complex. Therefore, I speculate 
that phosphorylation of enolase could impact the formation of RNA degradosome complex in vivo 
which could in turn affect ptsG mRNA degradation. Future experiments will test whether 
phosphorylation of enolase affects activity in RNA degradosome by examining ptsG mRNA levels 
in WT or ∆yegI strain under phosphosugar stress using qRT-PCR. If indeed YegI phosphorylates 
enolase and inhibits enolase activity then we should observe stabilization of ptsG mRNA in ∆yegI 
strain even in the presence of phosphosugar stress. Alternatively, if YegI phosphorylation has no 
impact on enolase activity in the degredasome, then we would observe decreased ptsG levels due 
to rapid degradation.  
Phosphorylation of elongation factor-Tu (EF-Tu) is observed in multiple phosphoproteomics 
studies (130). In E. coli, EF-Tu is reported to be phosphorylated on multiple Ser/Thr residues (114, 
123, 134) but the kinase responsible for this phosphorylation is not known. Using in vitro kinase 
assay, I demonstrated YegI-dependent phosphorylation of EF-Tu (Fig. 4.18). Furthermore, EF-Tu 
purified from an E. coli strain co-expressing an active YegI truncation was less active in 
stimulating protein synthesis than EF-Tu that has been purified from E. coli in the absence of co-
expressed YegI (Fig.4.19B). This result hints at a possible role of phosphorylation mediated 
regulation of EF-Tu activity in protein translation. In the future, I would like to dissect the exact 
mechanism by which YegI dependent phosphorylation of EF-Tu affects protein synthesis. To 
address this question, I would like to first ensure that co-expression of EF-Tu with YegI-NTD 
leads to phosphorylation of EF-Tu using mass spectrometry. While several commercially available 
non-radioactive phosphorylation detection methods such as Phos-tag (172, 225), pIMAGO (226) 
as well as phosphospecific antibodies exist, I have been unable to detect any specific 
phosphorylation event using these methodologies. Thus, following validation of phosphorylation 
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of EF-Tu using mass spectrometry, I will compare the sites of phosphorylation obtained from in 
vitro phosphorylated EF-Tu (Thr-94, Ser-198, Ser-220) to the in vivo phosphorylated EF-Tu and 
assess the impact of single phosphoablative mutants on protein translation. While Thr-94 is located 
in the GTP binding domain, Ser-198 and Ser-220 are located in the C-terminal domain responsible 
for functional interaction with the ribosome. If Thr-94 is phosphorylated, then one could directly 
assess the impact of this modification on GTP hydrolysis. The adjacent glycine residue (Gly-95) 
is crucial for release of inorganic phosphate after GTP hydrolysis which is a crucial step for 
function of GTPases like EF-Tu (227), therefore I speculate that phosphorylation of Thr-94 could 
affect EF-Tu GTPase activity. Similarly if Ser-220 is phosphorylated, then one could assess the 
impact of this modification on GTP hydrolysis. Since Gly-223 is necessary for ribosome dependent 
activation of GTP hydrolysis (217, 218), phosphorylation of Ser-220 could affect ribosome 
dependent activation of GTPase activity. Together, these studies would offer insight into 
phosphorylation mediated regulation of E. coli EF-Tu function.  
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Appendix A: Strains used in this study 
 
     Strains used in Chapter 3 
 
Strain Relevant 
Genotype 
Description Reference 
DH5α   Invitrogen 
C43(DE3)   (1)   
BL21(DE3)   Stratagene 
LOBSTR 
(BL21(DE3)  
  Kerafast (2)  
JDE2944 pKR16 amp C43(DE3) expressing N terminal 
6X-His tagged WT PphC from 
E.coli REL606 
This study 
JDE2946 pKR17 amp C43(DE3) expressing N terminal 
6X-His tagged D46N PphC E.coli 
REL606 
This study 
JDE2908 pKR02 amp C43(DE3) expressing N terminal 
6X-His tagged WT PphC from 
E.coli MG1655 
This study 
JDE3039 pKR60 amp C43(DE3) expressing N terminal 
6X-His tagged S174A PphC from 
E.coli REL606 
This study 
 
 
JDE1715 pSFP65 BL21(DE3) expressing C terminal 
StrepII tagged WT PrpC from 
B.subtilis 
(3) 
KR81  pKR31 amp LOBSTR-BL21 (DE3) expressing N 
terminal 6X-His tagged WT YegI 
from E.coli REL606 
This study 
 
  
KR87 pKR29 amp LOBSTR-BL21 (DE3) expressing N 
terminal 6X-His tagged WT YegI-
NTD from E.coli REL606 
This study 
JDE2117 pEN03 amp C43(DE3) expressing N terminal 
6X-His tagged WT HipA from 
E.coli MG1655 
This study 
JDE2916 pKR07 amp C43(DE3) expressing N terminal 
6X-His tagged WT GltX from  
E.coli MG1655 
This study 
  
     Strains used in Chapter 4 
 
Strain Relevant 
Genotype 
Description Reference 
DH5α   Laboratory 
stock 
JDE2735 REL606  (4) 
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JDE2487 MG1655  Laboratory 
stock  
KR70 pKR31 amp C43 (DE3) expressing N terminal 
6X-His tagged WT YegI from E.coli 
REL606 
This study 
 
KR81  pKR31 amp LOBSTR-BL21 (DE3) expressing N 
terminal 6X-His tagged WT YegI 
from E.coli REL606 
Chapter 3  
 
KR71 pKR29 amp C43 (DE3) expressing N terminal 
6X-His tagged WT YegI-NTD from 
E.coli REL606 
This study 
 
KR87 pKR29 amp LOBSTR-BL21 (DE3) expressing N 
terminal 6X-His tagged WT YegI-
NTD from E.coli REL606 
Chapter 3 
KR245 pKR81 amp LOBSTR-BL21 (DE3) expressing N 
terminal 6X-His tagged K39D YegI 
from E.coli REL606 
This study 
KR251 pKR83 amp  LOBSTR-BL21 (DE3) expressing N 
terminal 6X-His tagged D141N YegI 
from E.coli REL606 
This study 
KR289  pKR90 amp LOBSTR-BL21 (DE3) expressing N 
terminal 6X-His tagged K39A YegI 
from E.coli REL606 
This study 
KR314 pKR97 amp LOBSTR-BL21 (DE3) expressing N 
terminal 6X-His tagged 
S160FD161G YegI from E.coli 
REL606 
This study 
KR135 pKR64 amp LOBSTR-BL21 (DE3) expressing N 
terminal 6X-His tagged S602SS644A 
YegI from E.coli REL606 
This study 
KR137 pKR67 amp  LOBSTR-BL21 (DE3) expressing N 
terminal 6X-His tagged 
S153AS160AS162A YegI- NTD 
from E.coli REL606 
This study 
KR03 pBAD24 amp DH5α expressing pBAD24 plasmid  This study  
KR223 pKR78 amp DH5α expressing N terminal 6X-His 
tagged PhoA (aa 21-471) lacZα (aa 
5-60) 
This study  
KR221 pKR72 amp DH5α expressing N terminal 6X-His 
tagged YegI (aa 1-646) fused with 
PhoA lacZα from E.coli REL606 
This study 
KR211 pKR73 amp DH5α expressing N terminal 6X-His 
tagged YegI (aa 1-439) fused with 
PhoAlacZα from E.coli REL606 
This study 
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KR213 pKR74 amp DH5α expressing N terminal 6X-His 
tagged YegI (aa 1-432) fused with 
PhoA lacZα from E.coli REL606 
This study 
KR215 pKR75 amp DH5α expressing N terminal 6X-His 
tagged YegI (aa 1-414) fused with 
PhoA lacZα from E.coli REL606 
This study 
KR218 pKR76 amp DH5α expressing N terminal 6X-His 
tagged YegI (aa 1-390) fused with 
PhoA lacZα from E.coli REL606 
This study 
KR219 pKR77 amp DH5α expressing N terminal 6X-His 
tagged YegI (aa 1-340) fused with 
PhoA lacZα from E.coli REL606 
This study 
KR154  ∆yegI::[FRT-kan-
FRT] 
In frame deletion of (∆aa 9-624) of 
yegI in JDE2735 (E.coli REL606) 
This study  
KR156 ∆yegI::FRT/pcp20 Removal of kan marker from KR154 
using pcp20 flippase  
This study  
KR160  ∆yegI ∆yegI in JDE2735    
KR168 ∆yegI ::[FRT-
lacZY kan] 
Generation of yegI (aa 1-8) 
translational fusion to lacZ by 
transforming pCE40 into KR156 
This study 
KR178 ∆lacZ::[FRT-kan-
FRT] 
In frame deletion (∆aa 10-1011) of 
lacZ in JDE2735 
This study 
KR181 ∆lacZ  Removal of kan marker from KR178 
using pcp20 flippase 
This study 
KR188 ∆lacZ ∆yegI 
::[FRT-lacZY kan] 
yegI lacZ translational fusion in 
∆lacZ strain.  
This study 
KR257  ∆yegI ∆yegI in JDE2487 (E.coli MG1655) This study 
KR199 pBAD24 amp REL606 WT (JDE2735) expressing 
pBAD24 empty vector  
This study 
KR200 pBAD24 amp REL606 ∆yegI (KR160) expressing 
pBAD24 empty vector 
This study 
KR206 pKR31 amp  REL606 ∆yegI (KR160) expressing 
N terminal 6X-His tagged WT YegI 
from E.coli REL606 
This study 
KR244 pKR81 amp  REL606 ∆yegI (KR160) expressing 
N terminal 6X-His tagged K39D 
YegI from E.coli REL606 
This study 
KR250 pKR83 amp  REL606 ∆yegI (KR160) expressing 
N terminal 6X-His tagged D141N 
YegI from E.coli REL606 
This study 
KR230 pKR29 amp REL606 ∆yegI (KR160) expressing 
N terminal 6X-His tagged YegI-NTD 
from E.coli REL606 
This study 
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KR231 pKR30 amp REL606 ∆yegI (KR160) expressing 
N terminal 6X-His tagged YegI (aa 
1-300) from E.coli REL606 
This study 
KR292 pKR93 amp REL606 ∆yegI (KR160) expressing 
N terminal 6X-His tagged YegI (aa 
301-646) from E.coli REL606 
This study 
KR295 pKR92 amp REL606 ∆yegI (KR160) expressing 
N terminal 6X-His tagged YegI (aa 
436-646) from E.coli REL606 
This study 
KR309 pKR95 amp REL606 ∆yegI (KR160) expressing 
N terminal 6X-His tagged YegI (aa 
536-646) from E.coli REL606 
This study 
KR311 pKR96 amp REL606 ∆yegI (KR160) expressing 
N terminal 6X-His tagged YegI (aa 
566-646) from E.coli REL606 
This study 
KR329 ∆tolC::Kan In frame deletion of (∆aa 10-475) of 
tolC in JDE2735 
This study 
KR337 ∆tolC Removal of kan marker from KR329 
using pcp20 flippase 
This study 
KR338 ∆yegI ∆tolC ∆tolC in ∆yegI (KR160) strain  This study 
KR205 pKR71 amp BL21 (DE3) expressing N terminal 
6X-His tagged WT Eno from E.coli 
REL606 
This study 
KR255 pKR85 amp BL21 (DE3) expressing N terminal 
6X-His tagged S400A Eno from 
E.coli REL606 
This study 
KR114 pGEX6p-1 amp BL21(DE3) expressing GST tag 
alone from pGEX6p-1 vector 
This study 
KR113 pKR61 amp BL21(DE3) expressing N terminal 
GST tagged EF-Tu from E.coli 
MG1655 
This study  
KR322 pKR103 amp  BL21(DE3) expressing N terminal 
6X-His tagged EF-Tu from E.coli 
E.coli MG1655 
This study 
KR324 pKR105 amp  BL21(DE3) expressing N terminal 
6X-His tagged EF-Tu  from E.coli 
MG1655 and YegI-NTD (aa 1-300)  
from E.coli REL606 
This study 
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Appendix B: Plasmids used in this study 
 
          Plasmids used in Chapter 3 
 
Plasmid Name Description  Reference 
pBAD24 Cloning vector, ampR (5) 
pET11a Cloning vector, ampR Novagen 
pKR02 yegK(pphC) was amplified from MG1655 
genomic DNA using KR08/KR02 primers, 
digested with NcoI/PstI and ligated into 
pBAD24 
This study 
pKR16 yegK(pphC)  was amplified from REL606 
genomic DNA using KR38/KR39 primers, 
digested with NcoI/PstI and ligated into 
pBAD24 
This study 
pKR17 REL606 D46N yegK(pphC)  was generated by 
two step PCR using KR38/KR41 and 
KR39/KR40 primer pairs followed by 
amplification with KR38/KR39. Resulting 
product was digested with NcoI/PstI and 
ligated into pBAD24 
This study 
pKR29 yegI (aa 1-390) was amplified from REL606 
genomic DNA using KR58/KR60 primers, 
digested with NcoI/SphI and ligated into 
pBAD24 
This study 
pKR31 yegI was amplified from REL606 genomic 
DNA using KR58/KR59 primers, digested 
with NcoI/SphI and ligated into pBAD24 
This study 
pKR60 REL606 S174A yegK(pphC)  was generated 
by two step PCR using KR38/KR129 and 
KR128/KR40 primer pairs followed by 
amplification with KR38/KR39. Resulting 
product was digested with NcoI/PstI and 
ligated into pBAD24 
This study 
pEN3  hipA was amplified from MG1655 genomic 
DNA using EN05/EN02 primers, digested 
with XbaI/PstI and ligated into pBAD24 
Laboratory 
Stock  
(Liz 
Nagle)  
pKR07 gltX  was amplified from MG1655 genomic 
DNA using KR23/KR25 primers, digested 
with NdeI/BamhI and ligated into pET11a 
This study 
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       Plasmids used in Chapter 4 
 
Plasmid Name Description  Reference 
pBAD24 Cloning vector, ampR (5) 
pGEX6p-1 Cloning vector, ampR GE healthcare 
pETduet-1 Cloning vector, ampR Novagen 
pCE40  oriR6K𝜸 kan FRT lacZ+ lacY+  (6) 
pETPhos  Cloning vector, ampR (7) 
pKD13 oriR6K𝜸 kan FRT kan bla , ampR (8) 
pKD46 repA101ts araBp-gam-bet-exo oriR101 bla, 
ampR 
(8) 
Pcp20 λpR-FLP  λcI857+ Repts bla cat (8) 
pKR81 REL606 K39D yegI  was generated by two 
step PCR using KR58/KR246 and 
KR245/KR59 primer pairs followed by 
amplification with KR58/KR59. Resulting 
product was digested with NcoI/SphI and 
ligated into pBAD24 
This study 
pKR83 REL606 D141N yegI  was generated by two 
step PCR using KR58/KR248 and 
KR247/KR59 primer pairs followed by 
amplification with KR58/KR59. Resulting 
product was digested with NcoI/SphI and 
ligated into pBAD24 
This study 
pKR90 REL606 K39A yegI  was generated by two 
step PCR using KR58/KR264 and 
KR263/KR59 primer pairs followed by 
amplification with KR58/KR59. Resulting 
product was digested with NcoI/SphI and 
ligated into pBAD24 
This study 
pKR97 REL606 S160FD161G yegI  was generated by 
Q5 site directed mutagenesis using 
KR285/KR286 and pKR31 as a template.  
This study  
pKR62 REL606 S602A yegI  was generated by two 
step PCR using KR58/KR153 and 
KR152/KR59 primer pairs followed by 
amplification with KR58/KR59. Resulting 
product was digested with NcoI/SphI and 
ligated into pBAD24 
This study  
pKR64 REL606 S602AS644A yegI  was generated by 
two step PCR using pKR62 as template and  
KR58/KR155 and KR154/59 primer pairs 
followed by amplification with KR58/KR59. 
This study  
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Resulting product was digested with 
NcoI/SphI and ligated into pBAD24 
pKR65 REL606 S153A yegI (aa 1-390)   was 
generated by two step PCR using 
KR58/KR158 and KR157/60 primer pairs 
followed by amplification with KR58/KR60. 
Resulting product was digested with 
NcoI/SphI and ligated into pBAD24 
This study 
pKR67 REL606 S153AS160AS162A yegI (aa 1-390)   
was generated by two step PCR using pKR65 
as template KR58/KR160 and KR159/60 
primer pairs followed by amplification with 
KR58/KR60. Resulting product was digested 
with NcoI/SphI and ligated into pBAD24 
This study 
pKR72 REL606 yegI-phoA-lacZ fusion  was 
generated by overlap extension PCR using 
KR223/KR224 , KR225/KR226, 
KR227/KR228 primer pairs followed by 
amplification with KR229/KR228. Resulting 
product was digested with NheI/KpnI and 
ligated into pBAD24 
This study 
pKR73 REL606 YegI E439-phoA lacZ was generated 
by Q5 site directed mutagenesis using 
KR230/KR231 and pKR72 as a template. 
This study 
pKR74 REL606 YegI T432-phoA lacZ was generated 
by Q5 site directed mutagenesis using 
KR230/KR232 and pKR72 as a template. 
This study 
pKR75 REL606 YegI R414-phoA lacZ was generated 
by Q5 site directed mutagenesis using 
KR230/KR233 and pKR72 as a template. 
This study 
pKR76 REL606 YegI E390-phoA lacZ was generated 
by Q5 site directed mutagenesis using 
KR230/KR234 and pKR72 as a template. 
This study 
pKR77 REL606 YegI E340-phoA lacZ was generated 
by Q5 site directed mutagenesis using 
KR230/KR235 and pKR72 as a template. 
This study 
pKR78 Control phoA lacZ was generated by Q5 site 
directed mutagenesis using KR230/KR240 
and pKR72 as a template. 
This study  
pKR30 yegI(1-300)  was amplified from REL606 
genomic DNA using KR58/KR61 primers, 
digested with NcoI/SphI and ligated into 
pBAD24 
This study 
pKR93 REL606 YegI (301-436) was generated by Q5 
site directed mutagenesis using KR274/KR275 
and pKR31 as a template. 
This study 
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pKR92 REL606 YegI (436-646) was generated by Q5 
site directed mutagenesis using KR276/KR275 
and pKR31 as a template. 
This study 
pKR95 REL606 YegI (536-646) was generated by Q5 
site directed mutagenesis using KR287/KR288 
and pKR31 as a template. 
This study 
pKR96 REL606 YegI (566-646) was generated by Q5 
site directed mutagenesis using KR289/KR290 
and pKR31 as a template. 
This study 
pKR71 eno was amplified from REL606 genomic 
DNA using KR211/KR212 primers, digested 
with NdeI/BamHI and ligated into pETPhos 
This study  
pKR85 REL606 S400A eno  was generated by two 
step PCR using KR211/KR250 and 
KR249/KR212 primer pairs followed by 
amplification with KR211/KR212. Resulting 
product was digested with NdeI/BamHI and 
ligated into pETPhos 
This study 
pKR61 tufB was amplified from MG1655 genomic 
DNA using KR145/KR146 primers, digested 
with BamHI/NotI and ligated into pGEX6p-1 
This study 
pKR103 tufB was amplified from MG1655 genomic 
DNA using KR293/KR294 primers, digested 
with BamHI/NotI and ligated into pETDUET-
1 
This study 
pKR105 yegI(aa 1-390)  was amplified from REL606 
genomic DNA using KR62/KR64 primers, 
digested with BglII/ Xho1 and ligated into 
pKR103  
This study 
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Appendix C: Oligos used in this study 
 
      Oligos used in Chapter 3 
 
Oligo Sequence ( 5’-3’) Features Origin 
KR02 cgtccactgcagTCACTCTGCCCACAGCGC 
 
PstI;STOP This 
study 
KR08 ggaaaaccatggcacatcatcatcatcatcatAGCTGGCGTC
TGGTCTATG 
 
NcoI; 6X-
His tag 
This 
study 
KR38 ggaaaaccatggcacatcatcatcatcatcatAGCTGGCGTC
TGGTTTATGC 
 
NcoI; 6X-
His tag 
This 
study 
KR39 cgtccactgcagTCATGGTAACCACAGCGCCA 
 
PstI; STOP This 
study 
KR40 TTCCTTGCTAATGGCGCAGGT 
 
D46N  This 
study 
KR41 ACCTGCGCCATTAGCAAGGAA 
 
D46N  This 
study 
KR58 ggaaaaccatggcacatcatcatcatcatcatAAACCCACTT
TATATACTGCTAC 
 
NcoI; 6X-
His tag 
This 
study 
KR59 cgtccagcatgcTCAGCAGCGGCTTAAATCTG 
 
SphI; STOP This 
study 
KR60 cgtccagcatgctcaTTCGCGCCGTAACAGGCCT 
 
SphI; STOP This 
study 
KR128 CTTTCACCGCCACTGAGCG 
 
S174A This 
study 
KR129 CGCTCAGTGGCGGTGAAAG 
 
S174A This 
study 
EN5 ctaggaattcatggctcatcatcatcatcatcattcgcgcCCTAAA
CTTGTCACTTGGAT 
 
EcoRI; 6X-
His tag 
This 
study 
EN2 aaaactgcagtcaCTTACTACCGTATTCTCGGC 
 
PstI; STOP This 
study 
KR23 ggaaaacatatgatgcatcatcatcatcatcacAAAATCAAA
ACTCGCTTCGCG 
 
Nde1; 6X-
His tag 
This 
study 
KR25 cgtccaggatccTTACTGCTGATTTTCGCGTTCA 
 
BamHI; 
STOP 
This 
study 
 
Homology sequences to gene are shown in uppercase. Non homology sequences are indicated in 
lower case including His6-tag (italics), restriction enzyme sites (underlined). Point mutations are 
highlighted in bold. 
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         Oligos used in Chapter 4 
 
 
Oligo Sequence ( 5’-3’) Features Origin 
KR58 ggaaaaccatggcacatcatcatcatcatcatAAACCCA
CTTTATATACTGCTAC 
 
NcoI; 6X-His 
tag 
This 
study 
KR59 cgtccagcatgcTCAGCAGCGGCTTAAATCT
G 
 
SphI; STOP This 
study 
KR60 cgtccagcatgctcaTTCGCGCCGTAACAGGC
CT 
 
SphI; STOP This 
study 
KR61 cgtccagcatgctcaTAGAGAATCCAGTGCTG
CTAC 
 
SphI; STOP This 
study 
KR245 AGCGTCGCCGACATTTATCAC 
 
K39D This 
study 
KR246 GTGATAAATGTCGGCGACGCT 
 
K39D This 
study 
KR247 GTCGTGGGGAACGTAAACCA 
 
D141N  This 
study 
KR248 TGGTTTACGTTCCCCACGAC 
 
D141N This 
study 
KR263 AGCGTCGCCGCGATTTATCA 
 
K39A This 
study 
KR264 TGATAAATCGCGGCGACGCT 
 
K39A This 
study 
KR285 GTTGATCGATTTTGGCTCCTTTCAGAT
TAACGCCAATG 
 
S160FD161G This 
study 
KR286 ACCACTTTGCTGTCGCGA 
 
S160FD161G This 
study 
KR152 GGCTGGAAGCGGCGTTGAC 
 
S602A This 
study 
KR153 GTCAACGCCGCTTCCAGCC 
 
S602A This 
study 
KR154 GCAGATTTAGCCCGCTGCTGA 
 
S644A This 
study 
KR155 TCAGCAGCGGGCTAAATCTGC 
 
S644A This 
study 
KR157 GTCGCGACGCCAAAGTGGT 
 
S153A This 
study 
KR158 ACCACTTTGGCGTCGCGAC 
 
S153A This 
study 
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KR159 TTGATCGATGCTGACGCCTTTC 
 
S160AS162A This 
study 
KR160 GAAAGGCGTCAGCATCGATCAA 
 
S160AS162A This 
study 
KR223 ccatggcacatcatcatcatcatcatAAACCCACTTT
ATATACTGCTACT 
 
NcoI; 6X-His 
tag 
This 
study 
KR224 catttctggtgtccgggcgctaccgctgccgctaccGCAG
CGGCTTAAATCTGCCTG 
 
PhoA; Linker This 
study 
KR225 GCCCGGACACCAGAAATG 
 
PhoA This 
study 
KR226 gacggccagtgaatccgtTTTCAGCCCCAGAGC
GGC 
 
LacZ; PhoA This 
study 
KR227 ACGGATTCACTGGCCGTCGTT 
 
LacZ This 
study 
KR228 cgtccaggtaccttaGCGCCATTCGCCATTCAG
GC 
 
Kpn1; STOP This 
study 
KR229 ggaaaagctagcaggaggaattCCATGGCACATC
ATCATCATCAT 
 
Nhe1; His tag  This 
study 
KR230 GGTAGCGGCAGCGGTAGC 
 
Q5 
SDM_Linker 
This 
study 
KR231 TTCTGCTTTATAAGCTTTGCTTGTCAGA
CTG 
 
Q5 
SDM_E439 
 
This 
study  
KR232 TGTCAGACTGCCAATAATCCAGATAGC 
 
Q5_SDM_E4
32 
 
This 
study 
KR233 ACGCGGTTCTGCCTGAAGG 
 
Q5_SDM_E4
14 
 
This 
study 
KR234 TTCGCGCCGTAACAGGCC 
 
Q5_SDM_E3
90 
 
This 
study 
KR235 TTCGCCGAGATCAATAAAATAGATAAC
GCC 
 
Q5_SDM_E3
40 
 
This 
study 
KR240 ATGATGATGATGATGATGTGCCATGGT
G 
 
Q5_SDM_ph
oAlacZ 
This 
study 
KR176 gcgctgtggttaccatgaaacccactttatatactgctacGAT
CCGTCGACCTGCAGTTC 
 
yegI, pKD13 This 
study 
 
 
188 
KR177 ctgagccagtttttctgccgcctgacgtaacggttccatcaaTG
TGTAGGCTGGAGCTGCTT 
 
yegI, pKD13 This 
study 
KR185 cacacaggaaacagctatgaccatgattacggattcactgGT
GTAGGCTGGAGCTGCTT 
 
lacZ, pKD13 This 
study 
KR186 tttttgacaccagaccaactggtaatggtagcgaccggcCAT
ATGAATATCCTCCTTAGTTC 
 
lacZ, pKD13 This 
study 
KR274 CGCCAACAGTTAAAGAAATG 
 
Q5 
SDM_L300 
This 
study 
KR275 ATGATGATGATGATGATGTG 
 
Q5 SDM_His This 
study 
KR276 AAAGCAGAAATCCAGCAAC 
 
Q5 
SDM_K437 
This 
study 
KR287 ATTGAAACAGCAGCGGATG 
 
Q5 
SDM_G536 
This 
study 
KR288 ATGATGATGATGATGATGTGC 
 
Q5 SDM_ 
G536 
This 
study 
KR289 GCGAGCTGTGAACGCCGT  
 
Q5 
SDM_G566 
This 
study 
KR290 ATGATGATGATGATGATGTGCCATGG 
 
Q5 
SDM_G566 
This 
study 
KR299 aaggaatgcaaatgaagaaattgctccccattcttatcggGAT
CCGTCGACCTGCAGTTC 
 
tolC, pKD13 This 
study 
KR300 ttatgaccgttactggtggtagtgcgtgcggatgtttgctTGT
GTAGGCTGGAGCTGCTT 
 
tolC, pKD13 This 
study 
KR211 ggaaaacatATGTCCAAAATCGTAAAAATC
ATC 
 
Nde1 This 
study 
KR212 cgtccaggatccTTATGCCTGGCCTTTGATCT 
 
BamH1 This 
study 
KR249 TGAGCCGTGCTGACCGTGT 
 
S400A This 
study 
KR250 ACACGGTCAGCACGGCTCA 
 
S400A This 
study 
KR145 ggaaaaggatccTCTAAAGAAAAGTTTGAAC
GTACA 
 
BamH1 This 
study 
KR146 cgtccactcgagTTAGCTCAGAACTTTTGCTA
CAA 
 
Xho1 This 
study 
KR293 ggaaaaggatccgTCTAAAGAAAAGTTTGAA
CGTAC 
BamH1 This 
study 
 
 
189 
 
KR294 cgtccagcggccgcTTAGCTCAGAACTTTTGC
TACAA 
 
Not1 This 
study 
KR62 ggaaaaagatctaAAACCCACTTTATATACTG
CTAC 
 
BglII This 
study  
KR64 cgtccactcgagtcaTTCGCGCCGTAACAGGC
CT 
 
Xho1 This 
study  
Homology sequences to gene are shown in uppercase. Non homology sequences are indicated 
in lower case including His6-tag (italics), restriction enzyme sites (underlined). Point mutations 
are highlighted in bold. Homology sequences for deletion of gene (40nt) is highlighted in blue.  
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